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SUMMARY 
Regulation of the immune system and of uterine tissue homeostasis, growth, and 
remodelling are deeply intertwined during pregnancy and are essential for 
successful reproduction. Recent findings showed that tissue-resident innate 
lymphoid cells (ILCs) are crucial regulators of both physiology and pathology of 
the tissues they populate. Uterine natural killer (uNK) cells are a subtype of ILCs 
known to regulate trophoblast invasion, uterine vascular adaptation to pregnancy, 
and foetal growth. We recently described additional types of ILCs in the uterus 
of women and mice. However, the role of these ILCs during reproduction is 
unknown. Among them, group 2 ILCs (ILC2s) have been previously 
characterised in other tissues, in which they modulate immune cells and tissue 
homeostasis by producing type-2 cytokines and growth factors (i.e. IL-4, IL-5, 
IL-13, and Amphiregulin). Based on these premises, I hypothesized that uterine 
ILC2s (uILC2s) regulate uterine immune homeostasis and thus contribute to 
successful reproduction. To test this, I first characterised the uILC subtypes 
present in humans and mice at various stages of the reproductive cycle. 
Secondly, I addressed the functional role of uILC2s during pregnancy by taking 
advantage of a uILC2 knockout mouse model. 
My results show that uterine ILC2s represent <1% and <0.1% of murine and 
human uterine leukocytes, respectively. However, as they can quickly produce 
large amounts of cytokines, uILCs are capable of potently affect both other 
immune cells and the surrounding tissue. Indeed, I found that compared to other 
tissue-resident ILC2s, uILC2s produce high levels of IL-5 and Areg even in the 
absence of any stimulation. On the contrary, non-uterine ILC2s mainly produce 
IL-13, which is lowly expressed by uILC2s. To further characterize the tissue-
specific properties of uILC2s, I then performed RNAseq on uILC2s isolated from 
virgin, midgestation, and term murine uterus, and I compared their 
transcriptomes with those of ILC2s from lung, intestine, and bone marrow. 
Interestingly, uILC2s specifically express granzymes and genes typical of 
regulatory T cells. Therefore, uILC2s have tissue-specific properties and are 
modulated during pregnancy. Furthermore, the ability of uILC2s to produce IL-5 
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and Areg suggests that they may be crucial in the regulation of uterine type-2 
immunity. 
I then studied the phenotype of Roraflox/flox Il7racre/wt (ILC2KO) mouse models, as 
well as that of mice lacking the ILC2 activating cytokine IL-33 (IL33cit/cit; IL-
33KO). I examined the immune microenvironment in both the myometrium and 
decidua in ILC2KO mice and found alterations in type-2 cytokines and myeloid 
cell homeostasis. In particular, in absence of ILC2s, IL-4 and IL-5 are 
dramatically reduced, IL-13 is absent, and decidual inflammatory cytokines IL-
1β and IL-6 are increased. Furthermore, uterine dendritic cells (uDC), uterine 
macrophages (uMac), and uterine neutrophils (uN) increase, while uterine 
eosinophils (uEo) are virtually absent. These results show that uILC2s regulate 
uterine type-2 immunity, suggesting that uILC2s could be important during 
pregnancy. Accordingly, I found that lack of uILC2s leads to insufficient spiral 
artery remodelling and restricted foetal growth. Type-2 cytokines and in 
particular IL-4 regulates alternative activation of Macrophages (Mac) and 
Dendritic Cells (DCs), which promote the development of an anti-inflammatory 
environment and facilitate tissue remodelling. I hypothesised that similar 
mechanisms occur in the uterus and that uILC2s have a central role in the 
polarisation of the immune response. To explore this, I studied in more detail the 
characteristics of uEo, uMac, and uDCs dissected from wild type and ILC2KO 
mice. I found a reduction in genes associated with alternative activation in uMac 
and uDCs in the uterus of pregnant ILC2KO mice. Additionally, I showed that 
uEo are the main producers of the IL-4. This demonstrates that uILC2s promote 
alternative activation of myeloid cell population by modulating the uterine 
immune microenvironment. I then assessed the role of uILC2s-dependent type-2 
immunity in inflammatory pathology following a type-1 response to bacterial 
infection. When challenged with LPS, pregnant ILC2KO mice showed more 
pronounced foetal demise. Therefore, uILC2s regulate uterine type-2 immune 
homeostasis and this prevents inflammatory pathology.  
 vi 
Collectively, my work advances our knowledge of the innate immune 
mechanisms that control physiological and pathological events during pregnancy. 
These findings have implications to the field of immunology of pregnancy and 
may lead to clinical progress in diagnosis and prevention of infection-induced 
abortion in human pregnancies. 
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1.1 Phenotypic characteristics of ILCs. 
Over the last decade, a group of cells, widely referred to as innate lymphoid cells 
(ILCs), has attracted particular attention from the scientific community, thus 
changing the field of innate immunity1,2. ILCs are lymphoid cells that develop 
independently of the recombination activating genes (Rag1 and Rag2). Thus, 
they lack rearranged antigen-specific receptors and do not express markers 
associated with other immune cell lineages3. ILCs share many characteristics 
with helper T cells and express cytokines typical of T cells. In contrast to T cells, 
however, they do not undergo stimulation-induced clonal selection or expansion. 
Instead, ILCs respond to tissue-derived signals (infections, injuries, and 
homeostatic signals) and produce cytokines to activate effector cells4. ILCs can 
be divided into three major groups according to their developmental trajectories, 
cytokine panel, and expression profile of lineage-specific transcription factors: 
ILC1s express T-BET and produce type-1 cytokines (e.g. IFN-g and TNF-a); 
ILC2s express GATA-3 and induce type-2 immune responses (IL-4, IL-5, IL-9, 
IL-13); ILC3s express ROR-gt and produce either IL-17 or IL-221,5–7. 
1.1.1 Group 2 ILCs 
ILC2s produce IL-5 and IL-13 when activated by IL-33, TSLP, or IL-25, and 
contribute to type-2 inflammation7–10. ILC2s have been discovered 10 years after 
the observation that Rag-2-/- mice, which lack B and T cells, were still able to 
mount type-2 responses11. ILC2s were originally named natural helpers cells 
(NHCs)12, nuocytes13, and innate helper 214 (Ih2c). ILC2s are identified by the 
expression of different surface markers such as CD25, CD69, CD90.2 (Thy1), 
CD117 (c-Kit), CD127 (IL-7Rα), Sca-1, CD278 (ICOS), IL-33R (T1/ST-2), and 
IL-17RB (IL-25R)7–10,15. A list of markers that identify mouse ILC2 is presented 
in Table 1 (and a summary in Figure 1). Several transcription factors have been 
related to ILC2 development and function. First of all, the transcription factor 
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GATA-3, which has been shown to be essential for all helper ILCs 
development16 and maintenance. GATA-3 also promotes ILC2 function17,18. 
Other transcription factors such as RORa19,20 and BCL11B21 are also required for 
ILC2 development and differentiation (ILC2 development is described in detail 
in Chapter 1.2).  
Activation, proliferation, and survival of ILC2 are mainly regulated by IL-25, IL-
33, TSLP, and TL1A8. Exogenous IL-33 increases the number of ILC2s, and 
studies on mice lacking the IL-33 receptor ST-2 have reduced ILC2s, 
demonstrating the importance of IL-33 for ILC2 expansion13,22. Similar studies 
have been performed in mice knockout (KO) for the IL-25 receptor IL-17RB, 
which support the importance of IL-25 in maintaining ILC2 homeostasis and 
expansion13. Additionally, survival signals by IL-2 and IL-7 appear important to 
ILC2s10,19,23. In contrast to NK cells and to other ILCs, ILC2s have been shown 
to express high-affinity IL-2 receptors24. Indeed, IL-2 signalling induced by IL-2-
anti-IL-2 antibody complexes promotes in vivo proliferation and activation of 
ILC2s24,25. Accordingly, in vivo treatment with IL-2 induces ILC2 expansion, 
increases expression of CD25, ICOS, CD69, T1/ ST2, and CD49d, and leads to 
upregulation of IL-5 and IL-1324. Finally, ICOS is another important factor for 
ILC2 activation, homeostasis, and survival, but is not required for their 
proliferation26,27. Indeed, Maazi et al., showed that Icos-/- mice have less ILC2s. 
The remaining ILC2s in this model have low expression of the anti-apoptotic 
factor BCL-2, providing evidence that ICOS-ICOS-L signalling protects ILC2s 
from apoptosis. ICOS promote STAT5 signalling in ILC2s, which is important 
for IL-2 and IL-7 signalling and for cytokine production26,27. These studies also 
showed that ILC2s themselves could provide ICOS-L to promote their own 
activation and homeostasis. 
Having described the main markers important for the identification, survival, and 
activity of ILC2s, it is important to underline the plasticity of this cell population. 
In fact, the phenotype of ILC2s can be modulated by the microenvironment, as 
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they can either become ILC1-like or ILC3-like (an aspect that will be explained 
in more detail in Chapter 1.3). The maintenance of the ILC2 phenotype requires 
GATA-3, GFI1, and BCL11B. While both RORa and GATA-3 are involved in 
ILC2 development18–20, in contrast to GATA-3, RORa is not essential for ILC2 
cytokine production and maintenance of ILC2 maturity28. Cell-intrinsic and dose-
dependent expression of GATA-3 maintains the responsiveness of ILC2s by 
inducing IL-17RB, IL-2R, IL-1RL1 receptors17,29. Activation of ILC2s induces 
GATA-3 phosphorylation by p38 resulting in GATA-3 binding to the IL-5 and 
IL-13 promoters28, thus promoting type-2 cytokine production. GFI1 is an 
upstream regulator of GATA-3 and IL-1RL122. This transcription factor not only 
controls ILC2s development, but it is also required for GATA-3 expression in 
mature ILC2s and for repression of the ILC3 regulator Rorc. Further upstream in 
this pathway, BCL11B regulates GFI1 expression by direct association with its 
promoter. Studies in Bcl11b-/- mice demonstrated that BCL11B is needed for 
ILC2 maturation, a phenomenon dependent on GFI1 and GATA-3 expression 
and on the repression of the ILC3 genes Rorc and Ahr. The loss of ILC2s 
maturity due to loss of BCL11B drives acquisition of an ILC3 phenotype and it 
increases IL-22 and IL-17 production 22,30.  
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Table 1. Phenotypic characteristics of tissue-resident mouse ILC2s  
	 Skin	 Small	
intestine	
Adipose	
tissue	
Lung	
Cell	type	 ILC2	 ILC2	 ILC2	 ILC2	 iILC2*	(ILC3-
like)	
Ref.	 24,31		 	13,32,33	 	12,34	 	13,14,23,32,35	 35,36		
CD11b	 -		 -		 -		 -		 -		
CD127	 	+	 	+	 	+	 	+	 	+	
CD90.2	 	+	 	+	 	+	 	+	 	+/-	
CD25	 	+	 	+	 	+	 	+	 nd		
ICOS	 +		 +	 +	 	+	 nd		
SCA-1	 	+	 +		 	+	 +		 	-	
ST-2	 	+	 +		 	+	 	+	 	-	
c-Kit	 -		 	+	 	+	 	+/-	 	+	
MHC	II	 	nd	 	+	 	nd	 +/-		 	+	
IL17RA	 	+	 +		 	+	 +		 	+	
IL17RB	 	+	 	+	 	+	 	+	 	+	
CD69	 	+	 	+	 	+	 +		 nd		
CD103	 	+	 	nd	 	nd	 nd		 nd		
GATA-3	 	+	 	+	 	+	 	+	 	+	
CXCR6		 	+	 nd		 	nd	 nd		 nd		
CD27	 	+	 nd		 	+	 nd		 nd		
FLT3	 	+	 nd		 	-	 nd		 nd		
CD44	 	+	 	+	 	+	 	+	 	+	
CD38	 	+	 nd	 	+	 nd		 nd		
GITR		 	+	 	nd	 	+	 nd		 	nd	
KLRG1	 	+/-	 nd		 	nd	 	+/-	 +		
ROR-γt	 -	 -	 -	 	-	 +		
IL-5	 +		 +		 +		 +		 +		
IL-13	 +		 +		 +		 +		 +		
IL-17	 	-	 	-	 	-	 	-	 +		
 
 
*Inflammatory ILC2s; see Chapter 1.3.3 
Human ILC2s have been initially described in the lung, gut, nasal tissues, and 
peripheral blood37. Human ILC2s lack T and B cell receptors and mast cell and 
basophil markers (such as FcεR1 and the IL-3 receptor IL-3R/CD123), while 
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they express CRTH2, CD161, and the lymphoid marker CD7. As in the mouse, 
IL-33 receptor (ST-2) and ICOS are important for human ILC2 activation, 
homeostasis and accumulation in mucosal tissues26,27,34,38,39. Further, CRTH2 is 
specifically required for human ILC2s. These factors together with high levels of 
GATA-3 are the main markers identifying human ILC2 human (Table 2 and 
Figure 1). 
 
Figure 1 Main markers to recognise ILC2s in mouse and humans 
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Table 2: Phenotypic characteristics of tissue-resident human ILC2s 
1.1.2 Group 1 ILC 
Natural killer cells (NK) are the prototypic members of the ILC family and 
mediate immune responses against viruses and cancers. They are a specific 
subpopulation of group 1 ILCs. They depend on IL-15 and the IL-2Rg chain for 
their development45 and produce IFN-g1,6,46. All ILC1s express the transcription 
factor T-BET, although NK cells do not strictly require it for their 
development47. In the murine liver, NK cells and ILC1s can be phenotypically 
	 Lung	 Blood	 Lamina	propria	 Skin	
Cell	type	 ILC2	 ILC2	 ILC2	 ILC2	
Ref.	 38,40,41	 20,37,42 37	 31,42–44	
	CD11b	 	-	 - - 	- 
CD127	 	+	 	- 	+ 	+ 
CD25	 	+	 	+ 	+ 	+ 
CD62L	 nd		 	+ nd	 	nd 
ST-2	 	+	 	+ +	 	+ 
c-Kit	 	nd	 +/-	 +/-	 +	 
CRTH2	 	+	 	+ 	+ 	+/- 
NKp44	 nd		 	- -	 	nd 
CD56	 	-	 	- 	- 	- 
CD161	 	+	 	+ 	+ +/-	 
MHC	II	 	nd	 +	 nd	 nd	 
IL17RA	 	+	 	+ 	+ +	 
IL17RB	 	+	 	+ 	+ 	+ 
CCR6	 nd		 	+ +	 nd 
AhR	 	nd	 	+ nd	 nd 
CD7	 nd		 	+ +	 nd 
GATA-3	 	+	 	+ 	+ 	+ 
ICOS	 	nd	 	+ nd	 	+ 
IL-5	 +	 + + +	 
IL-13	 +	 + + +	 
KLRG1	 nd	 nd nd +	 
CCR10	 nd	 nd nd +	 
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distinct by mutually exclusive EOMES and CD49a expression, respecitvelly48. 
However, ILC1s are extremely plastic and their markers are tissue-specific as 
well as being modulated in inflammatory conditions. Therefore, the precise 
identification of group 1 ILCs and their further specification into subsets is 
difficult and somewhat confusing (see below). 
Natural killer cells were discovered in the 70’s in the context of cancer. They 
were named “natural killers cells” by Rolf Keissling and colleagues due to their 
ability to kill a wide range of tumors49. NK cells have heterogeneous surface 
receptors that control their behaviour through interaction with self major 
histocompatibility complex I (MHC I) ligands and response to microbial 
products, cytokines, and stress signals45. During their maturation, mouse NK 
cells express a broad repertoire of modulatory receptors: NK1.1 (specifically in 
the C57BL/6 genetic background); NKG2 receptors and NKp46, which are 
involved in target cell recognition50; CD16, which mediates antibody-dependent 
cellular cytotoxicity (ADCC); integrin DX5 (CD49b). Finally, mature NK cells 
acquire a receptor 'repertoire' consisting of inhibitory and activating Ly49 
receptors, which are the functional homologues of human killer-cell 
immunoglobulin-like receptors (KIRs), see below50. NK cell activation leads to 
IFN-g and TNF-a production and/or degranulation of cytotoxic granules. This 
process is tightly regulated by the synergistic input of signalling through 
activating and inhibitory receptors and/or by the presence of stimulatory 
cytokines51. Both Ly49 and KIR can be either inhibitory or activating. These 
features are characteristic of conventional NK cells (cNK), which are 
predominantly found in blood and develop from the bone marrow. Aside from 
cNK cells, tissue-resident NK (trNK) cells have been described in the skin, 
uterus, and salivary glands in mouse models. CD49a is a specific marker of trNK 
cells48,52–56. Further specifying trNK, their development is independent of the 
transcription factor NFIL-3, which is required for the development of all other 
ILCs (described in detail in Chapter 1.2).  
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In humans, circulating NK cells are identified by CD56 expression and the 
absence of T cell receptor (CD3-ve). Such NK cells can be functionally 
distinguished on the basis of CD56 expression: CD56bright CD16-ve mainly 
produce cytokines, while CD56lo CD16+ve are cytotoxic46. However it is still 
unclear whether CD56bright NK cells are immature precursors of CD56lo cells57, or 
if they are two truly distinct lineages58. Human tissue resident NK cells have 
been recently identified in the liver and are characterised by the expression of 
CD49a and EOMES, similarly to murine trNK cells59,60 (List of markers used to 
identify human ILC1s are in  
Table 4 and summarised in Figure 2). In addition, another unique subset of NK 
cells includes decidual NK cells, which can be distinguished from both other 
tissue resident and conventional NK cells by the expression of CD956,61,62. This 
NK subset will be described in detail in Chapter 1.4.5. 
The discovery and the characterisation of thymic NK cells was the first evidence 
of the existence of IFN-g-producing ILC1s other than NK cells63. A list of 
markers used to identify mouse ILC1 is in Table 3 (and summarised in Figure 2). 
The thymic NK cells identified by Vosshenrich et al. have different 
developmental requirements than bone marrow-derived NK cells, as they need 
Gata3 and IL-7, and express IL-7Rα at late stages of maturity63. The discovery of 
non-NK ILC1s has made it necessary to reconsider populations throughout the 
body that was previously described as NK cells to determine whether they are 
genuine NK cells or ILC1s. The distinction of these two populations is subtle and 
still unclear, but now the overall accepted distinction between NK cells and ILC1 
is their different dependence on T-BET, their distinct expression of ROR-gt 
during development64,65, and the exclusive expression of the transcription factor 
EOMES in NK cells46,66. Based on this classification, cells originally classified 
liver trNK cells that do not express EOMES are now classified as liver ILC1s48. 
However, while the expression of transcription factors can ideally identify non-
NK ILC1s from NK cells, this is not the case for many extracellular factors as 
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many ILC1 markers are shared with activated NK cells. For instance CD49a, a 
marker of tissue residency in both human and mice can be induced on NK cells 
after MCMV infection67. TRAIL is another potential marker of tissue-resident 
ILC1s in mice48,54,68–70 but it is expressed on human activated NK cells and can 
be induced by interferons in mouse NK cells71,72. ILC1 cytotoxicity can be 
indeed induced by TRAIL rather than perforin (which is instead used by NK 
cells)46 and it may be functionally relevant in the context of cancer 
immunosurveillance73. Further confirmation of how similar group 1 ILCs are 
between each other was shown by Robinette et al,70. Gene expression analysis of 
ILC1s, NK cells, ILC3s, and ILC2s sorted from mouse lamina propria, spleen, 
and liver showed that despite ILC1s and NK cells derive from different 
progenitors, they are transcriptionally similar. Despite all these similarities 
among group 1 ILCs, ILC1s are more tissue resident than bona fide NK cells as 
confirmed from parabiosis experiments on the liver and adipose tissue ILC1s48,74. 
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Table 3: Phenotypic characteristics of mouse ILC1s 
	 Decidua*+	 Liver/intestine	
Cell	type	 trN
K	
cNK	 uILC
1	
ILC
1	
Ex-
ILC2	
or	ex-
ILC3**	
cNK	
CD27+	
CD11b-++	
cNK	
CD27-	
CD11b++
+	
Ref.	 48,56,75,7
6	
48,56,75,76	 48,56,75,76 68,70 8,46,68,77 68,70 68,70 
CD3	and	
CD19	
-	 -	 -	 -	 -	 -	 -	
CD11b	 +/-	 +/-	 - - - - + 
CD27	 +/-	 +/-	 +/- + - + - 
CD49a	 +	 -	 + + + - - 
CD49b	 -	 +	 - - - + + 
CD69	 +	 -	 + + +/- - - 
CD103	 -*	 -*	 +* nd - - - 
CD127	 -	 -	 + + + - - 
CD160	 +	 +*	 + + + - - 
KLRG1	 +*	 +*	 +* - - +/- +/- 
NKG2D	 +*	 +*	 +* + + + + 
NK1.1	 +	 +	 + + + + + 
NKp46	 +	 +	 + + + + + 
Ly49A	 +*	 +*	 -* + - +/- +/- 
Ly49C/I	 +*	 +*	 +* +/- - +/- +/- 
Ly49D	 +*	 +*	 -* - nd +/- +/- 
Ly49G2	 +*	 +*	 +/-* +/- - +/- +/- 
Ly49H	 +*	 +*	 -	* - - +/- +/- 
EOMES	 +	 +	 - - - + + 
T-BET	 +	 +	 + + + + + 
TRAIL	 +	 +	 -	 +	 nd	 -	 -	
Granzyme	B	 +*	 +*	 +* +/- - - + 
Perforin	 +*	 +*	 +* - - - + 
*Unpublished data from Jean-Marc Doisne (data collected in collaboration) 
*+Decidual ILC1s (trNK, cNK, uILC1) will be described in Chapter1.4.5 
** ILC1 derived from ILC2 or LC3 will be described in Chapter1.3.3 
++ cNK cells CD27+/-ve and CD11b-/+ve correspond to different developmental stages of cNK cells 
described in Chapter 1.2 
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Table 4: Phenotypic characteristics of human ILC1s 
*+Decidual ILC1s (trNK, cNK, uILC1) will be described in Chapter 1.4.5 
** ILC1 derived from ILC2 or LC3 will be described in Chapter 1.3.3 
	 Decidua	 Blood	 Liver	
Lung	and	
intestine	
Cell	type	 dNK	 dILC1	 ILC1	 CD56hi	 CD56lo	 trNK	 ILC1	
Ex-
ILC2	
or	ex-
ILC3	
Ref.	 75,78–81	 75,76	 82,83	 46,58	 46,58	 59,60	 46,84	 85,86	
CD3	and	
CD19	
-	 -	 -	 -	 - - - - 
CD4	 	 -	 +/-	 -	 - - - + 
CD16	 -	 -	 -	 -	 	 - nd - 
CD9	 +	 nd	 nd	 -	 - nd nd nd 
CD27	 nd	 nd	 +	 +/-	 +/- +/- - + 
CD49a	 +	 +	 nd	 -	 - + + nd 
CD49b	 nd	 nd	 nd	 +	 + - - nd 
CD49e	 nd	 nd	 nd	 nd	 nd - nd nd 
CD56	 +	 +	 -	 +	 + + + - 
CD69	 +	 +	 -	 -	 - + + + 
CD94	 +	 +	 -	 +	 +/- + + - 
CD103	 +/-	 +	 -	 -	 - - + - 
CD127	 -	 -	 +	 -	 - - - + 
CD161	 +/-	 nd	 nd	 +	 +/- +/- - + 
NKG2D	 +	 +	 nd	 +	 + + + nd 
NKp30	 +	 +	 nd	 +	 + + + nd 
NKp44	 -	 -	 nd	 -	 - + + - 
NKp46	 +	 +	 nd	 +	 + + + + 
KIR	
(inhbitory)	
+	 +	 nd	 -	 +/- -/+ +/- nd 
KIR	
(Activatory)	
+	 +	
nd	
-	 +/- - nd nd 
T-BET	 +	 +	 +	 +	 + - + + 
EOMES	 +	 -	 -	 +	 + ++ + - 
TRAIL	 nd	 nd	 nd	 -	 - nd - nd 
Granzyme	 +	 +	 -	 +/-	 + +/- + - 
Perforin	 +	 +	 -	 -	 + - + - 
CXCR6	 nd	 nd	 nd	 -	 - + nd nd 
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Figure 2 Main markers to recognise ILC1s in mouse and humans 
Robinette et al.70 showed extensive transcriptional overlaps between ILC1s, 
ILC3s, and T cells. Similarities between ILC1s and ILC3s may be related to their 
shared origin68,87 (see Chapter 1.2) or their plasticity. Both mouse and human 
ILC2s and ILC3s can trans-differentiate into ILC1s in inflammatory 
conditions64,65,86,88,89. Further, ILC1s ex-ILC2s can revert back to ILC2s in 
presence of IL-490, and ILC1s ex- ILC3s can switch back if exposed to IL-1b and 
IL-2384 (ILC plasticity will be described in more detail in Chapter 1.3). 
Transcriptional similarities between T cells and ILCs are not surprising, as ILCs 
are phenotypically and functionally similar to T helper cells. Indeed, while the T 
cell receptor (TCR) is not expressed on ILCs and ILCs develop independently of 
RAG genes, Cd3e transcripts were found in ILC1s70. Furthermore, studies on 
human PBMCs from multiple sclerosis patients and inflamed tonsils showed that 
ILC1s can express typical T cell markers, including CD4, CD5, CD6, CD8, 
CD27 and CD2882,83.  
The first evidence of non-NK human ILC1s came from Fuchs et al. and Bernink 
et al. with the description of intraepithelial, lamina propria, and tonsil ILC1s and 
of their plasticity with ILC3s77,91. Intestinal human ILC1s express high levels of 
CD127 and T-BET but lack the NK markers CD56, CD94, Perforin, Granzyme B 
and EOMES. Intraepithelial CD103+ve ILC1s resemble more closely NK cells as 
they express EOMES and Perforin, but have low levels of CD12777. However, 
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both these subsets of ILC1s were largely independent of IL-15Rα for their 
development, thus suggesting they are distinct from NK cells. 
1.1.3 ILC3 
Group 3 ILCs are a heterogeneous subset that comprises natural cytotoxicity 
receptor (NCR)-positive ILC3s and CD4-positive ILC3s (also known as 
lymphoid tissue inducer-like (LTi) cells) that produce cytokines typical of Th17 
and/or Th22 cells, namely IL-17 and/or IL-22. A full description of mouse and 
human ILC3 markers is included in Table 5 and Table 6 and summarised in 
Figure 3. LTi and then the so-called NK22 were the first cells described from 
group 3 ILCs almost 20 years ago92–94. They have been discovered in connection 
with the requirement for ROR-gt+ve cells for Peyer’s patches formation93,95–97. 
ILC3s are now considered a plastic group of cells64,65,84,98 which plays important 
roles in tissue homeostasis in adult99,100 and foetal life101,102, as well as against 
extracellular pathogens103. However, plasticity with group 1 ILCs64,65,84,98 and the 
expression of NK cell markers (NKp46, NKG2D, NKp30, NKp44, CD56, 
CD161 or NK1.1 in mice)64,92,93,104 make it difficult to clearly distinguish ILC3s 
from NK cells. The main difference is in the expression by ILC3s of ROR-gt and 
CD127 (IL-7 receptor) for lineage specification, in fact, mice lacking ROR-gt 
have no ILC3s104–106. CCR6high ILC3 are now identified as LTi cells, and they 
follow a distinct path of development than NCR+ve or NCR-ve ILC3s7,70 (this will 
be covered in chapter1.2). Plasticity among ILCs will be discussed in detail in 
Chapter 1.3. Here it should suffice to say that NCR+ve and NCR-ve ILC3s express 
only low amounts of CCR668 and the transcription factor T-BET modulates 
NKp46 expression and the subsequent differentiation of ILC3s into ILC1s65,68. 
CCR6-ve ILC3s are strictly dependent on AhR, while LTi cells can develop in 
Ahr-/- mice. However, Ahr deficiency affects the expression of IL-22, c-Kit and 
CD127 Lack of AhR also increases the expression of anti-apoptotic 
genes Bcl2 and Bcl2l1107,108. This suggests a role for AhR in regulating ILC3s 
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maturity and survival. Similar mechanisms occur in human tonsils and in 
hematopoietic progenitors, where AhR agonists prevent ILC3s plasticity into a 
CD56bright NK cell phenotype109,110. However, we still do not know which AhR 
ligands activate ILC3s. While Kiss et al. 107proposed a major role for AhR 
ligands derived from food components, these data could not be confirmed by Lee 
et al.111. Similarly to Ahr, retinoic acid and retinoic acid receptor alpha (RARa) 
regulate ROR-gt stability by modulating the Rorc locus102. Additionally, retinoic 
acid favours ILC3s by suppressing type-2 immune responses112. Finally, another 
molecule important for ILC3s stability is IL-7. IL-7 is important for the 
development of all ILCs, but in addition, it stabilizes ROR-gt expression, 
enabling ILCs to maintain IL-22 production64,113,114.  
ILC3s can be activated by cytokines released by the epithelial cells or antigen 
presenting cells. For instance, activation of ILC3s is regulated by IL-1b, which 
can synergise with IL-7 or IL-23 secreted from the epithelium or DCs or Mac. 
This cytokine combination promotes IL-22 production and ILC3s 
proliferation115,116. In addition, also NCR can modulate ILC3s activation, as they 
do for NK cells. Mouse splenic ILC3s can be triggered to produce IFN-γ and 
TNF-a, but not IL-22 via NK1.1 engagement115,117. In human, NKp44 
engagement can induce ILC3s cytokines production even in absence of 
inflammatory cytokines115. However, engagement of NKp46, NK1.1, or 2B4 
cannot induce IFN-γ or IL-22 expression in mouse NCR+ve ILC3s from the gut. 
 
Figure 3 Main markers to recognise ILC3s in mouse and humans 
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Table 5: Phenotypic characteristics of mouse ILC3s 
 
 
 
 
	 Small	intestine	 Spleen	
Cell	type	 LTi	 NCR-ve	ILC3	 NCR+ve	ILC3	 cNK	
Ref.	 7,70,94,113	 7,65,113	 7,65,113	 7,113	
CD127		 +	 +	 + - 
c-Kit	 +	 +	 + +/- 
CD122		 nd	 lo	 lo + 
NK1.1	 -	 -	 +/- + 
CCR6	 +	 +	 − - 
NKG2D	 -	 -	 + + 
NKp46	 -	 -	 + + 
Perforin	 -	 -	 - +/- 
CD16	 nd	 -	 - + 
Ly49	 -	 -	 - + 
CD94	 nd	 -	 + + 
CD4	 +	 +	 - - 
RANKL	 +	 +	 + +/- 
T-BET	 -	 +	 + + 
EOMES	 -	 -	 - + 
ROR-γt	 +	 +	 + - 
GATA-3	 -	 lo	 lo +/- 
AhR	 +	 +	 + − 
TNF-a	 +	 +	 + + 
IFN-γ	 -	 +/-	 +/- + 
IL-17	 +	 +	 - - 
IL-22	 +	 +	 + - 
GM-CSF	 nd	 nd	 nd nd 
IL-2	 nd	 nd	 nd nd 
LTa/LTb	 +	 +	 + lo 
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Table 6: Phenotypic characteristics of human ILC3s 
	 Small	intestine	 Blood	
Cell	type	 LTi	 NCR-ve	ILC3	 NCR+ve	ILC3	 cNK	
Ref.	 93,113	 83,98,113	 83,98,113	 113	
CD127		 +	 +	 + +/- 
c-Kit	 +	 +	 + +/- 
CD122		 nd	 lo	 lo + 
CD161	 +	 +	 + +/- 
CCR6	 +	 +	 + - 
NKG2D	 -	 +/-	 +/- + 
NKp30	 +	 +	 + + 
NKp44	 +/-	 -	 + +/- 
NKp46	 -	 +	 + + 
CD56	 +/-	 +	 + + 
Perforin	 -	 -	 - +/- 
CD16	 -	 -	 - + 
KIR	 -	 -	 - + 
CD94	 -	 -	 - + 
CD4	 -	 -	 - - 
RANKL	 +	 +	 + - 
T-BET	 -	 -	 +/- + 
EOMES	 -	 -	 - + 
ROR-γt	 +	 +	 + - 
GATA3	 +/-	 +/-	 +/- +/- 
AhR	 +	 +	 + − 
TNF-a	 +	 +	 + + 
IFN-γ	 -	 +/-	 +/- + 
IL-17	 +	 +/-	 +/- − 
IL-22	 +	 -	 + − 
GM-CSF	 nd	 +	 + + 
IL-2	 nd	 +	 + - 
LTa/LTb	 +	 +	 + lo 
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1.2 Development of ILCs 
ILCs as other lymphocytes develop in lymphatic organs. Lymphocytes (as well 
as ILCs) develops from primary or central lymphoid organs (e.i. bone marrow 
and thymus), which are the primary source of lymphocytes from immature 
progenitor cells. Matured lymphocytes then circulate to secondary or peripheral 
lymphoid organs (which include lymph nodes and the spleen), where they can 
further mature or be activated. In tissues, lymphocytes and stromal cells can 
accumulate, proliferate and form organised structures called tertiary lymphoid 
organs, or ectopic lymphoid structures. ILCs are relatively rare in lymphoid 
tissues, compared to adaptive lymphocytes. Tissues that ILCs preferentially 
populate include barrier surfaces and mucosal-associated lymphoid tissues9,118. 
Recent studies have shown that the preferential location in tissues of ILCs can be 
explained by their tissue residency48,74,119. In particular, Gasteiger et al. showed 
that ILCs and NK cells from the small intestine lamina propria, salivary gland, 
lung, and liver are poorly replenished by circulating progenitors, thus raising the 
possibility that tissue-resident ILCs may develop from tissue-resident 
progenitors119. Bando et al. showed that this hypothesis may be true, indeed, they 
identified a multipotent early-linage progenitor of ILCs in the foetal intestine120. 
While tissues may be the primary sites of ILCs development in homeostatic 
conditions, hematopoietic-derived ILCs may be generated during stress and 
chronic inflammation121. Instead, cNK cells circulate more freely from blood to 
tissues, unlike ILCs74,119. Additionally, it has been proposed that tissue homing of 
ILCs and their progenitors can be regulated by α4β7, and chemokine receptors 
CCR9, CCR6 and CXCR6 in a specific time window during 
embryogenesis8,18,122.  
ILCs from hematopoietic tissues develop from the common lymphoid progenitor 
(CLP) in the bone marrow. Transcription factors subsequently involved in ILC 
development include nuclear factor, interleukin 3 regulated (NFIL-3), inhibitor 
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of DNA binding 2 (ID2) and Promyelocytic leukaemia zinc finger protein 
(PLZF)53,105,123–126. CLP can be identified in the bone marrow as Lin-ve (Gr-1, 
CD11b, B220, CD11c, Ter-119, CD5, NK1.1, CD3e CD3gd) c-Kitlow, Sca-1low, 
CD127+ve, FlLT3+ve, a4b7-ve125. Indeed, this progenitor, when isolated from 
foetal liver and bone marrow, can generate all ILCs including NK cells and 
CD127+ve ILCs68. However, CLPs are early progenitors not exclusively 
committed to ILC development but from CLP also B cells and T cells develop. 
From this comes the need to identify a more committed progenitor committed 
towards ILCs from the CLP. As mentioned in Chapter 1.1, all ILCs develop 
independently from Rag genes. However, fate mapping experiments in Rag1cre 
Rosa26Stop-flox-dtRFP from Karo et al. it was discovered that ~ 40% of NK cells and 
~30-50% of ILC2s and ILC3s have a history of Rag1 expression. This work 
suggests that ILCs may have alternative developmental programs or that ILCs 
can develop from multiple progenitors developing from the CLP and more 
efficiently from the upstream LMPPs127. Recently, two populations downstream 
of these multipotent progenitors have been identified, which are named: a4b7+ve 
lymphoid progenitor (aLP)53,125,128 and early ILC progenitors (EILP)129, both 
developmentally related to the CLP but committed to the ILC lineage because 
they can differentiate into ILCs having lost the potential to become T or B cells. 
The common helper-like innate lymphoid cell progenitor (CHILP) identified by 
Constantidines et al., is a later committed precursor to ILCs, with the exception 
of NK and LTi cells. CHILP highly express PLZF and ID268,123. NFIL-3 and ID2 
are both crucial for the development of this population87 Nfil3 -/- mice have 
indeed an early block in helper ILCs development and NK cells. NFIL-3 
deficiency perturbs ID2 and the expression of essential ILCs lineage-defining 
transcription factors, such as GATA-3, EOMES, and T-BET87,124,125,130. Figure 4 
recapitulates all the steps of ILCs development.  
The importance of NFIL-3 for the development of all ILCs53,87,125,126 was 
established by several groups in 2014. This transcription factor is express at the 
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level of the CLP under the direct control of IL-787,125. NFIL-3 induces thymocyte 
selection-associated high mobility group box protein TOX (TOX) expression in 
CLP125 and then, later in the development, it promotes the expression of ID2. ID2 
is a member of the basic helix-loop-helix family with the role of inhibiting the 
transcription activity of E proteins131, in particular, E2A132, thus promoting NK 
cells maturation, LTi development and ILC3 stability133. Progenitors downstream 
of CLP, aLP and EILP, do not express any ILC lineage-defining transcription 
factors (GATA3, EOMES, T-BET or ROR-gt) yet, they express Nfil3 and Id2, 
although ID2 is not yet required for their development125,128,129. Unlike CLPs, 
aLPs express a4b7, CXCR6, PD-1128,134 and cease expressing FLT3135. Single-
cell RNA sequencing of a4b7+ve progenitors demonstrated that CLP can develop 
into aLP1 and aLP2, which may recapitulate two different stages of 
development from CLP to CHILP. aLP1 still retain the potential to develop into 
T or B cells, express TOX and FLT3 and, at a lower level, ID2. aLP2s do not 
express FLT3 and have ID2 down-regulated and could be a more refined ILC 
progenitor135. Among aLPs, aLP2 Thy1.2-ve are Id2low, Tox and Tcf7-ve and 
generate mainly ILC1s and ILC3s (see Figure 7). aLP2 Thy1.2+ve cells express 
Gata3, Nfil3 and Bcl11b and preferentially give rise to ILC2 (see Figure 5). 
Finally, aLP2 cells enriched in Rorc, Cxcr6, Il18r1, Tbx21 and Eomes +ve are 
biased toward ILC3 and may also differentiate into ILC1135 (see Figure 7). Other 
ILC-committed progenitors are EILP, which express Transcription factor 7 
(TCF-1) and are functionally similar to aLP. Studies on TCF-1 have shown the 
importance of this transcription factor early in the development of ILCs, 
upstream to the CHILP and the NK precursor (NKp). In fact, Tcf7-/- mice have a 
marked reduction in ILCs, as well as in NKp and CHILP. Yang et al. have 
identified EILPs from Tcf7GFP reporter mouse. All ILCs can develop from these 
progenitors, which do not express CD127129. Identification of EILP has shown 
the importance of TCF-1 in ILC development but has also suggested that ILCs 
can follow either an IL-7-dependent or alternative developmental pathways. The 
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relationship between EILP and αLP is yet not fully characterized: these two 
progenitors functionally overlap but it is not clear whether one is the progenitor 
of the other or if they contribute to different paths of ILC development.  
 
Figure 4 Stages of ILC development and transcriptional regulation of ILC 
progenitors. 
From the CHILP more lineage-restricted precursors can develop to then generate 
ILC1, ILC2 or ILC3 (except LTi and NK cells)68. ILC2 precursors (ILC2p) have 
been identified with the expression of ILC2 lineage determinants transcription 
factors such as GATA-318, RORa19 and Arg-1120 and extracellular markers PD-
1128,134, α4β7, CD127, Sca-1 and CD2518. ILC2s can develop in vitro from these 
precursors in the presence of NOTCH136 and c-Kit ligands, IL-7, IL-2 and IL-
3318,19,68,123. The maintenance of ILC2 phenotype involves GATA-3, GFI1 and 
BCL11B (as described in section1.1.1) and is induced by NOTCH signalling136, 
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the expression of TCF-1137, Protein C-ets-1 (ETS1)138 and RORa19,20,135,138 The 
NOTCH pathway does not alter the capacity of lymphoid precursors to 
differentiate into ILCs, but it affects aLP2 proliferation. In particular, it affects 
the aLP2 subset expressing Het1 and committed to the ILC2 lineage135. NOTCH 
signalling can induce TCF-1 early in ILC development129,135,137,139. Tcf7-/-mice 
fail to induce type-2 immune responses. Induced expression of TCF-1 in ILC 
hematopoietic progenitors can bypass NOTCH signalling in the generation of 
ILC2s129,137. However, NOTCH is not required when ILCs derive from EILP 
where TCF-1 is already expressed129. Furthermore, TCF-1 is not required for 
ILC2s survival. Although its forced expression in ILC progenitors induces 
expression of Gata3 and Il7r137. ETS1 is required in ILC2p development from 
the bone marrow and mesenteric lymph node. In fact, Ets1-/- mice have a 
substantial reduction in ILC2s in the bone marrow and lymphnodes140. The 
expression of this transcription factor promotes the right expression of ID2140. 
Lung ILC2s do not require ETS1 for their development but Ets1-/- lung ILC2 
cannot expand and are not functional138 (Figure 5 shows the transcriptional steps 
of ILC2 development).  
 
Figure 5 ILC2 development from the aLP2 (II) to ILC2s 
Summary and schematic representation of the transcriptional changes regulating the development of 
ILC2s (described in the text). Seillet et al., described a transcriptionally different aLP2s with the potential 
to differentiate into ILC2128. 
The developmental pathways that lead from NKp to mature NK cell are well 
described from both the bone marrow141 and the tymus66,142. Both NK cells and 
ILC1s express CD122 (the β-chain of the receptor for IL-15 and IL-2)143 and for 
NK cells the expression of CD122 at the progenitor level represents an essential 
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step for its further development, proliferation and survival141. IL-15 or IL-15 
signalling deficiency in mouse models is characterised by reduced NK cell 
development. On the other hand, IL-15 over-expression has increased NK cell 
numbers 144–146. CD122 is the beta chain shared by IL-2 and IL-15 receptors, and 
it forms the IL-15 receptor in combination with CD132 (the common gamma 
chain) and CD215 (high-affinity alpha chain)141. The further described 
developmental stage of NK cells after CLP is pre-NKp. This population has been 
identified in the bone marrow by two parallel studies147,148 and it has been 
characterised as Lin−ve CD27+ve 2B4+ve c-Kitlo CD127+ve CD122−ve NK1.1−ve 
NKG2D+ve FLT3-ve and ID2low. These works also refined the phenotype of early 
NKps which differ from their precursors because they acquire CD122 
expression147,148 and express high levels of ID2147. However recent studies have 
raised the possibility that the population defined in 2011 as pre-NKp can be 
contaminated with progenitors related to ILC1s. Similarly, the NKp potential 
towards ILCs is still currently unexplored121. At this stage, the transcriptional 
regulation of these progenitors is similar to the CHILP, NFIL-3 and TOX 
regulate ID2, ID2 then inhibit E proteins and EOMES expression124,130,149,150. 
However, in these progenitors, PLZF expression is not induced68.  
NKps go through an immature stage (iNK) before becoming mature NK 
(mNK)121,141. Constantidines et al. studied iNK cell, among which ~80% have 
been wrongly assigned to the NK linage, being instead ILC1s.123 iNKs cells 
express NK1.1, NKG2D and NKp46141, and unlike ILC1s, they do not express 
a4b7, CD49a, and CD12769. Additionally, expression of mouse Ly49 receptors 
(which are the functional homologues of KIR in human) begins at the iNKs 
stage. Ly49 are critical for NK cell missing-self recognition, education and for 
the detection of invading pathogens and viruses143,151. Transcriptionally, ILC1 
and NK cells have different requirement for T-BET and EOMES (as described in 
1.1.2). T-BET is absolutely required for the generation of ILC1 and the 
production of effector cytokines, and although T-BET also promotes CD122 
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expression152, it is not required for cNK cells69. In particular, the timing of T-
BET expression determines the fate towards NK or ILC1s. Daussy et al. 
identified different transcription factors dependency for NK and ILC1: they 
identified that T-BET expression is low in developing NK cells and that 
increased T-BET expression reduces EOMES expression69. This suggests that 
EOMES is repressed in ILC1 thanks to high expression of T-BET. It follows 
that, potentially, expression of T-BET should be limited for NK cells to develop. 
Similarly to bone marrow-derived NK cells, thymic NK cells development 
depends on NFIL-3 and EOMES, but it doesn’t require T-BET63. Indeed, NK 
cells develop in Tbx21-/- mice66,153. Thymic NK cells require also GATA-3 and 
develop independently of ID266,153. 
Later in the development, EOMES and T-BET are both required for NK cells 
maturation, so that mature NK cells (mNK) can acquire their effector 
functions154. T-BET induces expression of the transcription factor ZEB2 to 
induce NK cells terminal maturation155. Maturation process from iNK cells can 
be detected by the expression of all functional NK receptors, including Ly49s141. 
The first step of maturation is characterised by the expression of the co-
stimulatory receptor CD27. CD27+ve cells produce cytokines although they are 
not cytotoxic yet121,141. Subsequently, mNK cells express CD11b. CD27-ve 
CD11b+ve cells acquire full cytotoxic capacity121,141. Furthermore, although ID2 
expression is induced already in NKps, ID2 expression keeps increasing during 
maturation. Studies in Id2-/- mice showed that ID2 starts to be required only in 
mNK133,156and it is required for IL-15 dependent survival of mNK cells156. 
However, the increase of ID2 expression in mNK cells is unlikely to be 
dependent on NFIL-3. Indeed, conditional deletion of NFIL-3 in immature NK 
cells has shown that NFIL-3 is no longer required during NK cell maturation157. 
Therefore, induction of ID2 expression is probably not always regulated by 
NFIL-3 and this can explain why some ILCs and some NK cells can develop 
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independently of this transcription factor48,56,76. Figure 6 summarises NK cells 
development. 
 
Figure 6 Transcriptional regulations leading to the development of NK cells 
This picture summarise the main transcriptional steps required for cNK cells development. Main 
difference with ILCs development is that NK cells do not require the expression of PLZF on their early 
progenitors. Inspired and modified from Zook et al.121 
ILC3s need ROR-gt for lineage specification and development. Early expression 
of this transcription factor directs the development towards the ILC3 lineage. 
Early ILC3 precursors (ILC3p) express several factors important for ILC3 
development and stability, such as AhR, IL-1R, IL-23R and TOX65,98,111,158. The 
factors driving ROR-gt expression in progenitors are not fully understood, but the 
subsequent expression of ID2 and NOTCH signalling are known to drive the 
development of LTi and ILC3159. Similarly to all ILCs, TOX is another important 
factor that needs to be expressed early in the development, however, NCR+ve 
ILC3s can develop independently from TOX150. During embryogenesis ROR-gt 
expression is induced by retinoic acid102. Van de Pevert et al. demonstrated that 
vitamin A rich diet in pregnant females is critical for the development of LTi 
cells in the progeny and consequently also Peyer’s patches formation102. ROR-gt 
regulates multiple genes involved in mature ILC3 function  (Il17a and Il22), but 
it also promotes the expression of AhR30,102. Ahr-/- mice lack crypto patches 
suggesting the need for AhR in the development of LTi. However, CCR6-ILC3s 
in Ahr-/- mice fail to control Citobacter Rodentium infections, thus suggesting the 
importance of this receptor for the function of mature ILCs 65,160. Another 
regulator of Rorc locus is Runx3 and in KO mouse models it has been shown to 
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be essential in the formation of secondary lymphoid organs161. Runx3 act on the 
expression of its partner Cbfb and its early deletion blocks the development of 
ILC1s and ILC3s but not ILC2s.162. ILC2-linage-defining transcription factor 
GATA-3 is also important for the correct development of ILC3163. Yagi et al. 
identified that conditional ablation of GATA-3 from hematopoietic stem cells 
affects all ILCs16 but in particular ILC3163. This transcription factor has a role in 
mature ILC3 too, although its expression is low. Indeed, GATA-3 maintains and 
promotes CD127 expression and controls the plasticity of ILC3 towards ILC1121. 
Finally, ILC3s, similarly to NK cells, require ID2 expression even once mature. 
ID2 affects early resistance to colonization by C. Rodentium through a pathway 
involving AhR and IL-23R (the expression of which is Rorc dependent)164. This 
study suggests that ROR-gt, AhR, and ID2 cooperatively control the function of 
mature ILC3s164. 
 
Figure 7 Transcriptional regulation of ILC1 and ILC3 development 
Schematic representation of the transcriptional changes that regulate the development of non-NK ILC1s 
and ILC3s. Seillet et al., described transcriptionally different aLP2s which both have the potential do 
differentiate into ILC1 and ILC3s128. This picture summarise the main transcriptional steps required for 
ILC1 and ILC3 differentiation. 
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1.3 Function of ILCs in tissue homeostasis and plasticity 
ILCs are an important component of the immune response to a wide range of 
pathogens, particularly at epithelial barrier surfaces. Despite many similarities 
with T helper cells, ILCs do not depend on antigen-dependent activation but 
respond to endogenous cell-derived factors including neuropeptides, hormones, 
eicosanoids, cytokines and alarmins to regulate the activation of other immune 
cells1. ILCs can be activated in both pathogenic and homeostatic conditions. 
1.3.1 ILCs protect towards infections  
As described in 1.2 the recruitment of ILCs to barrier tissues takes place during 
embryonic development and further migration occurs during inflammation119,120. 
The main role of ILCs in a pathogenic setting is to expel extracellular helminths 
and to protect against viral and bacterial infections10,1. Cytokines produced by 
epithelial cells and myeloid cells after infections or tissue damage, promote ILCs 
activation and plasticity1,8. IL-12, IL-15 and IL-18 activate NK cells and 
ILC1s68,77, whereas IL-224,25, IL-4165, IL-25, IL-33 13,166, TSLP44, IL-9167, 
prostaglandin D2,38 leukotriene D4 168and TL1A169 activate ILC2s. By contrast, 
IL-1β and IL-23 stimulate ILC3 responses8. 
 
Figure 8 Cytokine production by activated ILCs. 
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Different cytokines can induce ILCs activation. NK cells are characterised by the expression of EOMES 
and all ILC1 by T-BET. When activated by IL-12, IL-15 and/or IL-18 they produce type-1 cytokines 
(IFN-g, TNF-a, IL-2). Non-NK ILCs can also produce granzymes and perforin and CD127-ve epithelial 
ILC1s and trNK cells can additionally express TRAIL. IL-33, IL-25, TSLP and IL-2 activate ILC2s to 
produce IL-5 and IL-13. However high doses of IL-25 promote ILC2 plasticity and it induces 
inflammatory ILC2s. ILC3s are activated by IL-1b, IL-23 and IL-7 to produce IL-22, and IL-17. 
ILC1s and ILC3s promote innate immunity in response to viruses, intracellular 
bacteria and parasites, as well as fungi. Among ILC1s NK cells have a well-
established role in killing virus-infected cells and tumour cells through 
granzymes and perforin-mediated cytolysis. However other mechanisms of cell 
killing (i.e. FASL and TRAIL) have been characterised45,170. Cells recognition is 
mediated by NK cells activating or inhibitory receptors; viral hemagglutinin is 
recognized via NKp46, CD16 recognizes the Fc portion of immunoglobulin G 
IgG (IgG) to eliminate specific targets via antibody dependent cell-mediated 
cytotoxicity (ADCC), NKG2D recognizes stress-induced ligands and 
CD94/NKG2 receptors and Ly49s (or KIR in human) recognize MHC I 
molecules45,170–172. The recognition of infected cells with activating receptors 
needs to be coupled with the recognition of self-antigens. NK cells need to be 
“educated” to respond more powerfully towards aberrant MHC I expression (i.e. 
absence of self-MHC class I or presence of allogeneic MHC class I ligands)173. 
Additionally, similarly to non-NK ILC1s, NK cells can be activated by 
cytokines, such as type I IFNs, IL-15, IL-12, IL-18174, IL-2 and IL1045,170,175 
which induce the release of IFN-g and TNF-a46. IFN-g expression has diverse 
effects on the microenvironment: it promotes T helper 1 (Th1) differentiation, 
M1 polarisation of Mac and upregulation of MHC I and MHC II molecules176. 
Overall IFN-g potentiates the antimicrobial, antiviral, and anti-tumour immunity 
of NK cells. During pregnancy, it promotes vascular remodelling (this will be 
cover in chapter 1.4.5). In a similar fashion, IFN-γ-producing ILC1s contribute to 
the resistance to Salmonella Enterica and Toxoplasma Gondii infection in the 
intestine65,68. Klose et al. demonstrated that some T-BET-dependent ILC1s could 
derive from ROR-gt ILC3s, which makes it difficult to discriminate the relative 
importance of ILC1s or ex-ILC3s in this context. Both ILC3s and ILC2s have 
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shown plasticity towards ILC1s in inflammatory conditions, thus implicating not 
only ILC1s but also ex-ILC2s and ex-ILC3s in many ILC1 dependent 
pathologies. 
In the intestine, ILC3s induce early responses against C. Rodentium by producing 
IL-22. This cytokine activates epithelial and stem cells in the intestine and 
triggers the secretion of antimicrobial peptides (RegIIb, RegIIg, S108a, S109a) to 
fight the infection. Additionally, IL-22 stimulates cell proliferation and 
fucosylation of epithelial cells to prevent tissue damage and promote tissue 
remodelling1,8,103. Indeed, Il22-/- mice have excessive intestinal inflammation and 
damaged epithelial barrier 1,177. However, since T cells also produce IL-22, 
redundant functions of ILC3s and Th17 cells have been debated in this model. In 
this context, Dendritic Cells (DCs)178 or CX3CR1+ve phagocytes179 provide IL-23 
to activate ILC3s, but not T cells. Il23a-/- mice are indeed more susceptible to the 
infection than WT mice8. Furthermore, specific depletion of NCR+ve ILC3s has 
confirmed the importance of this cell population to fight the infection before T 
cells activation180. However, depletion of NCR+ve ILC3s in different T-cell 
deficient mouse models has shown contrasting results, thus further complicating 
this model8.  
ILC2-dependent type-2 immunity is required for the expulsion of extracellular 
helminths parasites. As mentioned in chapter 1.1.1 ILC2s can be activated by 
different cytokines that modulate their function in both pathological and 
homeostatic conditions. ILC2 activators TSLP, IL-33, and IL-25 are usually co-
expressed in epithelial cells and have multiple distinct cellular targets in vivo, 
including effects on mast cells, basophils, eosinophils (Eo), dendritic cells (DCs), 
macrophages (Mac), and T cells181–188. However, this triad of epithelial cell–
derived cytokines also exhibits a high degree of cross-regulation. TSLP can 
synergize with IL-33, resulting in greater cytokine production from ILC2s20,29. 
IL-25 have similar effects, and in combination with IL-33, it potentiates IL-13 
production13,166,188. IL-25 however, is known to have higher stimulatory and 
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proliferative effect on Multipotent progenitors type-2 (MPPtype-2) cells rather than 
ILC2s188. Instead, high doses of IL-25 induce the expression of ILC3 genes and 
the development of inflammatory ILC2s (iILC2s)35,36(ILC plasticity will be 
described in chapter 1.3.3). Consistent with this, IL-33 is more potent alone than 
IL-25 in promoting type-2 cytokine–dependent inflammation in vivo39,188. IL-33 
is a member of the IL-1 family and is expressed in a variety of cells including 
fibroblasts, epithelial cells, endothelial cells, and adipocytes. Full-length IL-33 is 
released from cells upon necrotic cell death and stimulates ILC2s, but also B 
cells, DCs and T regulatory cells (Treg)34,189. Full-length IL-33 is active, but it 
can be cleaved to other active forms by mast cells proteases, which cleave the IL-
33 central domain in vivo185. While proteases promote the availability of active 
IL-33 caspase 1 in vitro189 or apoptosis inactivate IL-33. In human studies ILC2 
activation is mediated also by Prostaglandin D2 produced by mast cells43. 
Prostaglandin D2 activates CRTH2 on human ILC2s and promotes typical ILC2 
cytokine production but also production of IL-4, IL-3, IL-8, IL-9, IL-21, 
Granulocyte macrophage colony-stimulating factor (GM-CSF) and colony-
stimulating factor 1 (CSF-1)43,190. Additionally, Prostaglandin D2 potentiates the 
response to IL-33 and IL-25 because it increases the expression of ST2 and IL-
17A38,43,190. Once activated, ILC2s (as mentioned in chapter 1.1.1) produce IL-13 
to promote smooth muscle contractility that promote parasite expulsion, IL-5 and 
IL-4 which activate Eo and Mac, IL-2 and IL-9 which further enhance the 
response191. In particular ILC2s have been shown to be the main source of IL-13 
in the context of Nippostrongylus Brasiliensis infections13,14. Indeed ILC2 
deficient mice fail to expel the parasites and adoptive transfer of ILC2 can 
efficiently restore worm expulsion13,14. ILC2s have been shown to promote direct 
and indirect development of type-2 adaptive immune responses. Oliphant et al. 
identified MHC class II expression on lung ILC2s, which can activate directly T 
cells. Moreover by producing IL-2, ILC2s can promote Th2 cytokines production 
and ILC2 proliferation as autocrine effect32. An indirect role of ILC2-mediated T 
cell activation has been shown by Halim et al. who demonstrated that lung ILC2s 
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affect DCs migration to the draining lymph node via IL-13192. Furthermore, this 
process is able to promote the development of T cell memory response which 
confers additional protection towards the infection193. Additional evidence shows 
that ILC2s contribute to the expulsion of Trichuris Muris194 and Strongyloides 
Venezuelensis195. 
1.3.2 Function of ILCs in tissue repair and immune homeostasis  
Other than protection towards infections, ILCs also promote tissue remodelling40 
and contribute to tissue and metabolic homeostasis.	 For example, ILC2s are 
involved in insulin resistance, adipocyte differentiation and promote tissue repair 
after a lung infection. Another example is provided by ILC3s that interact with 
the microbiota and prevent excessive inflammation in the intestine4,8.  
Among ILC3s, CXCR6+ve LTi cells have been studied for more than a decade for 
their role in embryogenesis, where they promote the formation of secondary 
lymphoid organs (the Peyer’s patches) in the gut196. LTi cells bind LTbR on 
stromal cells because they express LTa1b2. This results in secretion of 
chemokines together with upregulation of adhesion molecules with the ultimate 
goal of attracting leukocytes and forming the lymphoid structure197,198. 
Additionally, the interaction of LTa1b2 on LTi with LTbR is important also in 
the adult to fight infections, where it amplifies the release of ILC3 activator IL-
23 by DCs8. In the adult gut, ILC3s have the additional role to maintain the 
integrity of the mucosal barrier. Firstly, ILC3s prevent excessive inflammation of 
the gut. This has been demonstrated in the context of C. Rodentium, Crohn’s 
disease and in inflammatory bowel disease (IBD)8,199. Patients with IBD and 
Crohn’s disease have altered numbers of ILC3s and MHC II+ve ILC3s mediate 
cell death of pathogenic T cells to limit inflammation200. Secondly, ILC3s play 
an important role in the interaction with the microbiota. LTi cells develop 
without the need of microbiota, but the development of crypto patches require 
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environmental signals such as bacteria-derived peptidoglycans and AhR ligands 
(which can also derive from diet)201,202. Intestinal ILC3s collaborate with the 
adaptive immune system to promote microbiome homeostasis and 
conteinment203. On the one hand, ILC3s express MHC II (as mentioned, this 
process limits inflammation) to limit commensal-specific T-cells process and to 
induce tolerance towards the microbiota200. On the other, ILC3s express LTa3 to 
promote IgA production by plasmacells197. Additionally, for the correct 
regulation of ILC3s, the microbiota triggers ILC3s with the right signals to 
produce IL-22 and then promote Fut2 expression and endothelial cells 
fucosylation to protect against Candida Albicans and Salmonella 
Typhimurium204.  
ILCs have been involved in tissue repairing of damaged tissues other than in the 
intestine. LTi cells interact with stromal cells in secondary lymphoid organs to 
promote the restoration of damaged lymphoid tissue following acute viral 
infetion205. IL-22 produced by ILC3s stimulates endothelial cells proliferation 
after C. Rodentium infection or irradiation1,8,103. In the lung and skin, ILC2s 
promote the regeneration of the epithelium by releasing Areg after influenza 
infection40 or wound healing206. However, Areg can be produced by multiple cell 
types following a different way of stimulation: IL-33 stimulation induce Areg 
expression in ILC2s40; IL-33, Prostaglandin E2, Insulin-like growth factor 1 
(IGF-1), Transforming growth factor beta (TGF-b), TCR stimulation enhance 
Areg expression in Tregs34,194,207. In particular, Tregs expression of Areg is 
induced by viral infection208 and potentiates Tregs immunosuppressive 
functions207. This suggests that ILC2s may collaborate with Tregs to promote 
tissue regeneration and immune suppression after tissue damage or infection. 
ILCs contribute to metabolic homeostasis in the adipose tissue and they may 
respond to nutrients and metabolic stress. In two subsequent studies, Molofsky et 
al. described the role of visceral adipose tissue ILC2s in the maintenance of 
homeostasis by promoting Eo, alternatively activated Mac and Tregs34,209. IL-33 
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is essential for the maintenance of this adipose cellular architecture and 
homeostasis, and it is counterbalanced by IFN-g, which instead, promotes 
activation of M1 Mac, increases inflammatory T cells and is associated with the 
development of type-2 diabetes and obesity34,74,210. Indeed, expansion of IL-33 
induced ILC2s has beneficial metabolic effects. It reduces adiposity and 
promotes beiging of white adipose tissue34,209,211,212. More in detail, IL-33 
activated ILC2s contribute to type-2 immunity homeostasis by promoting Eo 
expansion and localisation in the vascular adipose tissue via IL-5. Then Eo 
produce IL-4 that induces alternative activation of adipose tissue Mac209. 
Additionally, ILC2-intrinsic IL-33 signalling and ICOS-L expression promote 
Treg cell accumulation in the adipose tissue to further sustain Mac alternative 
activation34. The establishment of this mechanism, on the one hand, promotes 
M2 Mac that produce epinephrine and catecholamines to further regulate energy 
expenditure by adipocytes213,214. On the other, ILC2s have also a direct role in 
regulating adiposity. It has been proposed that ILC2-activated Eo regulate 
PDGFRa adipocyte precursors and promote their differentiation into beige 
adipocytes215. Then, Eo independent mechanisms have been described, where 
ILC2s promote beiging by producing proencephalin A that acts directly on 
adipocytes differentiation 211. In this tissue also group 1 ILCs contribute to 
adipose tissue homeostasis by directly killing Mac expressing stress ligand Rae-
1210. In this context, adipose tissue homeostasis needs to be quickly regulated and 
balanced by ILC1s and ILC2s to prevent aberrant pro-inflammatory immune 
responses that will promote metabolic disorders and tissue damage. In obesity, 
the immune response is unbalanced towards type-1 and it is associated with the 
expansion of ILC1s, expression of IFNg, activation of M1 Mac, increase in stress 
signals and the increase of ILC1-mediated killing of M2 Mac over M174,210.  
Overall, ILCs collaborate with stromal cells, the microbiota and endothelial cells 
to maintain the mucosal barrier. They can act quickly by sensing nutrients, stress 
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signals and immune system perturbations to balance the immune 
microenvironment and to further contribute to tissue homeostasis. 
1.3.3 Pathological activation and plasticity of ILCs 
Since ILCs have such a central role in the maintenance of tissue and immune 
homeostasis, as well as protecting against pathogens and excessive inflammation, 
their responses require quick activation and inhibition. The cross-regulatory and 
inhibitory pathways that control ILCs responses are not yet fully defined, but the 
main inhibitory pathways known include competition for cytokines and survival 
factors. For example, ILC2s compete with ILC1s: ILC2s are inhibited by type I 
and II interferons and IL-27. Indeed, airway inflammation can be reduced by 
administration of these cytokines34,216,217. ILC3s compete with ILC2: ILC2-
promoting cytokines (IL-25 and TSLP) can suppress ILC3s and IL-22 
secretion8,99. In homeostatic conditions, epithelial cells produce IL-25 under the 
regulation of the microbiota and this acts on DCs. Indeed, administration of IL-
25 can be detrimental in colitis, where IL-22 is essential to reduce inflammation 
and promote tissue remodelling8. Additionally, also retinoic acid (or vitamin A) 
levels can favour ILC3s rather than ILC2s. ILC2s and ILC3s respond to changes 
in nutrient status. Retinoic acid favour ILC3s responses and suppress ILC2s, 
while retinoic acid deficiency promotes ILC2s ability to control helminths but it 
also increases the susceptibility to C. Rodentium1. Finally, T cells (in particular 
Tregs) compete with ILCs. Firstly, T cells compete for IL-2. Indeed, IL-2 
induces NK cells and ILC2s proliferation, and these events are favoured when T 
cells are depleted. Secondly, in allergic inflammation models, maresin and 
lipoxin are produced to resolve the inflammation. Maresin promotes Tregs 
expansion, which limits ILC2s responses, while lipoxin A reduces IL-13 
secretion directly on ILC2s1,177,218. 
When ILCs regulatory checkpoints are not effective, ILCs ability to powerfully 
produce cytokines and change the immune microenvironment can be detrimental. 
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For instance, when ILCs enhance pathological inflammation at mucosal and 
barrier surfaces, they can promote carcinogenesis219,220 and increase chronic 
inflammation8. In the adipose tissue, as mentioned in chapter1.3.2 ILC1s can 
play roles in obesity, when this population expands in high-fat diet mice via an 
IL-12- and STAT4-dependent pathway. Expansion of visceral adipose tissue 
ILC1s also increases IFNg expression and promotes pro-inflammatory Mac 
polarisation with the production of pro-inflammatory cytokines IL-6 and TNF-
a74. This change of microenvironment promotes weight gain, metabolic disorders 
and insulin sensitisation. 
Alteration of tissue remodelling can also promote cell proliferation and fibrosis. 
Group 1 ILCs and NK cells represent the ILC subset that shows protective role 
against tumours. They can release IFNg when activated, which is directly 
involved in the anti-tumour immune response, as well as direct cell killing via 
ADCC, TRAIL and FAS-ligand221. However, mouse and human studies have 
also reported that treatment of melanoma cells with IFNg can induce 
characteristics of tumour aggressiveness associated with increased 
metastatisation and recruitment of suppressor myeloid cells in the tumour 
microenvironment219. Additionally, other studies showed that IFN-g can induce 
the release of indoleamine 2,3-dioxygenase (IDO) by both tumour cells and 
dendritic cells, thus interfering with T cell proliferation and favouring the 
development of Tregs219. Therefore, ILCs may have opposite roles in cancer, 
participating both in immune surveillance and in tumour growth. Other than IFN-
g, producing ILC1-like cells, other cells have been recently described in mouse 
and human cell cancer models. In mouse, tumour associated ILC1-like cells have 
been involved in immune surveillance of oncogene-induced prostate and breast 
cancer models and they share similar characteristics with salivary gland ILC1s. 
In humans, tumour associated ILCs have been described in ovarian cancer, where 
they have a mixed gene expression profile that overlaps among ILC1s, ILC2s 
and ILC3s and they promote the induction of tumour T cell tolerance. ILC3s 
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have been described as well for their anti-cancer and cancer-promoting activity. 
However, very little is known about ILC2s in this context8,219 although, M2 
polarisation and IL-33 have been implicated in high metastatisation and poor 
prognosis in breast cancer and colorectal cancer219,222,223. ILC3s have been 
implicated in tumour rejection, where intra-tumoral injections of ILC3s can 
inhibit tumour growth224. However, the beneficial effects of IL-22 on epithelial 
tissue repairing could also promote carcinoma progression during chronic 
inflammation of epithelial tissues, including mucosae8. The release of bioactive 
IL-22 is regulated by DCs activation. IL-22 binds to its decoy receptor at steady 
state on immature DCs, but during chronic inflammation and DC activation IL-
22 decoy receptor expression is down-regulated. Additionally, activated DCs 
increase their release of IL-1β and IL-23, thus increasing IL-22 production219,225. 
Pathological immune responses of ILC2s have been described in the context of 
allergy, dermatitis and tissue fibrosis. ILC2s are essential in the establishment of 
type-2 immune responses via recruitment and activation of both innate and 
adaptive leukocytes: Eo and Th2 T cells, alternatively activated Mac and 
DCs85,209,226–228. In particular, studies on IL-5 reporter mice showed the essential 
role of ILC2s in producing the IL-5 needed by Eo for their proliferation in 
homeostatic conditions226,229. Il5rc-/- and Il5-/- mouse models showed that Eo 
require survival signals from IL-5. Without IL-5 residual Eo proliferate via IL-3 
or GM-CSF and eotaxins that sequester these cells into tissues229–233. Eo have 
been shown to help ILC2s in tissue remodelling and amplify type-2 immune 
responses by promoting T cells recruitment and alternative activation of Mac and 
DCs through IL-4213,229–233. The polarisation of the type-2 immune response is 
indeed critically dependent on IL-4, although Th2 cytokines are known for their 
redundancy and also IL-13 and IL-5 can compensate when IL-4 is absent 228,234. 
While this regulatory mechanism is important in homeostasis and it needs to be 
amplified to expel parasitic worms (chapter1.3.2 and 1.3.1), it becomes 
detrimental to allergic reactions. In this context, over-activation of Eo and the 
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excessive type-2 immune response induce IgE switching, the release of 
histamine, mucus production, and smooth muscle cell contraction10,235,236. ILC2s 
expand in the inflamed lung in response to cytokines and alarmins (see chapter 
1.3.1), eicosanoids and TL1A produced by type-2 pneumocytes, alveolar Mac 
and granulocytes177,237. Other than IL-5, ILC2s produce IL-13 to further 
coordinate DC activation of CD4+ve T cells at mucosal tissues192. The role of 
ILC2s in allergic patients is not yet established, however, IL-25 and IL-33 are 
increased in asthmatic patients. Moreover, ILC2s are increased in the peripheral 
blood of people with asthma 216,238,239. A similar increase of ILC2s can be 
identified in chronic rhinosinusitis, which is characterized also by eosinophilia 
and high levels of IgE in serum29,37. In this pathology, TSLP and IL-33 produced 
by epithelial cells of resected nasal polyps promote ILC2s activity and cytokine 
production. 
Another prominent type-2 disease is atopic dermatitis, where TSLP44, IL-25, IL-
33, and basophil-derived IL-4 165stimulates ILC2s to promote inflammation31. 
Skin inflamed ILC2s express KLRG1, which may have a regulatory role in the 
control of ILC2 activation during atopic dermatitis. In homeostasis, KLRG1 
ligand E-cadherin down regulates ILC2s cytokine production, but in atopic 
dermatitis lesions, this ligand is down-regulated, thus taking off the brakes to 
ILC2s. This suggests that in this pathology there is a defect in the 
downregulation of ILC2s immune response in the skin31.  
The potential of ILCs plasticity and to trans-differentiate into each other has been 
demonstrated in chronic inflammatory disorders (See Figure 9). The cytokine 
microenvironment can indeed change ILCs cytokine production and induce T-
BET upregulation with downregulation of GATA-3 and ROR-gt 46.  
Uterine group 2 innate lymphoid cells and reproduction 
38  Elisa Balmas - January 2018 
 
Figure 9 ILCs plasticity 
ILCs can trans differentiate into each other according to the environmental stimuli that they receive. 
Inflammatory microenvironment (i.e. Viral infection) can induce both ILC2s and ILC3s to trans-
differentiate into ILC1s. IL-4 can revert ex-ILC2 to trans-differentiate back to ILC2s. IL-7, IL-1b, AhR 
ligands and retinoic acid can revert ex-ILC3 into ILC3s. Finally, ILC2 Trans-differentiate into iILC2 or 
ILC3 when stimulated with high level of IL-25 or NOTCH signalling.  
The first example of ILC plasticity involved ILC1 and ILC3. Accumulating 
evidence showed first heterogeneous cytokine secretion by ILC3s116,240. Later, 
ROR-gt reporter mouse models showed the importance of IL-7 to keep the ILC3s 
identity, while IL-12 and IL-15 induced downregulation of ROR-gt and 
upregulation of T-BET in ILC3s65. Through this process, intra-epithelial ILC1s 
and IFN-g-producing ex-ILC3s induce inflammation in colitis65,77,84,241 Crohn's 
disease77,91. The mechanisms of ILC3s plasticity in human are similar to mouse 
ILC3s. Indeed, in vitro exposure of human ILC3s to IL-12 downregulates ROR-
gt and up-regulates T-BET and IFN-γ production, which is enhanced in the 
presence of IL-18 and IL-1b 84,91. Recently, also ILC2s have been shown to 
transdifferentiate into ILC1s and ILC3s. IL-25 and NOTCH signalling promote 
plasticity of ILC2s into ILC3s by increasing ILC2s responsiveness to IL-25 and 
cytokine production 35,136. In diseases such as chronic obstructive pulmonary 
disease (COPD), IFN-γ-secreting ILC1s accumulate to further promote tissue 
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damage and disease progression. Increased frequency of ILC1s inversely 
correlates with the reduction of ILC2s in this pathology and in this context these 
ILC1s may be ex-ILC288,90. Influenza viral challenge and tissue damage promote 
a type-1 immune microenvironment and inflammation (rich in IL-1b, IL-33, IL-
12, IL-18), which makes ILC2s transdifferenciate86,88,90. Akey factor for ILC2 
plasticity is IL-12, to which ILC2s respond by down regulating their expression 
of GATA-3 and up-regulating their expression of T-BET and acquisition of 
transcriptional accessibility to Ifng locus86,88. Paradoxically endothelial cell 
damage and release of alarmins IL-33 and TSLP increase ILC2s responsiveness 
toward inflammatory signals by up-regulating the IL-12 and IL-18 receptors and 
down regulating ST290. Additionally, strong IL-1β signalling triggers IL-12 
receptor upregulation and ILC1 trans-differentiation, whereas low-dose IL-1β 
signalling favours responsiveness to type-2 cytokines in mouse ILC2s86. 
Transdifferentiation is reversible. For example, both human and mouse ILC1s 
revert to ILC3s in the presence of DC-derived IL-1β and IL-2384, a process 
accelerated by retinoic acid84, whereas ILC1s ex-ILC2 revert to ILC2s in the 
presence of IL-490. It is not yet clear which myeloid cell type produce the IL-4 
required for ILC2s to ILC1 differentiation, although Eo are plausible 
candidates46,90.  
In conclusion of this section, ILCs have been demonstrated to be central in the 
development of physiological and pathological type-1, type-2 and type-17 
immune responses. ILCs are needed to fight infections and they are important in 
tissue remodelling and homeostasis. However, when they are overactivated they 
can be pathogenic by amplifying type-1 and type-2 inflammatory disorders or by 
promoting proliferation of cancer cells.   
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1.4 Immunology of pregnancy 
1.4.1 Murine pregnancy 
Mouse pregnancy is a process that takes ~19-20 days from conception to 
delivery. The fertilised egg develops into the blastocyst before implantation in 
the maternal endometrium. The endometrium of the adult mouse uterus consists 
of a simple columnar luminal epithelium surrounded by stromal cells containing 
glandular epithelial cells242. This tissue typically contains 10 to 20 glands, which 
are predominantly found in the anti-mesometrial region of the uterus242. The 
main role of uterine glands is to provide nutrients and growth factors to the 
developing embryo in a process called histiotrophic nutrition243–245. In this 
environment, the blastocyst develops into a structure of totipotent embryonic 
stem cells (the inner cell mass or ICM) surrounded by trophectoderm. At day 3.5, 
the blastocyst needs to hatch from the zona pellucida, a specialised glycoprotein 
matrix that protects the developing embryo, and the trophectoderm produces 
enzymes (strypsin and hepsin) for this purpose. At day 4.5 the blastocyst is ready 
to implant. Implantation involves trophectoderm apposition, attachment, 
adhesion to the luminal endothelium followed by penetration and growth of the 
trophectoderm into the decidualising stroma242,246. 
 
Figure 10 Embryo development up to implantation. 
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Embryonic development from conception to the formation of the blastocyst. Before implantation, uterine 
glands provide nutrients and growth factors to the developing embryo. At 3.5 the blastocyst is ready to 
hatch from the zona pellucida and trophendoderm guide this process by producing enzymes. At 4.5 the 
blastocyst is ready to implant. 
At the time of implantation, the embryo is composed of three lineages that are no 
longer interconvertible: the trophectoderm, the primitive endoderm, and epiblast. 
At this point, trophectoderm differentiates into further specialised trophoblast 
cells to invade the maternal tissue. Mural trophoblast giant cells are the first cell 
type to achieve terminal differentiation after implantation. They are initially 
differentiated from the mural trophectoderm and at midgestation (day 9.5-10.5) 
directly from the ectoplacental cone246. By day 5.5, the luminal epithelial cells at 
the implantation site, near the attached blastocyst, undergo apoptosis and are 
phagocyted by the invading trophoblast. This allows the trophoblast to come into 
contact with uterine stromal cells, which are differentiating into decidual cells. 
The implantation happens in the uterine anti-mesometrial region, opposite to the 
mesometrial region, where vessels and nerves reach the uterus and placentation 
starts. At both sites, decidualisation of the uterine stromal cells occurs and it is 
triggered by implantation. However, implantation-triggered decidualisation is 
typical of rodents, while in humans this is a cyclic process independent of 
pregnancy, but induced by progesterone. Human decidualisation initiates in the 
mid-secretory phase of the cycle around terminal spiral arteries of the superficial 
endometrial layer, and it progressively continues in pregnancy and ultimately 
involves the entire endometrium. This process is needed to develop the decidua, 
a new and specialized structure that develops in the pregnant uterus with the 
function of mediating feto-maternal interactions in both species and it is required 
for successful pregnancy and the formation of a functional placenta242,246. Here, 
(1) endometrial fibroblasts (uterine stromal cells) transdifferentiate into decidual 
cells; (2) endometrial extracellular matrix is remodelled; (3) many factors to 
regulate foetal and maternal interactions are produced; (4) new vessels are 
produced (angiogenesis) to establish the hemotrophic nutrition of the embryo; 
and finally (5) leukocytes infiltrate the uterine tissue246. Decidualisation of the 
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anti-mesometrial endometrium (decidua parietalis, Figure 11) gives support to 
conceptus development at the early stages of pregnancy through the 
choriovitelline placenta, whereas the mesometrial decidua (decidua basalis, 
Figure 11) contributes to the formation of the later and definitive chorioallantoic 
placenta. Until midgestation (days 8.5-9.5 of pregnancy), decidual cells 
proliferate and differentiate to sustain decidual growth and placentation starts 
(Figure 11).  
 
Figure 11 Decidua formation at midgestation 
After that, increased decidual cell death promotes a progressive thinning and 
involution of the anti-mesometrial decidua, until about day 12.5 when the 
placenta is formed. Mouse organogenesis (day 8.5–13.5) largely occurs during 
this period, while the embryo is nourished by the choriovitelline placenta, 
demonstrating the importance of this early placenta for the development of 
mouse embryos. Then at ~11.5, the definitive chorioallantoic placenta is 
sufficiently developed in structure and function to assume nourishment of the 
embryo. The development of definitive chorioallantoic placenta marks the 
transition from hemotrophic nutrition to placental nutrient exchange. Key process 
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is trophoblast invasion of the maternal vasculature, which is a well-regulated 
process that requires effective vascular remodelling in the decidua just before 
midgestation. In particular, in this specific window (from the start of 
placentation= day 8.5 up to 12.5) the maternal vasculature undergoes drastic 
changes. In the decidua basalis, the spiral arteries that branch from the uterine 
arteries (from the mesometrial uterine site) are transformed into wide vessels that 
gradually lose their vascular smooth muscle layer (Figure 12). This process is 
modulated by uterine NK cells (uNK)247–250 (chapter1.4.5). These changes in the 
maternal circulation happen together with the development of the functional 
capillary network of the labyrinthine zone of the foetal placenta. Here in the 
labyrinth of the definitive placenta, maternal blood flows for metabolic and gas 
exchange between maternal and foetal blood246.  
 
Figure 12 Vascular changes of the spiral arteries 
On the left side, the cartoon shows changes in vascular morphology before (left) and after (right) 
remodelling. Spiral arteries increase their lumen size and reduce the thickness of their muscular layer 
(smooth muscle cells) and extracellular matrix (ECM). On the right side of the figure, Smooth muscle 
actin (SMA) staining in brown shows an un-remodelled vessel in the myometrium and a remodelled 
vessel in the decidua basalis. Scale bar=10µm.  
Then, separated from the decidua is the muscular part of the uterus, the 
myometrium. This compartment surrounds the implantation site and its thickness 
in the mesometrial part where the spiral arteries branch before reaching the 
decidua and leukocytes aggregates into the mesometrial lymphoid aggregate of 
pregnancy (MLAp)246. 
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Figure 13 structure of the definitive chorioallantoic mouse placenta.  
The definitive consists of multiple distinct regions. The external domain is the decidua, bordered by three 
distinct trophoblast regions: an external thin band of trophoblast giant cells, a middle vacuolated layer of 
spongiotrophoblast, and an inner packed labyrinthine trophoblast. The labyrinth includes blood vessels of 
embryonic origin. Villi represent dense columns of trophoblast that guide blood vessels into the labyrinth. 
The labyrinth rests on the chorion, a flat and thick vascular plate that terminates with the umbilical cord.  
Alteration of these processes (i.e. arterial remodelling, trophoblast invasion and 
placentation) is associated with preeclampsia (PE; in human only), recurrent 
miscarriage or intra-uterine foetal growth restriction (IUGR). PE is one of the 
leading causes of maternal and perinatal mortality and morbidity. The pathology 
is characterised by hypertension and development of proteinuria at 20-32 weeks 
of gestation, and if not treated it can lead to maternal death. 8% of pregnancies 
are at risk and symptoms include high blood pressure, headache and abdominal 
pain to then worsen into renal, hepatic and pulmonary failure251,252. Human 
studies are trying to address biomarkers and causes of this pathology but the lack 
of animal models make the study of PE complicated. However, inflammation, 
impaired placentation and poor arterial remodelling have been shown to be 
associated with the development of this pregnancy coplication253–255. Recurrent 
pregnancy loss is associated with genetics and lethal disorders of the embryo, 
implantation disorders256–258 or inflammation259,260. Indeed, Toll like receptor 
(TLR) agonists such as poly (I:C) and lipopolysaccharide (LPS) injections are 
known to induce foetal death in animal models261–263. IUGR is a process of poor 
growth and development retardation of the foetus while in the mother womb. It is 
characterised by low birth weight in at birth and it is due to poor growth of the 
foetus during pregnancy. Growth-restricted newborns are identified as below the 
10th percentile for the gestational age. Foetal growth restriction increase 4-8 
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times the perinatal mortality rate and it can predispose to develop cardiovascular 
and metabolic disorders later on in life264–266. The main determinant of foetal 
growth is the placental supply of oxygen and nutrients. The placenta responds to 
both maternal and foetal signals and influences maternal–foetal resource 
allocation267,268. Therefore maternal stress, energy intake affect the placenta 
response, which tries to optimise foetal growth according to the available 
resources267–269.  
1.4.2 Maternal-foetal interface: trophic role of the immune system and 
tolerance 
The main pregnancy paradox in the immunology field is the formation of the 
feto-maternal interface. However, while pregnancy is commonly referred as 
semi-allograft with similarity with transplants270, it is now clear to be inaccurate. 
Embryonic tissue is not in direct contact with maternal cells, but the only 
specialised embryonic tissue that interacts with maternal uterine mucosa, 
vasculature and the decidua early in gestation, is the trophoblast. Later in 
gestation, the placental tissue of human and mice includes both foetal and 
maternal derived cells. Extra-embryonic trophoblast develops in intimate contact 
with decidual cells (maternal cells) and the maternal vasculature to then create 
the definitive placenta (as described 1.4.1). To some extent, indeed the maternal 
immune system is in contact with non-self-antigens as in the context of 
transplantation, where the main polymorphic antigens responsible for graft 
rejection are MHC antigens. However, in this context, MHC expression on 
trophoblast is not the same as in transplant settings. Trophoblast giant cells 
express only polymorphic H-2K MHC class I molecules in mice271, while in 
humans trophoblast express non-polymorphic human leukocyte antigen (HLA), 
such as HLA-C, HLA-G and HLA-E253,272. 
The maternal immune system is not immune suppressed273 but it is active and it 
is stimulated by the interaction with the foetus. Activation of uNK cells via 
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paternal antigens presented by class I molecules in pregnancy has shown in 
human and mouse that NK cells activation is essential to promote foetal growth 
and vascular remodelling. Firstly, foetal HLA-C2 binding to KIR2DS1 on uNK 
cells induce the production of GM-CSF and increase trophoblast cells migration 
and possibly it can enhance placentation274. In genetic association studies, this 
combination has been confirmed to impacts on birth weight and it promotes 
foetal growth275. In animal models, the suppression of NK cells by class I 
molecules is associated with reduced production of IFNg by uNK cells and 
reduced vascular remodelling and foetal growth276. This evidence shows that the 
immune system and in particular group 1 ILCs interact with the trophoblast and 
this interaction has a trophic role in promoting uterine vascular remodelling and 
trophoblast invasion62,248,277.  
The formation of tolerance towards the developing foetus is another important 
topic of study in the field of immunology of pregnancy. Elegant works in mouse 
models have shown the importance of Treg in maintaining foetal tolerance, 
where depletion of Treg leads to foetal demise by effector T cells 278–280. 
However, poorly is known about the mechanism of this and the specificity of 
uterine T (uT) cells activation that occurs at the feto-maternal interface. Limited 
class I expression by the trophoblast also limits cytotoxic T lymphocytes (CTL) 
activation. In human, a study found that Treg activation was increased by 10% in 
the decidua when mother and child had mismatched HLA-C. This observation 
was attributed to the presentation of paternal HLA-C-derived peptides by 
maternal APCs. However, HLA-C-specific CD4 T cells were not directly 
identified and no change was observed in the frequency of decidual CD28 
effector CD8 T cells281,282. In mice, studies with ovalbumin (OVA) expressed 
exclusively by the foetus, directly demonstrated the existence of foetal/placental 
antigens presentation to maternal T cells during murine pregnancy283–285. 
However, mechanisms are in place to prevent T cells to activate a response 
against the foetus: (1) The direct allorecognition pathway does not operate at the 
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feto-maternal interface and maternal T cells are ignorant of intact paternal MHC 
I molecules over the entire course of gestation283. (2) Th1 and CTL chemokines 
(CxCl10, Cxcl9, Cxcl11 and Ccl5) are epigenetically silenced in decidual stromal 
cells, thus reducing the number of effector T cells that can reach the decidua286. 
(3) Tregs maintain effector T cells in check 278–280. (4) Then, only the uterine 
draining lymph nodes (LN) have been found to be the preferential sites of 
placental antigen presentation, but surprisingly this is not the result of DCs 
migration from the decidua and it is unknown how foetal antigens are presented 
at this site281,287–289. In this context, activation of uT cells in the decidua needs to 
take into account the peculiar features of the murine pregnant uterus. The 
majority of the leukocytes are in the MLAp, between the two smooth muscle 
layers of myometrium: ~60-70-% uMac, uEo and uDCs, 20-30% uNK cells 
246,287,288,290 and 2% uT cells281. Then, in both species, the decidua at midgestation 
is the region where the majority of uNK cells and few myeloid cells are in 
contact with the trophoblast246,287,288,290 (as described earlier). Regulation of 
antigen presenting cells (APC) densities depends on the differential expression of 
growth factors in decidua and myometrium. Uterine DCs and Mac expand by a 
CSF-1 gradient more in the myometrium than in the decidua. Only residual uDCs 
and uMac remain entrapped in the decidua during decidualisation287,290 (see 
Figure 12, presenting a schematic of the leukocyte composition in myometrium 
and decidua). Studies on uterine dendritic cells migration showed that only uDCs 
in the MLAp can migrate to the draining lymph node while decidual uDCs are 
unable to move. Indeed, CCL21 (the CCR7 chemokine ligand important for DCs 
migration to the lymph node) is only expressed by the lymphatic vessels in the 
myometrium, while the decidua does not have any lymphatic287. Therefore, tissue 
characteristics limit uT cells activation and T cells are mainly activated through 
indirect allorecognition by resident uDCs of maternal secondary lymphoid 
organs 287,289.  
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To conclude, the establishment of the feto-maternal interface promotes a 
complex mechanism where the foetus, but more specifically the trophoblast, 
interacts with the maternal immune system to promote its own development. 
Therefore, it is much more than a semi-allograft: trophoblast and the maternal 
immune system have evolved and established a cooperative status, helping each 
other for the success of the pregnancy. 
 
 
Figure 14 Leukocyte composition in the different layer of the pregnant 
uterus. 
On the left side, leukocyte composition in the human decidua is compared to murine pregnancy (right). In 
the human pregnant uterus, there is not the development of a similar structure as the murine MLAp. 
Furthermore, trophoblast invasion in the human uterus is deeper, after implantation, the smooth muscle 
media of the artery is destroyed by the extra villus trophoblast and endothelium is then replaced by the 
endovascular trophoblast. Uterine NK cells participate in this process by producing pro-angiogenic 
growth factors and by directly interacting with the trophoblast 62,277. 
1.4.3 Th1/Th2 theory 
For almost 10 years a common model of Type-1/Type-2 cytokine regulation of 
the uterine microenvironment has been proposed as central to maintaining tissue 
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and immune homeostasis291–295. This model simplifies and describes the immune 
microenvironment as inflammatory (or type-1) during implantation and during 
labour while the microenvironment becomes type-2 polarised at midgestation. In 
this model, type-2 immunity has been proposed to be important at midgestation 
for foetal tolerance and foetal survival291. However, this hypothesis has been 
discarded, because the absence of type-2 cytokines does not affect litter sizes in 
either syngeneic or allogeneic matings234,296,297. This model is, however, an 
oversimplified hypothesis that does not take into consideration that during the 
various stages of pregnancy the pro- and anti-inflammatory cytokine milieu is 
dynamically regulated.  
 
Figure 15 Cytokine polarisation during pregnancy. 
Ref.295,298,299 
For example, IL-4 and IL-10 reduce when dams are injected with LPS or Poly 
I:C, IL-4 and IL-10 KO dams have early foetal loss when injected with LPS or 
Poly I:C 300, and they show stronger adverse outcomes than wild-type (WT) 
mice, such as embryo death and pre-term labour254,300–304. In human pregnancy, 
IL-4 and IL-10 deficiency has been described to be associated with PE and foetal 
growth restriction254. On the other end, pro-inflammatory cytokines IFN-g, IL-
1b, IL-12, TNF-a and IL-6, when in excess promote foetal death and inhibit 
vascular remodelling 259,260,305,306, but the uNK-regulated release of IFN-g is 
essential to promote vascular remodelling in homeostatic conditions in 
mice248,307. This overview, suggests that type-1 and type-2 immunity need to be 
tightly balanced at midgestation and in this context, type-2 KO mouse models 
need a deeper analysis of their pregnancy phenotype. In particular, little is known 
about the role of uterine type-2 immunity at midgestation in the context of spiral 
artery remodelling, where the maintenance of cellular and molecular uterine 
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homeostasis is essential. At midgestation, the maternal decidual vasculature is 
subjected to important, well-regulated and immune-mediated modifications 
resulting in increased blood flow to the developing foetus. During this process 
vascular smooth muscle cells are lost and the uterine arteries become 
thinner56,248,259,276,308–310. Failure of this remodelling process is a common 
pathogenic feature of pregnancy, that in mice often results in foetal growth 
restriction and in humans it is also associated with PE and early pregnancy 
loss258,311,312. In studies from the cardiovascular field, where vascular remodelling 
is pathogenic (vascular thickening), it is clear that the local immune cell 
environment is important312. For instance, in pulmonary arterial hypertension the 
increase of IL-1b and TNF-a promotes proliferation of vascular smooth muscle 
cells via inhibition of matrix metalloproteinases (MMP), at the same time also T-
cell mediated type-2 immunity (in particular IL-13) is involved in the pathology 
by inducing vascular fibrosis258,313–317. In the decidua, uNK cells in human and 
mice are known to directly interact with the invading trophoblast and to regulate 
the uterine arterial remodelling via IFN-g in mice318. When NK cells are 
functional and IFN-g production is unaltered, it has been demonstrated that TLR3 
activation by Poly I:C and the induction of inflammation can inhibit vascular 
remodelling 305. Furthermore, humans uMac and in particular M2 uMac help 
uNK cells in the remodelling by providing growth factors and MMP309. These 
examples suggest that as in the lung, also in the decidua the balance, the 
regulation and the co-operation of type-1 and type-2 immunity is essential to 
accomplish a well-regulated vascular remodelling. 
Effects of inflammatory stimuli on organogenesis, placental development and 
foetal growth are also known. LPS injections at low doses (without induction of 
foetal death) have been shown to inhibit foetal growth and induce defects in 
neural development263,319–322. Most-studied in this context are the pro-
inflammatory cytokines TNF-a and IL-1β. Both are expressed by the placenta 
and secreted by placenta explants in vitro and in vivo in response to hypoxia and 
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LPS263,319,322,323. LPS induce the production of inflammatory cytokines, 
prostaglandins and nitric oxide by acting on TLR4 expressed on maternal uMac, 
uDCs or the placenta263,319,324 and in Il10-/-300,302 mice LPS has worse outcomes. 
Indeed, in IL-10 deficiency uDCs have pro-inflammatory and unstable phenotype 
and LPS increase uterine inflammation and foetal demise324. Low doses of LPS 
at day 12.5 results in placental pathology and it affects the structure of the 
labyrinth zone and induces necrosis of the spongiotrophoblast. These placental 
abnormalities due to LPS have shown in mice and rats to affect strongly the 
foetal brain and its development263,319–322. In particular, a study showed that LPS 
affects oxygen levels and placental oxidative stress, and it induces the production 
of IL-1b, which affects foetal neurons growth, thus causing behavioural changes 
in the offsprings263,319,322. IL-1 receptors antagonists and IL-10300,302 have been 
shown to be protective towards foetal damage induced by inflammatory 
stimuly320,325. Another cytokine of the IL-1 family is IL-33. IL-33 drives type-2 
responses (as described in 1.3), which may be important for immunoregulation in 
normal pregnancy. A soluble splice variant of ST2L (sST2) is a decoy receptor 
and inhibits IL-33 functions. IL-33 and sST2 are both expressed by the 
placenta326,327, and sST2 is secreted by placental explants in response to pro-
inflammatory cytokines and hypoxia. Elevated plasma levels of sST2 are found 
in women with preeclampsia prior to the onset of the disease327. By blocking the 
action of IL-33, sST2 may contribute to the type-1 cytokine bias associated with 
this condition328. 
Finally, during parturition, an increase of pro-inflammatory cytokines is 
physiological, but pro-inflammatory stimuli induced by bacterial infections can 
trigger pre-term labour of premature foetuses329,330. Labour is regulated also by 
foetal development. For example, surfactant proteins (SP) SP-A and SP-D are 
secreted by foetal lungs into the amniotic fluid near term and this provides the 
signal for parturition331. Signals include those that trigger direct activation of 
Mac332, and those that increase of pro-inflammatory cytokines such as TNF-a 
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and IL-1b, which ultimately result in the production of prostaglandins and 
MMPs, via NF-kB. This triggers a cascade of pro-labour events including uterine 
contractility and foetal membrane rupture. NF-κB signalling induces 
prostaglandin F2 a (PGF2 a) synthase. PGF2 a plays an important role in 
controlling luteolysis and progesterone production. Progesterone is maintained at 
high levels throughout pregnancy and it needs to diminish near term to promote 
parturition. Indeed progesterone inhibitors can promote pre-term labour333. The 
contribution of inflammation and hormone regulation promotes the induction of 
contractility genes. Later, oxytocin is released from the posterior pituitary gland 
and it stimulates further expression of oxytocin receptors, inducing uterine 
contractility246,331,334,335. Inflammation is, therefore, an integral aspect of labour 
and it needs to be maintained in check to prevent pre-term labour. In mouse 
models, IL-10 has been shown to prevent pre-term labour. Its anti-inflammatory 
effects delay the onset of labour as it counterbalances the action of pro-
inflammatory cytokines and LPS301.  Progesterone itself also promotes protection 
from LPS-induced pre-term labour336. Progesterone reduces uterine contractility, 
but it also has immunomodulatory effects. Progesterone is able to suppress Th1 
differentiation and enhance Th2 differentiation in peripheral blood mononuclear 
cells in vitro and can up-regulates IL-4337,338. Furthermore, it was shown from a 
clinical trial that progesterone injections can reduce IL-1b and IL-8 and increase 
IL-10 in pregnant women, thus preventing preterm labour330.  
1.4.4 Uterine DCs and Macrophages  
DCs are the most potent antigen presenting cells of the immune system and are 
critically involved in the initiation of primary immune responses or the induction 
of immunological tolerance339. DCs are extremely plastic and their activity 
depends on their maturation state289,339–341. uDCs are mainly immature, express 
low level of T-cell costimulatory molecules, and they may contribute to 
peripheral tolerance under homeostatic conditions287,288. However, there is also 
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no direct evidence that uterine DCs locally induce antigen-specific tolerogenic T-
cell responses in vivo287,288.  Among uDC only these in the myometrium can 
migrate to the lymph nodes but are unlikely to be exclusively involved in T cell 
activation. Instead, uDCs have trophic roles288,290. uDCs have immature and 
tolerogenic phenotyping characteristics, they are involved in implantation256,257 
and collaborate with uNK cells to promote vascular remodelling and maintain 
immune homeostasis 342,343. Crosstalk between uDCs and uNK cells at the feto-
maternal interface is likely to be important for pregnancy. Human uDCs have 
been implicated in the production of IL-15 to sustain the maintenance of uNK 
cells344. Furthermore, trophoblast and placenta-derived TSLP activates type-2 
polarised uDCs and induces the expansion of IL-10 producing uNK cells345,346. 
This DC-NK interaction promotes the expression of IL-10 which may be 
primarily involved in the maintenance of uDCs tolerogenic state345,347,348, 
together with GM-CSF (which is produced also by uNK cells) 274,349,350, TGF-b 
(produced by uMac)309,351, and prostaglandin E2 can promote uDCs activation in 
the uterus349 (Figure 16). 
Studies on DC-deficient mouse models (in which DC deficiency is induced by 
conditional transgenesis) showed that besides their immunological function, the 
main physiological role of uDCs implantation and decidualisation256,257. These 
studies used CD11c-DTR transgenic mice, in which the CD11c promoter drives 
expression of the diphtheria toxin receptor (DTR), and thus making CD11c 
expressing cells susceptible to diphtheria toxin-mediated ablation. Ablation of 
uterine uDCs before implantation (at day 3.5) increases pregnancy failure with 
effects on embryo implantation and decidualisation256. Acute DC ablation 
inhibits the formation of embryo-induced deciduae, but also the formation of 
artificial deciduomas (decidua-like structures induced by intraluminal injection 
of sesame seed oil). Additionally, proliferation, differentiation of endometrial 
stromal cells, and vessels permeability, stability and angiogenesis are impaired 
when DCs are missing early in pregnancy. The physiological role of uDCs in this 
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context is to promote angiogenesis by expressing TGF-b1 and sFlt-1 (a decoy 
receptor for VEGF-A), which can then modulate the activity of uterine vascular 
endothelial growth factor A (VEGF-A) and uNK cells. This uDCs activity is 
strictly required in the implantation window, in fact, no effect on decidualisation 
was observed if uDCs were depleted at gestation day 5.5256. Further analysis of 
this mouse model and elimination of uDCs at different time points showed that 
uDC ablation affects uNK cells accumulation at gestation day 7.5. This study 
reinforces the importance of uDCs and uNK cells crosstalk to further promote 
uterine vascular remodelling257. On a side note, it is important to consider the 
limitation of this mouse model. CD11c diphtheria toxin ablation can potentially 
affect some uNK cells that express CD11c. Additionally, injections of diphtheria 
toxin can be toxic352, because the toxin may induce alterations by itself or in 
combination with excessive cell death and inflammation288,352. However, Krey et 
al., 257 showed that DTR depletion of CD11c+ve cells do not affect only uDCs and 
uNK numbers but also IL-15 expression. This suggests that the crosstalk between 
uDCs and uNK cells promotes uNK cells maturation and function257,353. This is 
additionally supported by further studies where impairment of CD11c+ve 
CD11b+ve trafficking and IL-15 expression affect uNK cells number, maturation 
and IFN-g production, decidua cellularity, and spiral artery remodelling353,354. 
However, the mechanism that induces uDCs to further promote decidualisation 
and uterine receptivity is unclear. It has been hypothesised that the embryo itself 
may change the uterine microenvironment or that the sperm may contain 
cytokines that can alter uDCs phenotype288,355. 
Further studies on the relationship between uDCs and uNK cells showed that 
alterations of uNKs and uDCs densities (both uDCs increase, or uDCs and/or 
uNK decrease) affect stromal cells development, decidualisation, implantation 
and foetal growth. In particular Gonzales et al.,342 showed that: (I) deficiency of 
uNK cells affects anti-mesometrial stromal cells proliferation; (II) deficiency of 
uDCs affects decidual stromal cells proliferation overall; (III) increase of uDCs 
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cannot counterbalance the reduction of uNK and instead decidualisation is 
strongly impaired. Interestingly, the increase of uDCs alone (with normal uNK 
cells quantity) does not alter implantation, but decidualisation and decidual 
angiogenesis are strongly affected. When uDCs are expanded early in gestation 
(gestation day 3.5-7.5) levels of IL-11 and phosphorylated histone H3 (PHH3), 
both involved in stromal cells proliferation, are reduced as well with the 
expression of gap-junction protein connexin-43 (Cx-43), which is important for 
decidual cells stability and upregulation of anti-angiogenic platelet factor 4 
(PF4)342. In light of these alterations when uNKs and uDCs densities are 
unbalanced, it is clear that uDCs and uNK cells cellular and molecular stability 
need to be tightly regulated. As mentioned in Chapter 1.4.3 IL-10 deficiency 
have strongest adverse outcome when LPS is injected300,302. In particular, the 
uterine microenvironment is more inflamed and the regulation of feto-maternal 
tolerance is altered when IL-10 is not produced345,346. IL-10 production is 
extremely important for the maintenance of uDCs immature and tolerogenic state 
and it is confirmed by the altered phenotype of uDCs and uterine T regulatory 
cells (uTreg)324 in this mouse model. Furthermore, if IL-10 is not available, 
uDCs expansion can induce foetal loss346. Additionally, it has been recently 
discovered that the resistance conferred by IL-10 to LPS challenge during 
pregnancy is indeed promoted by a specific subset of NK cells that uDCs help to 
expand346. In summary, uDCs and uNK cells tightly regulate each other (Figure 
16) and the maintenance of uDCs numbers and phenotype are essential for the 
effective decidualisation, implantation and foetal growth. 
The main function of Mac is the detection and ingestion of foreign material, dead 
cells and debris. They may be tissue resident or derive from circulating 
monocytes, which are recruited into tissues to replenish Mac at steady state or in 
inflammatory conditions356. In the mouse uterus, uMac derive from monocytes 
attracted in the decidua and myometrium by CCL2 and then CSF-1 sustains their 
proliferation and tissue location290. Mac are extremely plastic and according to 
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the stimuli they receive, they can change their function and phenotype357,358. 
These state of activation are classically referred to as M1 and M2. M1 are pro-
inflammatory and participate in the protection from infections, while M2 
macrophages are immunomodulatory, inducing tolerance and resolution of 
inflammation357,358. However, the vision of M1 and M2 polarised Mac is 
oversimplified and instead, Mac (in any tissues) should be mainly defined 
according to their activation. Classically activated macrophages (or M1) are 
those activated by IFN-g, while M2 are heterogeneous and include all the 
alternatively activated macrophages, including those activated by IL-4, IL-13 and 
IL-10358. This new definition of Mac makes the characterisation of tissue-resident 
Mac in in vivo settings complex. Indeed, the characterisation of only extracellular 
markers may be misleading. Instead, the identification of M1 or alternatively 
activated Mac requires the combination of extracellular markers together with 
transcription factors and cytokine production358.  
uMac in mice are identified by Tagliani and colleagues as CD45+ve, CD11b+ve, 
F4/80+ve/high MHCII+ve Ly6G-ve Ly6c-ve/low290. Murine uMac have been shown 
to express different levels of MHC II, where the high expression marks M1 
macrophages and low MHC II expression marks alternatively activated 
macrophages290. However little is known about the role of both populations in 
mouse uterus359, but inappropriate activation of pro-inflammatory M1 Mac 
producing IL-6 have detrimental effects and promote foetal demise259. Instead, 
M2 Mac have been hypothesised to promote tissue and vascular 
remodelling290,299,359. Human uMac are extremely plastic and inappropriate uMac 
polarization is usually associated with abnormal pregnancies, such as 
spontaneous abortion, preterm labour, PE, IUGR, and intrauterine parasitic 
infections299. uMac have been shown to secrete a wide range of cytokines (IL-1b, 
-2, -4, -5, -6, -8, -10, -13, -33, TNF-a and TGF-b), proteases (MMP-1, -2, -7, -9, 
and -10), and angiogenic growth factors (angiogenic, keratinocyte growth factor, 
FGF-B, VEGF-A, and angiopoietin-1 and -2)309,360.  Human uMac and in 
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particular alternatively activated uMac have been involved in implantation, 
arterial remodelling and maintenance of tolerance299,359. For instance, TGF-b 
production by uMac is able to shape uNK cells activity to promote their function 
as tissue remodellers and their tissue residency75,351,361 (Figure 16). Furthermore, 
the interaction with uNK cells and CD14+ve cells induces the expression of IDO 
and further activation of uTreg362. Additionally, they express a high level of 
similar angiogenic factors and MMPs as uNK cells (as described in 1.4.5) 309 and 
they may collaborate or have similar functions on the uterine artery. Finally, at 
term, pro-inflammatory uMac have been shown to be important in both human 
and mouse models for the induction of labour by producing IL-1b and TNF-a 
(1.4.3) 301,363–366. The LPS-TLR-4 axis induces the expression of inflammatory 
cytokines by M1 macrophages. Indeed, at term, injection of LPS treatment 
activates the NOTCH pathway in uMac and it triggers inflammatory cytokines 
that can affect prostaglandin production. Additionally, uMac MMPs may be 
involved in active extracellular matrix remodelling to induce ripening of the 
cervix366,367. 
 
Figure 16 Schematic of some regulatory effects at the maternal-foetal 
interface 
Summary of uDCs and uMac function and crosstalk with uNK described in this Chapter 1.4.4. uNK cells 
activity is further explained in the Chapter 1.4.5 below. 
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1.4.5 uNK cells and uILC1 
In the mouse virgin and pregnant uterus different uterine group 1 ILCs (uILC1) 
can be identified: uILC1s include uterine NK cells (uNK) and non-NK 
uILC156,76. uNK cells have been studied for many years and they have been 
referred as “granulated metrial gland cells” until the 1990s when they have been 
recognized as NK cells instead368. Mouse uNK cells have been initially 
recognised as reactive for dolichus biflorus agglutinin (DBA) but then it was 
recognised that DBA does not identify all uNK cells because a population of 
DBA-ve uNK cells is also present in the uterus369,370. DBA+ve subset expresses 
mainly angiogenic molecules, while DBA-ve cells appear to be the primarily IFN-
γ producers371. Subsequent studies on NK cells development identified in the 
uterus the existence of uterine tissue-resident NK cells (utrNK) which are 
independent to NFIL-3 for their development48. However, works form our group 
(in this dissertation in Chapter 3.3.2 and published in ref.56,76) identified that 
utrNK cells described by Sojka et al., were instead a heterogeneous population 
that included utrNK cells and non-NK uILC1s. utrNK cells phenotypically differ 
from uILC1s because they express T-BET and EOMES, while non-NK ILC1s, 
like their counterpart in other tissues, do not express EOMES. These works also 
established that the historically defined uNK cells are heterogeneous and include 
conventional NK cells (cNK which are Lin-ve, NK1.1+ve, NKp46+ve CD49a-ve, 
DX5+ve, T-BET+ve and EOMES+ve), utrNK cells (Lin-ve, NK1.1+ve, NKp46+ve 
CD49a+ve, DX5+/-ve, T-BET+ve and EOMES+ve) and uILC1 (Lin-ve, NK1.1+ve, 
NKp46+ve CD49a+ve, T-BET+ve and EOMES-ve). Additionally, DBA-ve uNK cells 
were instead largely overlapping with non-NK uILC1s56. Human uNK cells have 
been identified as CD56 super-bright CD16-ve 372. Also CD56+ve human uNK cells are 
heterogeneous and include ucNK cells EOMES+ve expressing CD49a, utrNK 
EOMES+ve expressing CD49a along with other markers of tissue residency 
(CD103, integrin β7, CD9, and CD69) which are the main source of IFN-g75, and 
ILC3s expressing NKp44 and ROR-gt (in this dissertation in Chapter 3.3.2 and 
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published in ref. 76,373). In this dissertation, I will be referring to specific 
subgroups of uILC1 with ucNK, utrNK, uILC1, or to group 1 uILC when no 
specification of the subset has been defined in the past (uILC1 include all CD3-ve 
NK1.1+ve or CD3-ve CD56+ve). 
The origin of uILC1s is debated. uILC1s may differentiate in utero from in situ, 
or from blood-derived CD34+ve progenitors350,374,375, or from peripheral blood NK 
cells that can transdifferentiate by TGF-b or when in contact with the uterine 
cytokine microenvironment75,80,361,376,377. Alternatively, tissue-resident uILC1s 
from the endometrium378 may contribute to the production of uILC1s during 
pregnancy and they may be regulated by stromal cells after response to 
progesterone 379. Also, trophoblast-secreted hormones, such as adrenomedullin 
have been implicated in the recruitment of uNK cells in the pregnant uterus380. 
However, the dependency or not on NFIL-3 among heterogeneous uILC1, 
suggests that these of cells may derive from multiple sources48,56,76.  
I mentioned in Chapter 1.4.2 how activation of uILC1s by trophoblast cells is 
important and have positive effects on pregnancy outcome. uILC1s have indeed 
essential functions including crosstalk with other leukocytes (i.e. uDCs and 
uMac288,299,326,342,346,351,359,381), remodelling of the uterine artery248,382–385 and 
regulation of trophoblast invasion.376,383,386 Such important role has been defined 
with the use of mouse models lacking NK cells387 (NK deficient mouse models 
such as Rag2-/-Il2rg-/-, p56lck−/−-Il2rb−/−, Il15-/-, Irfn1-/-, Nfil3-/-)56,387. ILC1s 
deficient mice present tissue abnormalities in the decidua, myometrium and 
MLAp, defective vascular remodelling, and reduced foetal weight 56,248,384,387. 
uILC1 cells quantities also are regulated and reflect their function. uILC1s pick 
at midgestation, while their number drop after the process of vascular 
remodelling is complete and the definitive placenta is established369,388. 
uILC1 contribution to vascular remodelling may be different in human and mice. 
In mice administration of IFN-g between gestation day 6.5 and 12.5 reduces the 
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impaired vascular remodelling of ILC1 deficient mouse models. Additionally, 
adoptive transfer of IFN-g competent bone marrow in alymphoid mice, have 
confirmed the importance of IFN-g produced by uILC1s in uterine vascular 
remodelling248. However, the exact mechanism of uILC1-derived IFN-g is still 
unclear. Additionally, uILC1s may be promoting angiogenesis of the uterine 
arteries. This process may be mediated by murine DBA+ ucNK or utrNK cells, 
which are known to produce angiogenic molecules such as VEGF and placental 
growth factor (PLGF), and Angiopoietin which may be important for the 
recruitment of mural cells around endothelial cells371,389–392. Arterial remodelling 
regulation in humans may be more complex. Although Montaldo et al., recently 
identified that also utrNK cells expresses IFN-g in response to PMA and 
Ionomycin75, there is no evidence that IFN-g expression by human uILC1 affects 
vascular remodelling in human pregnancy62. Instead, uILC1s may be 
contributing to arterial remodelling in human by regulating trophoblast invasion, 
mediated by the production of IP-10, IL-8 and GM-CSF61,274,383, and by 
producing pro-angiogenic factors (i.e. PLGF and VEGF and 
Angiopoietin)310,382,383,393 and metalloproteinases (MMP-7, MMP-9, MMP-19, 
and MMP-23)308,394,395. 
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1.5 Hypothesis and specific questions 
Among all mucosal tissues, the uterus is the tissue where the function of ILCs 
still needs to be addressed and only the role of group 1 ILC subset uNK cells has 
been explored. This tissue has interesting and vast potential for the study ILCs 
because as described before immune-mediated mechanisms and immune 
homeostasis are essential for several processes: menstrual cycle, implantation, 
pregnancy-associated tissue growth, vascular remodelling and labour (Chapter 
1.4).  
I hypothesised that ILCs other than ILC1 may be involved in the regulation of 
immune homeostasis in the uterus. Many studies indicated that innate immunity 
is important to sustain physiological processes during pregnancy (Chapter 1.4). 
ILCs, even if in low numbers, have been shown to be important in maintaining 
immune homeostasis in many tissues (Chapter 1.3). Also in the uterus ILCs can 
be as important as uNK, and their ability to quickly produce cytokines can be 
extremely important to regulate the activation and maturation of cells in more 
sizable numbers. 
In Chapter 3 the first question is whether functional ILCs are present in the 
uterus in mouse models and human tissues. Once the functionality and phenotype 
of uILC2s are addressed, the second question is where uILCs develop. 
I then hypothesised that uILCs may be tissue-resident and important during 
pregnancy. In particular, uILC2s caught my attention. Our work on Nfil3-/- mice 
showed that in the absence of Nfil3, the number of uterine leukocytes is reduced, 
a specific subset of uNK cells is severely affected56, uILC2s are absent, and 
Nfil3-/-  dams have dramatic pregnancy problems (described in detail in Chapter 
3.3.4 and Table 12). Development of NK cells but also ILCs require Nfil3 
expression (Chapter 1.2) at the level of the Common Lymphoid Progenitor, thus 
suggesting that also uILCs may be affected in Nfil3-/- mouse uterus. Data from 
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Chapter 3.3.2 showed that pregnancy complications in Nfil3-/- mice may be 
caused by the absence of conventional NK (ucNK), but we cannot exclude that 
they may be also due to the combined lack of cNK and uILC2 instead56,76.  
In Chapter 4, I firstly characterised uILC2s starting with the question of how 
uILC2s may be activated and regulated. Specific functional characteristics of in 
vitro activated uILC2s showed partial but not complete overlapping 
characteristics between uILC2s and lung ILC2s (Chapter 4.2.2). I then 
hypothesised that the uterine tissue can modulate uILC2 activity. I further asked 
if uILC2s have other characteristics of tissue residency when compared to other 
ILC2s and if uILC2s are then further regulated by the uterine microenvironment. 
Once established how uILC2s are regulated during pregnancy, I asked whether 
uILC2s are relevant to pregnancy in vivo in ILC2 KO mouse models. 
I established that absence of uILC2s has implications in the physiology of murine 
pregnancy. Chapter 3.3.4 and Chapter 4 describe how ILC2s have been 
demonstrated to be important regulators of type-2 immunity in many different 
models. I hypothesised that uILC2s may be central in the establishment of 
uterine type-2 immunity during pregnancy and in the regulation of type-1/type-2 
immunity homeostasis to finally promote foetal growth and vascular 
remodelling. To assess this hypothesis, I asked whether uteri of ILC2KO mouse 
models were different from WT. Type-2 immunity in ILC2KO mice is defective, 
which made me hypothesise that uILC2 and type-2 immunity might be important 
to protect from excessive inflammation or from pro-inflammatory stimuli that 
can occur after a bacterial infection. I further asked whether foetuses from 
ILC2KO mothers are less protected in case of a bacterial infection and how 
uILC2s modulate the immune microenvironment in this setting.   
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1.6 Aims 
The aim of this dissertation is to characterise and to assess the role of uILCs. In 
particular, once I will establish whether uILCs other than uNK cells can be 
functional and have a role in the immune regulation of the uterine 
microenvironment, I am going to study uILC2s. I will study uILC2 function and 
phenotype in ILC2KO mice. Once I will assess the importance of ILC2 in the 
regulation of type-2 immunity and uterine myeloid cells, I will study the 
relevance of type-2 immunity regulation in vivo. The study on uILC2 aim to look 
at uterine type-2 immunity regulations from a new angle: instead of studying 
type-2 immunity in the context of T cells and tolerance, I will assess instead the 
importance of type-2 immunity for the establishment of a successful pregnancy 
and for the protection the foetus in complicated pregnancy conditions. To 
conclude, I am going to characterise for the first time uILC2 and their role in the 
regulation of type-2immunity during pregnancy.  
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2 MATERIALS AND METHODS 
2.1 Statement of source 
Certain methods in this chapter describe elements that are presented in the 
following first author manuscript written by the author of this dissertation. 
Therefore, some sections are taken verbatim or with minor changes from this 
source. 
Balmas E, Rana BMJ, Hamilton S R, Kieckbusch J, Hawkes DA, McKenzie 
ANJ, Colucci F Group 2 innate lymphoid cells prevent endotoxin-induced fetal 
demise. In preparation. 
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2.2 Human tissues 
A single patient undergoing a hysterectomy for benign disease was approached 
and consented. A uterine biopsy was taken following brief storage in culture 
media. Decidual biopsies were obtained from donors undergoing elective 
termination between 7 and 12 weeks of pregnancy. The Cambridge Research 
Ethics Committee approved this study (04/Q0108/23 and 
08/H0305/40).  Endometrial biopsies were timed between 6 and 10 days after the 
pre-ovulatory luteinizing hormone surge. All endometrial biopsies were obtained 
in ovulatory cycles and none of the subjects was on hormonal treatments for at 
least 3 months prior to the procedure. Subjects were recruited from the 
Implantation Clinic, a dedicated research clinic at University Hospitals Coventry 
and Warwickshire National Health Service Trust. The study was approved by the 
NHS National Research Ethics – Hammersmith and Queen Charlotte’s & 
Chelsea Research Ethics Committee (1997/5065). Written informed consent was 
obtained from all participants in accordance with the guidelines in The 
Declaration of Helsinki 2000. Human decidua and endometrium tissues were 
mechanically processed to preserve CD56 expression and leukocytes were 
enriched by layering on Lymphoprep (Axis-Shield). Uterine myometrium from 
hysterectomies was chopped into small pieces and digested with Collagenase V 
0.6 mg/ml in RPMI 10% FCS for 1 h. Then, the remaining tissue was smashed 
on 100um and 40um cell strainers and leukocytes were enriched by layering on 
Lymphoprep. The digestion and the use of different cell strainers were important 
to obtain a homogeneous single cell suspension. 
2.3 Mice 
C57BL/6 and BALB/c mice were purchased from Charles River. Il33cit/wt, 
Il33cit/cit (described in Hardman C.S. et al.396 and re derived in C57BL/6 
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background), Roraflox/flox Il7cre/wt (described in Oliphant C.J. et al. 32), Il7cre/wt 
generated by Dr. Hans-Reimer Rodewald (described in Schlenner S.M. et al. 397), 
Rag2-/- (described in Shinkai Y et al.398), Rag2-/- Il2rg-/- (described in Mazurier F. 
et al.,399), and Nfil3-/- (Gascoyne DM et al.130) were all in C57BL/6 background. 
Mice were used at 8-12 weeks of age for tissue analysis or mice were matched in 
ages for all experiments of time matings. Mice were mated and the day of the 
plug was considered gd0.5. Uterine tissues for analysis were collected from non-
mated mice (or virgin), uteri at midgestation (at gestation day 9.5) and uteri at 
term (at gestation day 18.5). Mice were bred, maintained and mated at the 
University of Cambridge Central Biomedical Service and in Medical Research 
Council (MRC) ARES animal facility, under pathogen-free conditions and 
housed according to UK Home Office guidelines. Every experiment was 
designed to include only mice breed and maintained in the same animal facility.  
2.4 Tissue preparation for cell isolation 
Pooled mesenteric, para-aortic and inguinal lymph nodes were passed through a 
70mm cell strainer using PBS 2% FCS. 
Mouse uteri, spleen, and lungs, were processed using two different enzymatic 
protocols to obtain either pure leukocytes or myeloid cells and stromal cells. A 
mild enzymatic digestion protocol followed by leukocyte gradient purification 
has been used when we studied rare leukocyte populations and we wanted to 
preserve their expression of extracellular markers. Additionally, a second 
enzymatic protocol was needed to favour the purification of cells that reside deep 
in the tissue, such as Macrophages. Uterine tissues have been collected from non-
pregnant (V), and pregnant uteri (gd9.5 and gd18.5). Unless specified, when 
midgestation uteri have been collected, myometri and deciduae tissues have been 
dissected (as described in Figure 17), digested and stained separately to further 
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dissect the contribution of uILCs, leukocytes and stromal cells on different parts 
of the tissue. 
 
Figure 17 Diagram describing the steps required for the dissection of the 
mouse uterine tissue at midgestation. 
Diagram describing the steps required to dissect mouse uterine tissue prior enzymatic digestion or RNA 
extraction. Firstly, ovaries are eliminated and the uterus is divided into two sections (uterine horns) by 
cutting at the level of the cervix. Then both the uterine horns are opened longitudinally and deciduae are 
squeezed out from the tissue by using forceps. Finally, embryos are eliminated and decidua and 
myometrium are collected into separate tubes for downstream analysis. The myometrium will include 
both the uterine muscular layer and the MLAp when dissected with the described method. 
Pure leukocytes from uteri (virgin, midgestation, and term), lungs, spleen, were 
obtained by incubating minced tissues 2 x 15 min with HBSS without Ca++ and 
Mg++ (Life Technologies), 10% FCS (Life Technologies), 5 mM EDTA (Sigma), 
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15 mM HEPES solution (Life Technologies) on a rotator at 37°C. Then digested 
for 30 min with RPMI containing 2% FCS, 30 µg/ml DNAse I (Roche) and 0.1 
WU/ml Liberase DH (Roche). After digestion tissues were filtered and smashed 
with a syringe plunger on a 100µm cell strainer to mechanically dissociate the 
remaining bites of tissues. Leukocytes were enriched on an 80%/40% Percoll 
(GE Healthcare Life Sciences) gradient. This protocol was mainly used for the 
analysis of uterine leukocytes and uILCs. Giving the small number of uILCs for 
every experiment mice have been pooled (~10 virgin uteri, ~5-10 mid-pregnant 
uteri and ~5 term uteri) to have enough events by flow cytometry. 
Myeloid cells and stromal cells were obtained from uteri by incubating minced 
tissues for 30 min with HBSS with Ca++ and Mg++ (Life Technologies), 30 µg/ml 
DNAse I (Roche) and 0.26 WU/ml Liberase TM (Roche) on a rotator at 37°C. 
Then, digested for 15 min with 5mM EDTA (Sigma) diluted in PBS. After 
digestion tissues were filtered and smashed with a syringe plunger on a 100um 
cell strainer to mechanically dissociate the remaining pieces of tissue.  
2.5 RNA sequencing 
Single cell suspensions from Virgin and pregnant uteri (only myometrium), lungs 
(isolated as previously described), pooled mesenteric, para-aortic and inguinal 
lymph nodes (isolated as previously described), were stained with CD127 
(A7R34), ST2 (RMST2-33), NK1.1 (PK136), CD3 (17A2), CD19 (6D5), GR-1 
(RB6-8C5), TER-119 (TER-119), CD11c (HL3), CD8a (53-6.7), CD90.2 (53-
2.1), CD45 (30-F11), CD11b (M1/70). All antibodies were purchased from 
Biolegend or BD bioscience (Full list of antibodies and dilutions are in Table 8). 
Viable cells were discriminated by using fixable viability dye ef450 from BD 
bioscience. Live, single cells, CD45+ve CD11b-ve NK1.1-ve, CD3-ve, CD19-ve, GR-
1-ve, Ter119-ve, CD11c-ve, CD8a-ve, ST2+ve, CD90+ve were sorted with BD FACS 
Aria III into PBS 2% FCS. After sorting, uILC2 pellets were collected into fresh 
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TRI Reagent (Sigma). RNA extraction was carried out by following TRI Reagent 
manufacturer instructions. The transparent part containing mRNA was then 
purified with RNAeasy mini kit (Quiagen), gDNA contamination was eliminated 
with Turbo DNAse (Ambion) and we then clean up ILC2 mRNA with RNAeasy 
micro kit (Quiagen). Library preparation and cDNA library amplification were 
carried out with NuGEN Ovation RNA-seq system V2 and NuGEN Ovation 
Ultralow DR Multiplex System kit by following manufacturer instructions. All 
quality controls for mRNA integrity and cDNA quantifications were performed 
with 2100 Bioanalyzer kits (Agilent Genomics). RNA sequencing was performed 
on Illumina Hiseq2500. Library preparation was carried out with the help of Dr. 
Batika Rana. RNAseq data analysis was then performed with Bioconductors as 
follows. Raw FASTQ files were adapter, and quality trimmed using 
trim_galore400 (v0.4.1). Quality control was performed with FastQC (v0.11.5)401. 
Data were aligned to GRCm38 mouse genome (Ensembl Release 86) with 
TopHat2 (v2.1.1, using bowtie2 v2.2.9)402 with a double map strategy. 
Alignments and QC were processed using custom ClusterFlow (v0.5dev)403 
pipelines and assessed using MultiQC (0.9.dev0)404. Gene quantification was 
determined with HTSeq-Counts (v0.6.1p1)405. Additional quality control was 
performed with feature counts (v 1.5.0-p2)406, qualimap (v2.2)407 and preseq 
(v2.0.0)408. Differential gene expression was performed with DESeq2 package 
(v1.16.1, R v3.4.0)409 and with the same package read counts were normalised on 
the estimated size factors. Custom scripts are available: https://github.com/CTR-
BFX/2017-Balmas-Colucci. 
Bioinformatic analysis was performed in collaboration with Dr. Russell S. 
Hamilton.  
Gene Ontology analysis was done with DAVID 6.8 by uploading gene lists and 
their fold changes. Gene Ontology Lists were then filtered and only GO lists with 
at least 4 genes and with significant p-value were considered and ranked per 
significance. 
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RNAseq data can be found at: 
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5803 (Uterus data) 
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5806 (Lung/Lymph 
node data) 
Validation for Granzymes, Ctla4 and Foxp3 expression has been performed on 
virgin and pregnant uteri. Pure leukocytes were isolated as follow and cells were 
stained with conjugated anti-mouse CD45 (30-F11), CD3 (17A2), CD19 (6D5), 
CD11b (M1/70), NK1.1 (PK136), NKp46 (29A1.4), CD90.2 (53-2.1), CD127 
(A7R34), ST-2 (RMST2-33), EOMES (Dan11mag), GATA-3 (TWAJ and 
16E10A23), CD4 (RM4-5), Ctla4 (UC0-4B9), FOXP3 (NRRF-30). Full details 
of Antibodies can be found in Table 8 Anti-mouse antibodies used for flow 
staining. 
2.6 Flow cytometry 
Human leukocytes purified from deciduae, endometrium or myometrium were 
stained with anti-human antibodies to identify uILCs: CD45 (HI30), CD3 
(UCHT1), CD19 (HIB19), NKp44 (P44-8), CD14 (M5E2), CD9 (M-L13), 
CRTH2 (BM16), CD56 (HCD56), CD117 (104D2), CD127 (A019D5), CD161 
(HP-3G10), GATA-3 (TWAJ and 16E10A23), T-BET (O4-46) and ROR-gt 
(Q21-559). A full list of anti-human Antibodies with fluorochromes and dilutions 
used for the staining can be found in Table 7. 
Pure leukocytes were isolated from non-pregnant and pregnant uteri at 
midgestation and term (gd9.5 and gd18.5) and stained with conjugated anti-
mouse antibodies to identify uILCs: CD45 (30-F11), CD3 (17A2), CD19 (6D5), 
CD11b (M1/70), NK1.1 (PK136), NKp46, CD90.2 (53-2.1), CD127 (A7R34), 
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ST-2 (RMST2-33), CD49a (Ha31/8), EOMES (Dan11mag), GATA-3 (TWAJ 
and 16E10A23), T-BET (O4-46) and ROR-gt (Q21-559).  
Pure myeloid cells and stromal cells were dissected from pregnant uteri and 
stained with conjugated anti-mouse antibodies to identify myeloid cells: CD45 
(30-F11), CD11c (HL3), CD11b (M1/70), F4/80 (BM8), MHC II I-A/I-E 
(M5/114.15.2), CD80, SiglecF (E50-2440), Ly6C (AL-21), Ly6G (1A8), GR-1 
(RB6-8C5), ARG-1 (Sheep IgG Polyclonal R&D system), CD31a (390), 
Podoplanin (8.1.1), SCA-1 (D7), CD34 (RAM34), PDGFRa (APA5), RELMa 
(Rabbit polyclonal Peprotech). AREG and RELMa antibodies were conjugated 
in-house by using lightning-link conjugation kit (Innova Biosciences). 
All antibodies were purchased from Biolegend, eBioscience, BD Biosciences, 
Peprotech or R&D Systems and the complete list is in Table 8. Cytokines and 
transcription factors were stained using the FoxP3 staining buffer set 
(eBioscience) according to the manufacturer’s instructions. Fixable viability dye 
eFluor 780, eFluor 450 and eFluor 506 (eBioscience) were used to exclude dead 
cells. Extracellular staining has been performed in BD ultraviolet buffer (BD 
Biosciences) and cells have been incubated with TruStain fcX Fc receptor 
blocking solution 1:100 diluted (Biolegend) to avoid non-specific staining.  
DBA staining was performed 5min at room temperature on fixed cells after 
extracellular staining and before intracellular staining for transcription factors. 
Samples for immune phenotyping were acquired on a LSR Fortessa (BD 
Biosciences) using FACS DiVa and analysed using FlowJo (Tree Star). A full 
list of Antibodies with fluorochromes and dilutions can be found in Table 8. 
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Table 7 Anti-human antibodies used for flow staining 
Table 8 Anti-mouse antibodies used for flow staining 
Antigen	 Clone	 Fluorocrome	 Company	 Dilution	
a4b7	 DATK32	 APC	 Biolegend	 1:100	
Areg	 Policlonal	 APC	 R&D	 1:400	
ARG-1	 IC5868F	 FITC	 R&D	 1:50	
B220	 RA3-6B2	 Biotin	 BD	Pharmigen	 1:50	
CCR6	 29-2L17	 BV5605	 Biolegend	 1:50	
CCR6	 29-2L17	 APC	 Biolegend	 1:25	
CCR7	 4B12	 PE/Dazle	 BD	 1:100	
CD11b	 M1/70	 BV650	 Biolegend	 1:100	
CD11c	 HL3	 PerCP-Cy5.5	 BD	Pharmigen	 1:50	
CD11c	 HL3	 APC	 BD	Pharmigen	 1:100	
CD122	 TM-b1	 PE	 Biolegend	 1:100	
CD127	 A7R34	 APC-ef780	 eBioscience	 1:100	
CD127	 A7R34	 BV605	 Biolegend	 1:12.5	
CD127	 SB/199	 BV510	 BD	Horizon	 1:25	
CD19	 6D5	 BV785	 Biolegend	 1:100	
CD19	 1D3	 APC	 Biolegend	 1:400	
Antigen	 Clone	 Fluorocrome	 Company	 Dilution	
ROR-gt	 Q21-559	 AF488	 BD	Pharmigen	 1:20	
CD117	 104D2	 PerCP-Cy5.5	 Biolegend	 1:20	
GATA-3	 TWAJ	 PE	 eBioscience	 1:20	
T-BET	 O4-46	 PE-CF594	 BD	Pharmigen	 1:20	
CRTH2	 BM16	 PECy7	 Biolegend	 1:40	
NKp44	 P44-8	 APC	 Biolegend	 1:50	
CD3	 UCHT1	 AF700	 Biolegend	 1:100	
CD19	 HIB19	 AF700	 Biolegend	 1:100	
CD14	 M5E2	 AF700	 Biolegend	 1:50	
CD56	 HCD56	 BV421	 Biolegend	 1:20	
CD9	 M-L13	 BV510	 Biolegend	 1:20	
CD45	 HI30	 BV570	 Biolegend	 1:40	
CD161	 HP-3G10	 BV605	 Biolegend	 1:40	
CD127	 A019D5	 BV650	 Biolegend	 1:40	
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CD25	 PC61	 APC-ef780	 eBioscience	 1:100	
CD25	 PC61	 APC-ef780	 eBioscience	 1:100	
CD3	 17A2	 BV785	 Biolegend	 1:50	
CD3	 17A2	 APC	 Biolegend	 1:200	
CD3	 17A2	 Biotin	 BD	Pharmigen	 1:50	
CD4	 RM4-5	 BV510	 Biolegend	 1:100	
CD4	 GK1.5	 PE	 Biolegend	 1:200	
CD45	 30-F11	 BV570	 Biolegend	 1:100	
CD45	 30-F11	 BUV395	 BD	Pharmigen	 1:200	
CD45	 30-F11	 AF700	 Biolegend	 1:200	
CD49a	 Ha31/8	 PE	 BD	Pharmigen	 1:400	
CD5	 C3-7.3	 Biotin	 BD	Pharmigen	 1:50	
CD8a	 53-6.7	 APC	 eBioscience	 1:200	
CD90.2	 53-2.1	 AF700	 Biolegend	 1:400	
CTLA4	 UC10-4B9	 BV421	 Biolegend	 1:100	
CTLA4	 UC10-4B9	 BV605	 Biolegend	 1:25	
DBA	 -	 FITC	 	 1:1500	
DX5	 DX5	 PECF594	 eBioscience	 1:100	
DX5	 DX5	 AF700	 eBioscience	 1:100	
EOMES	 Dan11mag	 AF660	 eBioscience	 1:200	
EOMES	 Dan11mag	 FITC	 eBioscience	 1:250	
F4/80	 BM8	 BV785	 Biolegend	 1:100	
FLT3	 A2F10	 PerCP-ef710	 eBioscience	 1:100	
FOXP3	 NRRF-30	 PE	 eBioscience	 1:100	
GATA-3	 L50-823	 PECy7	 BD	Pharmigen	 1:200	
GATA-3	 TWAJ	 PE	 eBioscience	 1:12.5	
GR-1	 RB6-8C5	 BV570	 Biolegend	 1:50	
GR-1	 RB6-8C5	 APC	 eBioscience	 1:100	
GR-1	 RB6-8C5	 Biotin	 BD	Pharmigen	 1:50	
Gzme	B	 GB11	 Pacific	Blue	 Biolegend	 1:100	
Gzme	
B/D/F/N/H/E	
Rabbit	
policlonal	 FITC	 Biorbyt	 1:100	
Gzme	C	 SFC1D8	 PE	 eBioscience	 1:100	
ICOS	 C398.4A	 PECy7	 Biolegend	 1:100	
IL-13	 eBio13A	 AF488	 eBioscience	 1:100	
IL-4	 11B11	 PECy7	 eBioscience	 1:100	
IL-5	 TRFK5	 PE	 Biolegend	 1:100	
Ly49A	 YE1/48.10.6	 Pacific	Blue	 Biolegend	 1:100	
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Ly49G2	 4D11	 PECy7	 BD	Pharmigen	 1:100	
Ly6c	 AL-21	 FITC	 BD	Pharmigen	 1:200	
Ly6G	 1A8	 BV605	 Biolegend	 1:50	
MHC	II	(I-A	I-E)	 M5/114.15.2	 APC-fire750	 Biolegend	 1:400	
NK1.1	 PK136	 PECy7	 Biolegend	 1:100	
NK1.1	 PK136	 BUV395	 BD	 1:50	
NK1.1	 PK136	 PECF594	 BD	 1:100	
NK1.1	 PK136	 PE	 Biolegend	 1:200	
NKG2	A/C/E	 20d5	 FITC	 BD	Pharmigen	 1:200	
NKG2D	 CX5	 PECy7	 eBioscience	 1:100	
NKp46	 29A1.4	 BUV737	 BD	 1:25	
RELMa	 Policlonal	 PECy7	 Pepprotech	 1:50	
ROR-gt	 Q31-378	 BV421	 BD	Bioscience	 1:100	
SCA-1	 D7	 Pacific	Blue	 Biolegend	 1:100	
SCA-1	 D7	 FITC	 Biolegend	 1:200	
Siglec-F	 E50-2440	 APC	 BD	 1:50	
ST-2	 RMST2-33	 PerCP-ef710	 eBioscience	 1:100	
Antigen	 Clone	 Fluorocrome	 Company	 Dilution	
T-BET	 O4-46	 PE-CF594	 BD	Pharmigen	 1:50	
TER-119	 TER-119	 APC	 eBioscience	 1:100	
TER-119	 TER-119	 Biotin	 BD	Pharmigen	 1:50	
CCR7	 4B12	 PE/Dazle	 Biolegend	 100	
IFN-g	 XMG1.2	 APC	 BDPharmigen	 200	
TNF-a	 TN3-19.12	 PE	 BDPharmigen	 100	
IL-22	 1H8PWSR	 PE	 eBioscience	 100	
IL-17	 TC11-18H10.1	 AF488	 Biolegend	 250	
2.7 Activation assays 
When ILC2 were activated, pure leukocytes (isolated as previously described) 
leukocytes isolated from uterine from myometri and lungs were activated with 
PMA/ionomycin activation cocktail (Biolegend) for 4 h at 37°C or with 20 ng/ml 
rmIL-25 and 20 ng/ml rmIL-33 for 4 h at 37°C in the presence of brefeldin A and 
monensin cocktail (Biolegend).  
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uILC1s activation was carried out on pure leukocytes (isolated as previously 
described) from non-pregnant uteri. We activated with 50 ng/ml PMA (Sigma) 
and 500 ng/ml Ionomycin (Sigma) during 4 h at 37°C or with 10 ng/ml 
recombinant murine IL (rmIL)-12 (Peprotech) and 50 ng/ml rmIL-15 (Peprotech) 
for 4 h at 37°C in the presence of brefeldin A and monensin cocktail (Biolegend).  
uILC3s activation was carried out on pure leukocytes (isolated as previously 
described) from non-pregnant uteri. We activated with 50 ng/ml PMA (Sigma) 
and 500 ng/ml Ionomycin (Sigma) during 4 h at 37°C or with 50 ng/ml rmIL-1β 
(Peprotech) and 50 ng/ml rmIL-23 during (R&D Systems) 4 h at 37°C in the 
presence of brefeldin A and monensin cocktail (Biolegend).  
After 4h activation, cells were stained for cell-surface markers, intracellular 
cytokines, and transcription factors. 
IL-4 expression on isolated myeloid cells was evaluated from fresh uterine 
myeloid cells incubated for 4 h in the presence of brefeldin A and monensin 
cocktail (Biolegend). Then cells were stained for cell surface markers, 
intracellular cytokines and transcription factors. 
2.8 uILC2s expansion in vivo 
We injected mice with a protein cocktail or with PBS (control) in three doses on 
three consecutive days. Protein cocktail was prepared with 5ng/µl of IL-2 
(Peprotech) and 25 ng/µl of anti-IL-2 (Bio Xcell) incubated in PBS for 20 min at 
37°C. Then, we added 12.5 ng/µl of IL-25 (Peprotech). After 3 days of 
injections, uteri were harvested (on day 4) and pure leukocytes (isolated as 
previously described) were stained for cell surface markers and transcription 
factors. 
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2.9 mRNA extraction and real time quantitative PCR 
DC, Mac, NK and T cells were sorted from myeloid and pure leukocytes isolated 
as described above. Cell preparations were stained with CD11c (HL3), CD4 
(GK1.5), NK1.1 (PK136), CD3 (17A2), CD45 (30-F11), MHC II I-A/I-E 
(M5/114.15.2), Ly6C (AL-21), Ly6G (1A8), CD11b (M1/70) and F4/80 (BM8). 
Fixable viability dye eFluor 450 (eBioscience) was used to exclude dead cells. 
Live, CD45+ve MHC II high, F4/80-ve and low, Ly6g-ve, Ly6c-ve, CD11c+ve were sorted 
as uDCs. Live, CD45+ve MHC II+ve, F4/80+ve, Ly6g-ve, Ly6c-ve, CD11b+ve were 
sorted as uMac. Live, CD45+ve F4/80-ve, Ly6g-ve, Ly6c-ve, CD3-ve, NK1.1+ve were 
sorted as uNK. Live, CD45+ve F4/80-ve, Ly6g-ve, Ly6c-ve, NK1.1-ve, CD3+ve, 
CD4+ve were sorted as uT cells. After sorting, cell pellets were collected into 
fresh TRI Reagent (Sigma). mRNA extraction was carried out by following TRI 
Reagent manufacturer instructions. The transparent part containing mRNA was 
then purified with RNAeasy micro kit (Quiagen). mRNA was quantified with 
2100 Bioanalyzer (Agilent Genomics) and retrotranscription was carried out with 
high capacity RNA-to-cDNA kit. mRNA was extracted from uterine tissues 
homogenised with TRI Reagent (Sigma) in Lysin matrix D (MP Bio). Then, the 
clorophorm-extracted (Sigma) transparent part containing mRNA was purified 
with RNAeasy mini kit (Quiagen). mRNA retrotranscription was carried out with 
high capacity RNA-to-cDNA kit. RT-qPCR data were generated on Quant Studio 
6-flex real-time PCR (Thermo Fisher) by amplifying cDNA with selected 
primers (Table 9) with Power SYBR green master mix (Thermo Fisher). The 2DCt 
was calculated per every gene as relative to Actb. Primers have been tested prior 
use and only primers with efficiency > 95% have been selected.  
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Table 9 Table of primers 
 
FW	 RW	
Il6	 GTGGAAATGAGAAAAGAGTTGTGC	 ATGGTACTCCAGAAGACCAGA	
Il1b	 TGCCACCTTTTGACAGTGAT	 CTGCCTGAAGCTCTTGTTGA	
Il10	 GCATTTGAATTCCCTGGGTG	 CACCTTGGTCTTGGAGCTTAT	
Tgfb	 CCTGAGTGGCTGTCTTTTGA	 GGGCTGATCCCGTTGATTT	
Actb	 AAGATCAAGATCATTGCTCCTCCT	 AAGGGTGTAAAACGCAGCTC	
Arg1	 GTGCCCTCTGTCTTTTAGGG	 CTCGAGGCTGTCCTTTTGAG	
Areg	 AGGACAATGCAGGGTAAAAGT	 AAGTGACAACTGGGCATCTG	
Il5	 GATGAGGCTTCCTGTCCCTA	 ACACTTCTCTTTTTGGCGGT	
Il13	 ACATCACACAAGACCAGACTC	 ACAGAGGCCATGCAATATCC	
Ifng	 GAGGAACTGGCAAAAGGATG	 GCTGATGGCCTGATTGTCTT	
Gapdh	 ACAACTCACTCAAGATTGTCAGCA	 ATGGCATGGACTGTGGTCAT	
Il12	 CAGTCCTGGGAAAGTCCTGC	 AGGAGGTAGCGTGATTGACAC	
Tnfa	 CCTGTAGCCCACGTCGTAG	 GGGAGTAGACAAGGTACAACCC	
Retnla	 ACTTCTTGCCAATCCAGCTAAC	 CAAGCACACCCAGTAGCAGT	
Chi3l3	 CCAGCAGAAGCTCTCCAGAAG	 TGGTAGGAAGATCCCAGCTGTA	
Clec7a	 GCATCCCAAACTACAGGAGGT	 TAGCTGGGAGCAGTGTCTCT	
Mrc1	 TCATTGGAAGATCCACTCTGG	 CAGCGCTTGTGATCTTCATTATAG	
Il4	 CTCGAATGTACCAGGAGCCA	 GTGGTGTTCTTCGTTGCTGTG	
Myd88	 GCACCTGTGTCTGGTCCATT	 TGTTGGACACCTGGAGACAG	
2.10 Dendritic cell Migration 
Before cell isolation, myometrium and decidua were dissected and only the 
myometrium was digested for cell preparation. Isolated myeloid cells (isolated as 
previously described) from pregnant uteri at midgestation (gestation day 9.5) 
were cultured on a 5mm trans-well insert (12 well plates Millicell from 
Millipore) with or without 0.1ng/µl IL-13 (Peprotech) in RPMI 10% FCS with 
penicillin and streptomycin. Every cell preparation per every uterus was split in 
two suspensions with an equal cell number to be treated or untreated. Both 
treated and untreated cell suspensions were cultured over a gradient of 0.1ng/µl 
of CCL21 in RPMI 10% FCS with penicillin and streptomycin. Cells were 
cultured for 14h and then cells from the upper and bottom chambers were 
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collected, counted and stained for flow cytometry analysis. Cells from the upper 
chamber were considered non-migrated, while cells from the bottom chamber 
were considered migrated. 
2.11 Immunohistochemistry and arterial remodelling 
Uterine tissues were dissected at gd9.5 and fixed in 10% formalin for 5h at RT, 
washed in PBS and stored in 70% ethanol. Then tissues were paraffin-embedded 
by an automatic processor and cut into serial sections at 7µm. Cut tissues at 
49µm of distance were dewaxed, re-hydrated, and stained in 50% Haematoxylin 
Gill (Sigma) and Eosin (Sigma). Tissue slides were scanned with Hamamatsu 
NanoZoomer-XR Digital slide scanner and then arterial remodelling was 
evaluated by two independent researchers as described in Kieckbusch et al, Jove, 
2015410. Spiral arteries cross-sections were determined microscopically within 
each block and analysed in triplicate using adjacent sections 49µm apart from 
each other. On each section, only the inner two-quarters of the decidua basalis 
were assessed to avoid the measurement of veins. We measured the five largest 
and roundest vessels by drawing a circle around the vessels borders (including 
media and pericytes) and the internal lumen area. We then calculated the mean 
areas for each section and determined by the average of the triplicates. 
Antigen retrieval was performed with either proteinase K (Sigma) or sodium 
citrate buffer. Sections were dewaxed, rehydrated, avidin-biotin blocking (Vector 
Labs) was performed and endogenous peroxidase activity was blocked (in 3% 
H2O2 in ddH2O for 30 min at RT) to avoid non-specific staining. Smooth muscle 
actin was stained with DAKO mouse anti-human smooth muscle actin (MO851) 
and it was stained with MOM kit (Vector Labs) following manufacturer 
instructions and combined with Vectastain Elite ABC-Alkaline phosphatase kit 
(Vector Labs). uMac were stained with Rat IgG2b anti-mouse anti F4/80 
(MCA497A488T BioRad) with Immpress Kit (Vector labs) and citrin was 
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stained with mouse anti-mouse anti-YFP (Abcam) and MOM kit (Vector Labs) 
combined with Vectastain Elite ABC-Alkaline phosphatase kit (Vector Labs). To 
stain for DCs, sections of cryo-embedded uterine tissue from pregnant females at 
gd9.5 were cut at 7µm and fixed in 4% formalin. Rat IgG2b anti-mouse anti-
MHC I-a/I-e (Biolegend) was used in combination with impress-AP (Vector 
Labs) and Hamster anti-mouse CD11c (Biolegend) was used in combination with 
biotinylated secondary anti-hamster IgG (Vector Labs) and Vectastain Elite 
ABC-HRP kit (Vector Labs). We used VectorRed (Vector Labs) and SigmaFast 
DAB (Sigma) as Alkaline Phosphate and Peroxidase substrate to stain for the 
selected antigens. Slides were then counterstained with 50% hematoxylin (5 sec), 
dehydrated and mounted using a xylene based media. 
Full descriptions of Antibodies and isotypes controls are in Table 10. 
Table 10 Table of antibodies used in immunohistochemical stainings 
Staining	
Antigen	
Retrival	
Antibodies	 Dilution	 Isotipe	
F4/80	(HIC-P)	 proteinase	K	 Anti-F4/80	from	AbD	
Bio-Rad	
MCA497A488T	
1:100	
Rat	IgG2b	
Double	staining	
for	DC	(HIC-F)	
None	(crio-
formalin	
fixed	slides)	
Rat	anti-mouse	MHC-
II:	Biolegend		
1:200		
Rat	IgG	Biolegend	
Hamster	anti-mouse	
CD11c	Biolegend		 1:100	
Purified	Armenian	
hamster	IgG	
BioLegend	
Anti-GFP	(HIC-
P)	
sodium	
citrate	buffer	
Anti-GFP	
1:50	
MOM	serum	
reagent	
(Vectorlab)	
Smooth	muscle	
actin	(HIC-P)	
sodium	
citrate	buffer	
Monoclonal	mouse	
anti-human	smooth	
muscle	actin	(DAKO	
M0851)	
1:100	
Mouse	IgG2a	
negative	isotype	
control	(DAKO	
X0943)	
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2.12 Foetal Ultra Sound biometry, foetal weight and foetal 
survival 
Foetuses and placentae from gd18.5 were weighted on an analytical scale and 
measures were recorded. Then, foetuses were collected in 4% PFA and hydrogel 
embedded for CT scan analysis. Foetal ultrasound biometry scan has been 
performed at the Department of Zoology (University of Cambridge) by Dr. 
Norman Shreeve. CT scan data were analysed on ImageJ (NIH) after selection of 
brain and abdomen sections. The weight of newborn pups from Il33cit/cit, Il33cit/het 
or C57BL/6 mothers mated with C57BL/6 males were recorded at day 7 and day 
14 after birth by Dr. Batika Rana. Statistics on newborn weights, foetal weights, 
placental weights and foetus-placental weight ratios were analysed as mix-model 
with SPSS (IBI) to take into account litter sizes. Breeding records from 
Roraflox/flox Il7cre/wt were analysed with GraphPad Prism by unpaired Student T-test 
to assess foetal loss in ILC2KO mouse models. 
2.13 LPS injections in pregnant mice  
Mice were mated and the day of plug was considered gd0.5. gd7.5 mice were 
injected IP with 0.02mg/g LPS E coli 055:B5 (Sigma) to induce ~50% embryo 
death. At gd9.5 uterine tissues were collected, and embryo death was evaluated 
as the percentage of implantation sites showing sign of death over the total 
number of implantation sites. Dead implantation sites were identified as black or 
puffy read and dysmorphic. Collected uteri were then processed for mRNA 
extraction and RT-qPCR and flow cytometry. Uterine tissues were not dissected 
in myometrium and decidua before isolation. Then, isolated myeloid cells 
(isolated as previously described) from treated and untreated uteri were stained 
for flow cytometry analysis. On a second experiment to evaluate LPS effect on 
the short-term and periphery, mice were injected with 0.02mg/g LPS E coli 
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055:B5 (Sigma) on gd8.5 and gd9.5 uteri and plasma samples were collected and 
homogenised to be processed with Pro-inflammatory cytokine assay (Mesoscale) 
described as followed. 
2.14 Single-plex and Multi-plex ELISA for cytokines 
IL-33 protein expression was evaluated on uterine tissues samples from virgin, 
midgestation myometrium, midgestation decidua and term mechanically 
homogenised using a tissue homogeniser (Stuart) with 1X cOmplete EDTAfree 
protease inhibitor tablets (Roche). Mouse IL-33 Ready-SET Go! (eBioscience) 
was used according to the manufacturer instruction to evaluate IL-33 
concentrations. IL-33 ELISA was done with the help of Dr. Batika Rana. Data 
were then normalised on the total protein per tissue, which was quantified using a 
Pierce BSA assay (Thermo Fisher). 
Pregnant uteri for multiplex analysis were weighted and 200mg of tissue was 
mechanically homogenised on ice with lysis buffer with 150 mM NACl, 20mM 
Tris (pH7.5), 1 mM EGTA (Sigma), 1% Triton X-100 (Sigma), Phosphatase 
inhibitors (Sigma) and Complete Protease inhibitors tablets (Roche). Plasma 
samples were prepared from fresh blood left to clot at room temperature for 30 
min, then blood was centrifuged 2000g for 15 min. IL-5 and IL-1b cytokines 
were tested with Pro-inflammatory cytokine assay (Mesoscale) by Core 
Biochemical Assay Laboratory (Addembrooke’s Cambridge University 
Hospital). 
2.15 Statistical analysis 
Graphs and statistics have been generated with Prism 7. One way-Anova was 
performed when we compared multiple independent variables on data normally 
distributed. Unpaired Student T-test was performed when two independent 
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variables were analysed on data normally distributed. Paired Student T-test was 
performed when two variables were compared from the same tissue (i.e. when 
the same cell population is split and then treated in different ways but the same 
variable is compared) on data normally distributed. Statistics comparing newborn 
weights, foetal weights, placental weights and feto-placental weight ratios were 
analysed with SPSS (IBM) with mix-model analysis to take into consideration 
the inter-litter variability. Foetal and newborns weight analyses contained 
foetuses from both the same litter and other litters. The mix-model approach 
takes into account for the partial interdependence of samples due to random 
factors (parental cross and different litter). The P values (showed) refer to the 
comparisons of different parental crosses. All data are presented as mean ± SEM 
and we represented p-value summary as: ns, not significant P > 0.05; *, P < 0.05; 
**, P < 0.01; ***, P<0.001; ****, P < 0.0001. 
Chapter 3: Uterine ILCs 
Elisa Balmas - January 2018   83 
3 UTERINE ILCS 
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3.1 Hypothesis and specific questions 
Considering the important role of innate immunity for the maintenance of 
pregnancy and the tissue modifications at the feto-maternal interface, we 
hypothesised that also ILCs may play important roles in the uterus. ILCs have 
indeed an essential role in immune defence, and regulation of tissue remodelling 
and immune homeostasis (Chapter 1.3). When we started uNK cells were the 
only uILCs characterised in the uterus. uNK cells have been studied and 
recognised as important players of tissue and immune homeostasis in the human 
and mouse decidua (Chapter 1.4.5). uILCs may be potentially involved in the 
maintenance of uterine immune and tissue homeostasis. In the uterus, tissue and 
hormonal changes happen very quickly, thus suggesting that the cytokine 
microenvironment needs to be constantly regulated. uILCs could be involved in 
this function, thanks to their ability to produce a vast range of cytokines when 
stimulated, and to their plasticity when inflammatory stimuli perturb the 
microenvironment. 
The aim of this chapter was to characterise and recognise uILCs in human and 
mouse uterine tissue. The identification and characterisation of uILCs other than 
uNK cells in human decidua and non-pregnant endometrium could open the 
study of these cells in the context of human physiology and pathology. However, 
the study of human tissues has obvious limitations, such as availability, large 
biological variability, and inability to study biological processes in vivo. 
Therefore, we focused most of our study on mice. The mouse is not a perfect 
model, but it allows the study of different tissues and stages of pregnancy that are 
not accessible from human samples. Furthermore, we aim to take advantage of 
KO and reporter mouse models to further characterise the function of these cells.  
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To set up the basis for the study of uILCs we asked the following questions: 
i. Can we identify uILCs in human tissues? 
ii. Are uILCs also present in mice, and does the genetic background affect 
them? 
iii. Do uILCs follow the canonical ILC classification, and are they 
independent of Rag genes? 
iv. What are the developmental requirements of uILCs, do they depend on 
Nfil3?  
v. Are uILCs tissue resident? 
vi. Are uILCs functionally active? 
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3.2 Uterine ILCs in Human tissues 
3.2.1 Phenotype of human uILCs  
We analysed samples obtained from first-trimester decidua and from 
endometrium of non-pregnant women during the luteal phase. Tissues were 
mechanically dissociated to avoid the loss of CD56 expression after enzymatic 
digestion. Indeed previous studies using this protocol showed that CD56 is 
affected by collagenase digestion and that CD56super-bright uNK cells can be only 
seen after mechanical isolation411. However, while the lack of enzymatic 
digestion will preserve extracellular markers expression, it may reduce the 
number of resident cells. 
According to the phenotypic characteristics of human ILCs (described in Table 2 
at page. 7,  
Table 4 at page. 12 and Table 6 at page. 17) we designed a panel that could 
identify all uILCs in one sample (gating strategy illustrated in Figure 18). 
Therefore, we included i) CD56 and T-BET to identify ILC1s; ii) GATA-3, 
CRTH2 and CD161 to identify ILC2s; iii) ROR-gt, NKp44 and c-Kit to identify 
ILC3s. We used a lineage strategy to eliminate the majority of B cells, T cells 
and myeloid cells (CD3, CD19, and CD14). While in the decidua the T cells are 
under-represented than other tissues, this lineage cocktail may include T cells 
down-regulating CD3. However, we expect CD3low T cells to be minimal and 
mostly eliminated by the use of the lineage cocktail on a bright fluorochrome. 
Then, we restricted our analysis on CD127+ve cells, with the assumption that all 
ILCs need CD127 for their development. With this strategy, the only sizeable 
population we could describe was that of uILC3s, defined as CD56+/-ve ROR-gt+ve 
c-Kit+ve NKp44+/-ve (Figure 18 and Figure 19). 
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Figure 18 Gating strategy to identify human uILCs 
Gating strategy with the aim to identify CD127+ve uILCs in human endometrium and decidua. This figure 
describes the steps required to exclude doublets, dead cells, cell debris and lineage (CD3, CD19, 
CD14)+ve cells. We did not select for CD56+ve cells (bona fide uNK cells included) to make sure we are 
not excluding ILC1s or ILC3s. We identified a small group of cells CD127+ve. CD127+ve FSC-Ahigh were 
not consistent among all patients, and they may be artefacts due to high auto-fluorescence of the tissue 
sample. Lin-ve CD127+ve cells were then analysed for the main transcription factors defining ILCs, but 
only ROR-gt showed consistently positive cells. We then compared uILC3s with uNK cells (identified as 
Live, CD45+ve, Lin-ve, CD9+ve, CD56+ve) Data representative of N=5 non-pregnant endometria and N=5 
first trimester decidua (here is presented a sample of decidua). This work has been performed in 
collaboration with Dr. Jean-Marc Doisne. 
We first identified that similar quantities of CD127+ve cells are present in both 
non-pregnant endometrium and decidua (Figure 19 A and E shows the statistics). 
We found that more than ~70% of CD127+ve cells were uILC3s and expressed 
ROR-gt (Figure 19 B and F show the statistics) in both non-pregnant 
endometrium and decidua and with similar frequencies. We then analysed 
NKp44, CD56 and c-Kit expression on these cells. The majority of uILC3s 
expressed NKp44 and should be considered NCR+ uILC3s, which are also co-
expressing higher levels of CD56 when compared to NCR-ve (or NKp44-ve) 
uILC3s (Figure 19 C and G shows the statistics). Interestingly, the proportion of 
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CD56+ve uILC3s increases during pregnancy (Figure 19 G). Furthermore, these 
cells express high levels of c-Kit. When compared to uNK cells (identified as 
Lin-ve CD56+ve CD9+ve CD127-ve) uILC3s express c-Kit, while it was undetectable 
in uNK cells.  
 
Figure 19 Identification of uILC3s 
(A and E) Identification of uILC3s from CD127+ve cells (gated as in Figure 18). (B and F) Identification 
of the proportion of ROR-gt expressing cells among CD127+ve cells. (C and G) NCR+ve and NCR-ve uILC3 
characterised respectively by presence or absence of NKp44. The majority of NKp44+ve cells are also 
CD56+ve. CD56+ve uILC3s increase their proportion during pregnancy. Data in A-D are representative of 
uILC3s in pregnant decidua. Data in E-G are displayed as mean ± SEM and were analysed using Student 
T-test. (N=5 non-pregnant endometria and N=5 first trimester decidua). This work has been performed in 
collaboration with Dr. Jean-Marc Doisne. 
Other than uILC3s, this gating strategy allowed the detection of extremely low 
numbers uILC2s (CD56-ve ROR-gt-ve GATA-3hi CRTH2+ve) with a frequency 
<0.01%. No CD127+ uILC1s (ROR-gt-ve T-BET+ve) could be detected in these 
samples. However, Vacca et al., reported that in the human decidua CD127-ve 
ILC1 are present373 and they were characterised by CD103 expression. We 
decided to further re-analyse our data without pre-gating on CD127 to define 
ILCs (Figure 20 A). 
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Figure 20 Gating strategy to identify human CD127+ve and CD127-ve uILC2s 
A) Gating strategy with the aim to identify both CD127+ve and –ve uILC2s in human endometrium and 
decidua. This figure describes the steps required to exclude doublets, dead cells, cell debris and lineage 
(CD3, CD19, CD14)+ve cells. We then gated on CRTH2+ve c-Kit-ve cells. We then identified uILC2w from 
their bright expression of GATA-3 and CD161. B) CRTH2low c-Kit+ve cells have been excluded because 
they are ROR-gt+ve/low CD56intermediate and GATA-3low. Expression of ROR-gt, CD56 and GATA-3 in 
CRTH2low c-Kit+ve was compared with uILC2s, uILC3s or uNK cells. uILC3s have been identified as in 
Figure 18; uNK cells have been identified as lineage (CD3, CD19, CD14)-ve CD9+ve CD56+ve cells. Data 
representative of N=10 non-pregnant endometria and N=10 first trimester decidua (here is presented a 
sample of decidua). 
With this new strategy, we identified uILC2s (Figure 21 A), and in this case, 
their proportion was similar to that ofuILC3s (~0.01%-0.04% of CD45+ve 
proportion). uILC2s are present in both non-pregnant and pregnant tissues in 
similar percentage (Figure 21 B). We further assess the expression of CD56 and 
CD127 on these uILC2s. As expected, uILC2s did not express CD56 and their 
level of CD127 was intermediate between uNK cells and uILC3 (Figure 21 C).  
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Figure 21 Analysis of uILC2s in pregnant decidua and non-pregnant 
endometrium 
(A) Representative plot identifying uILC2s (gated as in Figure 20). (B) Statistical analysis of uILC2s in 
non-pregnant endometrium and pregnant decidua. (C) Representative expression of CD56 and CD127 on 
uILC2s, uILC3 and uNK cells from the same sample (decidua). Data in A and C are representative of 
uILC2s and uILCs in pregnant decidua. Data in B are displayed as mean ± SEM and were analysed using 
Student T-test. (N=10 non-pregnant endometria and N=10 first trimester decidua).  
Additionally, we managed to obtain a single sample of uterine hysterectomy 
from a healthy patient from Dr. Miriam Baumgartner (a full human uterus which 
contains all the different uterine layers). We used a similar strategy to test the 
presence of uILCs. Given the nature of this hard muscular tissue, we had to 
perform an enzymatic digestion to obtain leukocytes and with this method, we 
found a proportion of uILC2s that was 0.17% of total CD45+ve leukocytes. In 
absolute number, this accounted for 2040 cells in total within the tissue analysed. 
As a rough estimate, and assuming an equal distribution within the uterus, one 
could expect to find ~20400 uILC2s in the whole organ. In this organ, only 
uILC2s have been analysed and further studies will be important to assess the 
presence of other ILCs (including uNK cells, uILC1s and uILC3s). 
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Figure 22 uILC2s human myometrium 
This plot represents the proportion of uILC2 in a sample of uterine hysterectomy (human myometrium 
and endometrium). Cells were gated from CD45+ve Lin-ve CRTH2+ve CD161+ve and then here we identify 
as uILC2s if GATA-3+ve and CD56-ve. 
In conclusion, these results show the presence of CD127+ve and CD127-ve uILCs 
in the pregnant decidua, non-pregnant endometrium and non-pregnant 
myometrium (Figure 23). uILC3s are the only uILCs that express CD127, while 
the others have low or no expression of this receptor (references to uILC1s from 
Vacca et.al.373). uILC2s can be found in both myometrium and decidua. Finally, 
we show that the uILCs composition is similar in non-pregnant uterine mucosa 
and in the decidua, and none of these populations expands predominantly in 
pregnancy. 
 
Figure 23 Summary of uILCs composition in the human tissue 
Schematic representation of the human pregnant uterus during the third trimester of human pregnancy. 
We identified uILC2s in both myometrium and mucosa and uILC3s in the mucosa. Vacca et al,. 
373identified CD127-ve uILC1s other than uterine NK cells75. 
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3.3 uILCs in mouse uterine tissues 
Once we discovered that uILCs are present in human decidua and myometrium 
we followed up this study in mouse models. 
3.3.1 Phenotyping of uILCs in C57BL/6 and BALB/c mice 
We characterised mouse uILCs in both virgin and pregnant mice, and in these, at 
two different stages of pregnancy: midgestation and term. In particular, uterine 
tissue at midgestation can be dissected into myometrium and decidua, while in 
humans, only the decidua is accessible from elected abortions. According to the 
expression of known extracellular and intracellular markers on mouse ILCs in 
other tissues (Table 1, Table 3 and Table 5), we refined a new gating strategy to 
identify ILCs in the mouse uterus (Figure 24). We started by characterising 
uILCs by their transcription factors and the lack of Lineage markers. As for the 
human decidua, also in mouse uterus, the quantity of T cells account for less than 
~5% of uterine leukocytes281. We used a Lineage cocktail to exclude mainly for 
T cells and B cells with CD3 and CD19. Additionally, we purified the leukocyte 
population from the majority of the granulocytes by using a percoll gradient and 
we gated out CD11b+ve cells independently from our lineage cocktail. We may 
expect some CD3low expressing T cells as a contaminant with this Lineage 
cocktail, therefore we used the lineage antibodies on a bright fluorophore (APC). 
We then identified uILCs by the expression of transcription factors. In particular, 
uILC1s were identified by the expression of T-BET and NK cells markers, 
uILC2s by GATA-3 expression and uILC3s by ROR-gt expression. 
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Figure 24 Gating strategy for the identification of uILCs 
Gating strategy with the aim to identify uILCs in mouse uterine tissues. This figure describes the steps 
required to exclude doublets, dead cells and cell debris. uILC1s have been identified from NK1.1+ve, 
CD11b-ve and low, Lin (CD3, CD19)-ve, NKp46+ve cells. Then bona fide NK cells have been excluded and 
only EOMES-ve T-BET+ve have been considered as uILC1s (blue) for further analysis. To gate on uILC2s 
and uILC3s we excluded NK1.1+ve, CD11b+ve, Lin+ve, and NKp46+ve cells. uILC2s are identified as 
GATA-3+ve and ST2+ve (black), and uILC3 as ST2-ve, CD127+ve, and ROR-gt+ve (red), all ILC3s have been 
back-gated for GATA-3 expression and all uILC3s are GATA-3low. This work has been performed in 
collaboration with Dr. Jean-Marc Doisne. 
 
Quantification of uILCs showed that the main ILC subset in the virgin uterus is 
uILC1 which accounts for ~1.4% of uterine leukocytes or ~3000 cells. Their 
proportion reduces during gestation, but their numbers remain stable over the 
course of pregnancy (Figure 25 A). This suggests that uILC1s do not 
preferentially expand among uterine leukocytes. Additionally, uILC1s (besides 
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uNK cells) are the only ILCs subset identified in the mouse decidua at 
midgestation. However, numbers and percentages of decidual uILC1s are lower 
when compared to the virgin uterus or the pregnant myometrium. uILC2s and 
uILC3s are instead deeper in the tissue and cannot be found in the decidua 
(Figure 25 B and C). These uILCs show also a tendency to increase at 
midgestation and to reduce at term (Figure 25 B and C). In particular, uILC3s are 
the rarest among uILCs in the mouse virgin and pregnant uterus (~0.6% of 
leukocytes or 2000 cells) and reduce down to ~500 cells at term. 
 
Figure 25 Proportion and quantification of uILCs in virgin and pregnant 
tissues 
uILCs quantification in the uterus of mice non-pregnant (V), at midgestation (Mid) and at Term. We 
dissected and analysed separately Myometrium (M) and Decidua (D) from Mid uteri. (A) Analysis of the 
distribution of uILC1s N=6 V and Mid uteri and N=5 Term uteri analysed. (B) Analysis of the 
distribution of uILC2s N=8 experiments with V and Mid uteri and N=experiments 5 with Term uteri 
analysed. (C) Analysis of the distribution of uILC3s N=7 experiments with V and Mid uteri and N=5 
experiments with Term uteri analysed. All experiments required pooling of ±10 virgin uteri or ±5 
pregnant uteri (Mid and Term) per experiment. Absolute numbers have been normalised to the number of 
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organs pooled per experiment. Data are displayed as mean ± SEM and were analysed using one-way 
Anova; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. This work has been partially 
performed in collaboration with Dr. Jean-Marc Doisne. 
We analysed the three different subsets separately and we tried to characterise 
specific extracellular markers to identify them. The main problem of ILC1s is 
their heterogeneity (as explained in Chapter 1.1.2) and so far, the main 
distinction between bona fide NK cells and ILC1s is EOMES expression, which 
marks NK cells. We compared uterine non-NK uILC1s with uterine cNK cells 
for their expression of CD49a and DX5 and their reactivity to DBA (Figure 26). 
We found that uILC1s can be distinguished from cNK cells because they express 
CD49a but not DX5. Interestingly, we found that uILC1s are negative or low for 
DBA. Therefore, uILC1s correspond to the subset that in the past was referred as 
DBA-ve uNK cells. However, description of uterine trNK cells from Sojka et al.,48 
and Boulenouar et al.,56 indicated that uILC1s resemble uterine trNK cells and 
that they differ for DBA expression.  
 
Figure 26 uILC1s phenotypic characteristics 
Identification of DBA, CD49a and DX5 expression on uILC1s and comparison with uterine cNK cells 
(CD45+ve Lin-ve NK1.1+ve T-BET+ve EOMES+ve CD49a-ve DX5+ve). Data are representative of N=3 uteri 
for DBA and DX5 expression and N=6 uteri for CD49a expression. This work has been performed in 
collaboration with Dr. Jean-Marc Doisne. 
uILC2s have been analysed for the main extracellular markers known to identify 
murine uILC2s from other tissues (See Table 1). We stained for ST-2, CD25, 
SCA-1, ICOS, c-Kit and IL-17RB. While CD25 and SCA-1 stain almost 100% 
of uILC2s, ICOS, c-Kit and IL-17RB stain the majority but not all GATA-3+ve 
ST-2+ve uILC2s (Figure 27 A). In this aspect, uILC2s are therefore similar to 
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uILC2s described in other tissues. Additionally, considering the low expression 
of CD127 on human uILC2s, we investigated CD127 expression on murine 
uILC2s and compared it with uILC3s and uILC1s expression. Interestingly, 
uILC3s express higher level of CD127 compared to other uILCs (Figure 27 B). 
uILC2s have intermediate CD127 expression and uILC1s (cNK cells and bona 
fide uILC1s) are negative. This peculiar pattern resembles CD127 expression on 
uILCs extracted from human samples (Chapter 3.2). We then investigated MHC 
II expression on uILC2s (Figure 27 B) but no expression could be detected. This 
suggests that it is unlikely that uILC2s participate in the antigen presentation and 
direct T cell activation at the feto-maternal interface. 
 
Figure 27 uILC2s phenotypic characteristics 
(A) Identification of CD25, SCA-1, ICOS, c-Kit and IL-17RB expression on uILC2s. Data shown are 
from virgin uILC2s gated as shown in Figure 24 and they are representative of N=18 experiments on V 
and Mid. (B) Identification of CD127 expression (representative of N=7 experiments on V and Mid) by 
uILCs and MHC II expression on uILC2s (N=2 independent experiments on V) and compared with 
uILC2s FMO for MHC II. This work has been partially performed in collaboration with Dr. Jean-Marc 
Doisne. 
We analysed uILC3s more in-depth and we found that ~30-35% of uILC3s 
express CCR6 and may be a subset of LTi-like uILC3s (Figure 28). However, 
unlike human uILC3s, this subset is NCR–ve, characterised by the lack of NKp46 
expression (Figure 28 A).  
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Figure 28 uILC3s phenotypic characteristics 
(A) Identification of NKp46 and CCR6 expression on uILC3s and comparison with uterine cNK cells 
(CD45+ve Lin-ve NK1.1+ve T-BET+ve EOMES+ve CD49a-ve). Data are representative of N=4 experiments for 
CCR6 and N=16 experiments for NKp46. (B) The proportion of CCR6 +ve ILC3s (LTi) in both virgin and 
pregnant uterus (Mid myometrium). Data in B are displayed as mean ± SEM and were analysed using 
unpaired Student T-test P =0.9751 (N=4 independent experiments). This work has been performed in 
collaboration with Dr. Jean-Marc Doisne. 
 
To assess whether the genetic background of mouse strains may affect uILCs, we 
characterised these cells in both C57BL/6 and BALB/c mice. These two mouse 
trains of mice are known to preferentially activate type-1 or type-2 immune 
responses respectivelly412, and therefore their background may influence uILC 
composition. Mouse models deficient in ILCs or cytokines can be found in 
different backgrounds. Therefore, we decided to analyse the composition and 
presence of uILCs in BALB/c to potentially take advantage of available BALB/c 
KO mouse models. Analysis of uILC1s in BALB/c needs to take into 
consideration that these mice do not express NK1.1. We changed our gating 
strategy to avoid using NK1.1, thus relying on NKp46 expression (which is 
brighter in BALB/c than in C57BL/6 mice). Additionally, we also wanted to 
identify trNK cells in this context, because there is no available record on these 
cells subsets in BALB/c mice. We focused on virgin and midgestation uterus for 
this analysis. We identified cNK cells, trNK cells and non-NK uILC1s (Figure 29 
A-C and Table 11). While in the virgin uterus and in decidua the majority of 
group 1 ILCs are ucNK cells, in the myometrium there is a preferential 
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expansion of utrNK cells. uILC1s account for ~6000 cells in virgin and remain 
stable during pregnancy. However, as we noticed for C57BL/6 mice, decidua 
have a lower number of uILC1s and they account for ~1000 cells (Table 11). We 
then identified uILC2s and uILC3s. Also in BALB/c, we could not detect any of 
these subsets in the decidua. We focus our analysis on myometrium and we 
found extremely low number and percentages of uILC2 (Figure 29 D-E) and 
uILC3s (Figure 29 F-G) in virgin uterus (~160 and ~50 cells respectively), which 
then increase at midgestation to ~2000 and ~300 respectively (although uILC3s 
numbers are still really low and lower than in C57BL/6 Table 11). 
 
Figure 29 Proportion and quantification of uILCs in virgin and pregnant 
BALB/c tissues. 
uILCs quantification in the uterus of BALB/c mice non-pregnant (V) and at midgestation (Mid). We 
dissected and analysed separately Myometrium (M) and Decidua (D) from Mid uteri. (A) uILC1s total 
cell numbers; (B) Proportion of uILC1s on total uterine leukocytes; (C) Ratio and proportions of uILC1s 
subsets among uILC1s. (D) uILC2s total cell numbers; (E) Proportion of uILC2s on total uterine 
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leukocytes; (F) uILC3s total cell numbers; (G) Proportion of uILC3s on total uterine leukocytes. All 
experiments required pooling of ±10 virgin uteri or ±5 pregnant uteri per experiment. Absolute numbers 
have been normalised to the number of organs pooled per experiment. N=3 experiments in V and N=3 
experiments in Mid. Data are displayed as mean ± SEM. Data in A-B were analysed by one-way Anova 
and D-G were analysed using unpaired Student T-test P >0.05; *, P < 0.05; **, P < 0.01.  
 
Table 11 Absolute cell numbers from C57BL/6 and BALB/c mouse uteri 
Table presenting absolute cell numbers. C57BL/6 N=8 experiments in virgin and midgestation (Mid); 
BALB/c N=3 experiments in virgin and N=3 experiments in Mid. All experiments required pooling of 
±10 virgin uteri or ±5 pregnant uteri per experiment. Absolute numbers have been normalised to the 
number of organs pooled per experiment. Data are displayed as mean ± SEM 
 
C57BL/6	 BALB/c	
3.3.2 uILCs in Nfil3-/- and Rag2-/- mouse models 
We took advantage of Rag2-/- and Nfil3-/- mouse models to study uILCs biology 
and development. First of all, once we identified uILCs by extracellular and 
intracellular markers, we needed to be sure that these cells do not require Rag 
genes to develop and therefore they do not belong to the T cell lineage. Giving 
absolute	cell	numbers	x	104	
CD45+ve	(Virgin)	 17.667±1.87	 12±1	
CD45+ve	(Mid	Myometrium)	 48.723±8.04	 66.667±13.33	
CD45+ve	(Mid	Decidua)	 73.429±7.09	 48±6	
uILC1	(Virgin)	 0.306±0.06	 0.618±0.07	
uILC1	(Mid	Myometrium)	 0.368±0.05	 0.793±0.3	
uILC1	(Mid	Decidua)	 0.092±0.02	 0.086±0.03	
cNK	(Virgin)	 0.809±0.21	 2.493±0.58	
cNK	(Mid	Myometrium)	 0.222±0.13	 2.681±1.4	
cNK	(Mid	Decidua)	 0.768±0.07	 0.941±0.35	
trNK	(Virgin)	 1.536±0.29	 1.007±0.09	
trNK	(Mid	Myometrium)	 0.958±0.58	 7.411±3.54	
trNK	(Mid	Decidua)	 1.071±0.23	 0.400±0.13	
uILC2	(Virgin)	 0.0720±0.03	 0.016±0.0003	
uILC2	(Mid	Myometrium)	 0.300±0.07	 0.313±0.08	
uILC3	(Virgin)	 0.048±0.02	 0.004±0.001	
uILC3	(Mid	Myometrium)	 0.215±0.05	 0.027±0.01	
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the many similarities that ILCs share with T cells, this distinction is extremely 
important and establishes them as part of the innate immunity. We started by 
analysing the virgin and pregnant uterus of Rag2-/-, which are devoid of T cells. 
In both pregnant and virgin tissues, we found all the three subsets of uILCs 
studied in this chapter (Figure 30). The presence of these cells in Rag2-/- mice 
demonstrates that they are not the result of T cells contamination in our C57BL/6 
and BALB/c data, but are instead bona fide ILCs. 
 
Figure 30 uILCs in Rag2-/- 
Representative plots of uILC1s (blue), uILC2s (black) and uILC3s (red) in Rag2-/- mice (N=2 
independent experiments). This work has been performed in collaboration with Dr. Jean-Marc Doisne. 
NFIL-3 is a transcription factor known for its importance for cNK cells biology. 
The lack of this transcription factor results in absence of cNK cells from the 
spleen or the liver55,130. However, liver ILC1s and utrNK cells are retained in 
these organs in Nfil3-/- mice as residual cells48,56, thus supporting the speculation 
that NFIL-3 independency may be a signature of tissue residency. Additionally, 
considering the importance of NFIL-3 for the development of all subsets of ILCs 
from the CLP (Chapter 1.2) we decided to study Nfil3-/- mice to further 
understand whether this transcription factor was involved also in uILCs 
development. Parallel experiments from Dr. Jean-Marc Doisne on the same mice 
showed the absence of Payer’s patches and ILCs in lung, intestine, liver and 
spleen 56. We analysed the virgin uterus from WT and KO mice, while pregnant 
uterus was analysed in the laboratory by Dr. Selma Boulenouar56 (Figure 31). 
ucNK cells numbers and percentages were extremely reduced in Nfil3-/- uteri as 
expected. However, uILC1s and uILC3s were not. In fact, uILC1s were even 
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increased in numbers. With utrNK cells mildly reduced, uILC2s were the only 
absent uILC subset in Nfil3-/- mice. Therefore, uILCs differ from other ILCs for 
their developmental requirements, with the exception of uILC2s and ucNK cells. 
 
Figure 31 uILCs in Nfil3-/- 
uILCs quantification in the uterus of C57BL/6 (WT) and Nfil3-/- non-pregnant mice. (A) Analysis of the 
frequency of uILCs (N=3 independent experiments). Giving the limited number of cells per organ, all 
experiments required pooling of ±10 virgin uteri per experiment. Absolute numbers have been normalised 
to the number of organs pooled per experiment (B) Analysis of the numbers of uILCs (N=3 independent 
experiments). (C) Representative plots comparing WT and Nfil3-/- uILCs distribution. Data in A and B are 
displayed as mean ± SEM and WT and KO data were compared and analysed using unpaired Student T-
test; *, P < 0.05. This work has been performed in collaboration with Dr. Jean-Marc Doisne. 
3.3.3 CHILP or ILC2 precursors cannot be found in the uterus 
Studies of parabiosis described in 1.2 have demonstrated that ILC1s, ILC2s and 
ILC3s are tissue resident and are rarely replenished from the bone marrow at 
steady state. Similarly, the lack of requirement for NFIL-3 during the 
development of tissue-resident hepatic ILC148, uterine trNK cells, uILC1 and 
uILC3 described in chapter 3.3.2 and from Boulenouar et al. 56 indicate that these 
cells do not necessarily follow the conventional path of development described 
from hematopoietic tissues. We hypothesised that uterine trNK cells, uILC1s and 
Uterine group 2 innate lymphoid cells and reproduction 
102  Elisa Balmas - January 2018 
uILC3s may be derived from a tissue-resident progenitor. cNK cells have been 
demonstrated to be a subset of circulating ILCs, but this is not the case for 
ILC2s, which in the lung can expand in inflammatory conditions, with only a 
small population coming from the circulation119. In this context, ucNK cells and 
uILC2s may be developing from bone marrow progenitors. Alternatively, 
uILC2s may start their early stage of differentiation in the bone marrow (in an 
NFIL-3-dependent fashion) and then complete their maturation in the tissue, 
similarly to the differentiation of naïve T cells into T helper effectors413. CD34+ve 
and progenitors with NK potential have been described in the human and mouse 
uterus350,374. We started preliminary experiments to assess the presence of early 
ILCs progenitors in the uterus, including ILCs committed progenitors CHILP, 
ILC2s committed progenitors ILC2ps, NK committed progenitors NKps. We 
started by setting up the gating strategy to identify these progenitors from bone 
marrow (Figure 32). These are rare populations and it may be challenging to find 
them in the mouse uterus, where the absolute number of leukocyte is much lower 
than in the bone marrow. For this reason, cells from many mice were pooled 
together to reach a suitable number and we used a more complex linage strategy 
that included CD3, CD5, CD19, B220, TER119 and GR-1. 
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Figure 32 Gating strategy for the identification of progenitors of ILCs and 
NK cells  
Gating strategy with the aim to identify CHILP, ILC2p and NKps in mouse bone marrow. CHILP were 
identified as CD45+ve, Lin-ve, CD11b-ve, NK1.1-ve, DX5-ve, CD127+ve and a4b7+ve. LC2ps were identified 
as CD45+ve, Lin-ve, CD11b-ve, NK1.1-ve, DX5-ve, CD127+ve and a4b7+ve, CD25+ve and SCA-1+ve. NKps 
were identified as CD45+ve, Lin-ve, CD11b-ve, NK1.1-ve, DX5-ve, NKG2D+ve and CD122+ve. Linage used for 
the identification of progenitors included CD3, CD5, CD19, B220, TER119 and GR-1. N=3 independent 
experiments. Giving the limited number of cells per organ, all experiments required pooling of ±10 virgin 
uteri or ±5 pregnant uteri per experiment. Absolute numbers have been normalised to the number of 
organs pooled per experiment. 
We identified CHILP as CD45+ve, Lin-ve, CD11b-ve, NK1.1-ve, DX5-ve, CD127+ve 
and a4b7+ve, which differ from ILC2p for the expression of CD25 and SCA-1. 
NKps were then identified among CD45+ve, Lin-ve, CD11b-ve, NK1.1-ve, DX5-ve, 
NKG2D+ve and CD122+ve (Figure 32). When we applied this strategy to the 
uterus, we could not identify any early or late ILCs precursors in either non-
pregnant or uteri at midgestation (Figure 33). The limiting number of cells per 
uterus (±1-1.5*106 cells from ±10 pooled virgin uteri or ±5 pregnant uteri) may 
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be the reason why we could not identify early ILC precursors in the uterine 
tissue. However, we cannot exclude that uterine ILC progenitors may have a 
different phenotype than bone marrow precursors.  
 
Figure 33 No uILC progenitors can be identified in the uterus 
(A) Representative plots for the identification of CHILP and ILC2ps in the bone marrow (BM), and in the 
virgin (V) and pregnant uterus (Mid). No distinction between Myometrium and Decidua has been done at 
this stage and the Mid uterus has been processed in full. (B) Quantification of ILC2ps and CHILP 
percentages and cell numbers extracted from BM, V and Mid uteri. N=3 independent experiments. All 
experiments required pooling of ±10 virgin uteri or ±5 pregnant uteri per experiment. Absolute numbers 
have been normalised to the number of organs pooled per experiment. Data in B are displayed as mean ± 
SEM and analysed using one-way Anova; *, P < 0.05. 
Interestingly, when we applied this strategy to identify early NK progenitors, we 
found a sizable population which has the same extracellular characteristics of 
bone marrow NKps147,148. These uterine NKps have a higher frequency in virgin, 
while their numbers remain stable in pregnancy (Figure 34). This finding 
indicates that this cell population may be indeed a pool of early progenitors that 
have the potential to differentiate into uterine NK-like ILC1s. This was very 
interesting, but because the origin of uterine NK cells goes beyond the main aim 
of this dissertation, and it was decided that another student would follow up this 
finding. To conclude this part, bona fide NK cells may indeed derive from tissue-
resident progenitors, while the origin of other uILCs is still unclear. 
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Figure 34 Identification of NK progenitors in the uterus 
(A) Representative plots for the identification of NKps in the bone marrow (BM), and in the virgin (V) 
and pregnant uterus (Mid). NKps were identified as CD45+ve, Lin-ve, CD11b-ve, NK1.1-ve, DX5-ve, 
NKG2D+ve and CD122+ve. No distinction between Myometrium and Decidua has been done at this stage 
and the Mid uterus has been processed in full. (B) Quantification of NKps percentages and cell numbers 
extracted from BM, V and Mid uteri. N=3 independent experiments. All experiments required pooling of 
±10 virgin uteri or ±5 pregnant uteri per experiment. Absolute numbers have been normalised to the 
number of organs pooled per experiment. Data in B are displayed as mean ± SEM and analysed using 
one-way Anova; ***, P < 0.001; ****, P < 0.0001. 
3.3.4 Activation of uILCs 
We extracted and in vitro activated uILCs to identify the cytokines that stimulate 
them and those they produce. We decided to use a short activation (4h) with 
cytokine-cocktails known to activate ILCs in other tissues. Activation with PMA 
and Ionomycin was used as positive control. uILC1s produce IFN-g only when 
stimulated by either PMA-Ionomycin or specific cytokines such as IL-12 and IL-
15 (Figure 35 A and B). In addition, Doisne et al., 76 showed that uILC1s 
response is similar also in midgestation, although both myometrium and decidual 
uILC1s produce a higher amount of IFN-g than virgin uILC1. Similarly, uILC3s 
produce a higher amount of IL-22 and IL-17 when stimulated. IL-22 production 
is increased only by specific activation with IL-1b and IL-23, but not by 
unspecific PMA-Ionomycin activation (Figure 35 E and F). Interestingly, uILC2s 
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and uILC3s produce cytokines even without any stimulation at all (only 4h of 
culture with Brefeldin A and Monensis before staining). uILC2s have the 
peculiar characteristic of producing a high amount of IL-5 with or without 
stimulation and they increase IL-5 expression with specific IL-25 and IL-33 
activation (Figure 35 C and D). However, this was not the case for IL-13, which 
was induced in uILC2s by PMA and Ionomycin activation but not upon IL-25 
and IL-33 specific stimulation. This is in stark contrast with the production of IL-
13 in lung ILC2s and this will be discussed in Chapter 4.3, Figure 51 at page 
132.  
 
Figure 35 Activation of uILCs and cytokine production 
(A) Representative plots for the identification of IFN-g producing uILC1s in virgin tissues. (B) 
Quantification of the percentage of uILC1s that produce IFN-g without stimulation (NS) or with PMA-
Ionomycin (P/I) stimulation, or with IL-12 and IL-15 4h stimulation (12-15). (C) Representative plots for 
the identification of IL-5 and IL-13 producing uILC2s in virgin tissues. (D) Quantification of the 
percentage of uILC2s that produce IL-5 and IL-13 without stimulation (NS) or with PMA-Ionomycin 
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(P/I) stimulation, or with IL-33 and IL-25 4h stimulation (25-33). (E) Representative plots for the 
identification of IL-17 and IL-22 producing uILC3s in virgin tissues. (F) Quantification of the percentage 
of uILC3s that produce IL-17 and IL-22 without stimulation (NS) or with PMA-Ionomycin (P/I) 
stimulation, or with IL-1b and IL-23 4h stimulation (1-23). N=6 independent experiments per cell type. 
All experiments required pooling of ±30 virgin uteri per experiment. Per every experiment, the single cell 
suspension had been equally distributed to be tested for all the three experimental conditions. Data in B 
are displayed as mean ± SEM and analysed using two-way Anova; ***, P < 0.001; ****, P < 0.0001. 
This work has been performed in collaboration with Dr. Jean-Marc Doisne. 
Other cytokine signals may be involved in the activation of uILC2s and IL-13 
induction, such as IL-2 or IL-7. Preliminary experiments on IL-2 showed that 
this cytokine could have indeed an effect on uILC2s numbers (Figure 36). In 
fact, 3 days in vivo IP injections of IL-2 and anti-IL-2 can stimulate ILC2s 
expansion. However, IL-2 may not be physiological since there is no expression 
of IL-2 production in the human decidua414 and there is no current evidence of 
IL-2 expression in murine myometrium or decidual tissues. However, further 
analysis of the uterine microenvironment combined with the analysis of cytokine 
receptors expressed by uILC2s may help to find the physiological conditions to 
induce IL-13 secretion and properly activate uILC2s. 
 
Figure 36 in vivo IL-2 induction of uILC2s 
Dot plots relative to a preliminary experiment with injections of IL-2 and anti-IL-2 antibodies in virgin 
mice. Mice have been injected IP for 3 days and then uteri analysed. N=1 experiment, 5 mice have been 
pooled per group.  uILC2s have been gated as shown in Figure 24. 
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Figure 37 uILC2s are the primary source of IL-5 
Quantification of the percentage of uILC2s and Lin+ve CD4+ve cells that produce IL-5 and IL-13 without 
stimulation (NS), or with IL-33 and IL-25 4h stimulation (+IL-25/IL-33), or with PMA-Ionomycin 
(PMA/IONO) stimulation. N=6 independent experiments. All experiments required pooling of ±30 virgin 
uteri per experiment or ±15-20 pregnant uteri per experiment. Per every experiment, the single cell 
suspension had been equally distributed to be tested for all the three experimental conditions. Data are 
displayed as mean ± SEM and analysed using two-way Anova; **, P < 0.01; ***, P < 0.001; ****, P < 
0.0001.  
Therefore, in the uterine tissue uILC2s preferentially express IL-5. In accordance 
with published studies226, ILC2s and not T cells (also in the uterus226) are the 
primary source of IL-5 (Figure 37). Indeed, among activated leukocytes, uILC2s 
were the only IL-5 and IL-13 positive cells after short activation. Uterine T cells 
may be responsive only after longer activation. In line with this, it is possible that 
also in the uterus uILC2s have the central role in regulating uEo homeostasis via 
IL-5232,415. We decided to explore this possibility by comparing uEo in Rag2-/- 
Il2rg-/- (these mice lack all ILCs, as well as T and B cells) with Rag2-/- (These 
mice have all ILCs, but lack T and B cells) and WT mice. Since Rag2-/- Il2rg-/- 
mice are alymphoid, they lack also T and B cells and therefore they are an 
imperfect model for the study of ILCs biology. Therefore, we need to compare 
their cellular phenotype with Rag2-/- as a control for the lack of T and B cells. 
Our preliminary results on these mouse models showed that uEo reside in the 
myometrium and none can be found in the decidua in either WT or Rag2-/- mice 
(Figure 38). Additionally, Rag2-/- Il2rg-/- mice have a strong reduction of uEo in 
both non-pregnant and at midgestation uterus when compared to WT mice. 
Instead, Rag2-/- mice are not devoid in uEo and show similar frequencies as WT 
mice. This suggests that uILCs (and potentially IL-5 producers uILC2s) are 
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involved in uEo homeostasis and it further confirms that uILCs and not T cells 
are the main producers of IL-5 in the mouse uterine tissue. 
 
Figure 38 IL-5 produced by ILC2s may be involved in uEo activation 
(A) Quantification of the percentage of uEo in virgin (V) and midgestation (Mid) uteri of C57BL/6 (WT, 
black), Rag2-/- (red) and Rag2-/- Il2rg-/- mice (purple). (B) Representative plots identifying uterine 
Eosinophils in WT and KO mouse uterine tissues (N=3 independent experiments). All experiments 
required pooling of ±10 virgin uteri or ±5 pregnant uteri per experiment. Absolute numbers have been 
normalised to the number of organs pooled per experiment. Cells were gated as CD45+ve, CD11b+ve, 
F4/80-ve, MHC II-ve, Ly6C-ve, Ly6G-ve. Data in A are displayed as mean ± SEM and WT data were 
compared with KO data and analysed using one-way Anova; *, P < 0.05; **, P < 0.01. 
Interestingly, uEo were not the only cells affected in this mouse model. uDCs 
and uMac were increased, in particular in the myometrium at midgestation. 
However, some cell type in this mouse model can increase in number due to 
homeostatic expansion following the increased availability of growth factors 
because of the lack of competition from the absent innate lymphocytes.  
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Figure 39 uILC deficiency affect uDCs and uMac numbers 
(A) Quantification of the percentage of uDCs and uMac in virgin (V) and midgestation (myometrium as 
M and Decidua as D). We analysed uteri from C57BL/6 (WT, black), Rag2-/- (red) and Rag2-/- Il2rg-/- 
mice (purple uDCs were gated as CD45+ve, F4/80low/-ve, MHC IIbright, Ly6C-ve, Ly6G-ve, CD11c+ve, 
CD80+ve/low. uMac were gated as CD45+ve, F4/80+ve, MHC II+ve/low, Ly6C-ve, Ly6G-ve, CD11b+ve.  (N=3 
independent experiments). All experiments required pooling of ±10 virgin uteri or ±5 pregnant uteri per 
experiment. Absolute numbers have been normalised to the number of organs pooled per experiment. 
Data in are displayed as mean ± SEM and WT data were compared with KO data and analysed using one-
way Anova; **, P < 0.01; ****, P < 0.0001. 
In conclusion, the preliminary analysis of these three mouse models justified 
further investigation of the role of uILC2s in mouse uterus using mice that 
selectively lack ILC2s.  
3.4 Conclusions and discussion 
We have shown in this Chapter that uILC3s and uILC2s are present in the human 
decidua in addition to CD103+ve CD127-ve uILC1s described by Vacca et al. 373 
and decidua uNK cells (Chapter1.4.5). The low CD127 expression is a shared 
characteristic of mouse and human uILC1s and uILC2s. In the uterus, cytokines 
signals may influence CD127 expression, such as high availability of IL-7416. 
Additionally, given the importance of TGF-b signalling in this organ75,361,417, 
TGF-b may also down-regulate CD127 expression on uILCs, as it has been 
shown in the context of T cell biology418. Additionally, high GFI1 expression in 
uILC2s may also down-regulate CD127 in this subset419. Alternatively, uILCs 
subsets may have a different pathway of development, as suggested by the NFIL-
3-independent development of uILC1s and uILC3s. Furthermore, we cannot 
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exclude that both human and mouse CD127-ve uILC1s may be also an 
intermediate step of uNK cells development. Also, uILC3s may be an additional 
source of uNK cells. The first report identifying human uILC3s 420 described 
them as stage 3 immature uNK cells and potentially their expression of NCRs 
may indicate that this subset is indeed plastic towards uILC1s (or uNK cells as 
described in Chapter 1.3.3). AhR inhibition on ILC3s can, for example, induce 
their transdifferentiation into NK cells109 and a similar mechanism may be 
involved in the uterus. Indeed, differentiation of IFN-g producing uNK cells is 
altered in Ahr-/- mice421. We believe that uNK cells and/or uILC1s may partially 
derive from uILC3s and current studies in the lab are trying to assess this 
hypothesis by using ROR-gT fate mapping mice. Furthermore, recent studies 
suggest the possibility that NK cells can convert into ILC1s422. This may be 
potentially assessed by studying group 1 ILCs (cNK cells, trNK cells and 
uILC1s) in SMAD-4-/- mice. Additionally, current studies in the lab are trying to 
assess the origin and relationship between group 1 ILCs and uterine NK cell 
precursors by bulk and single cell RNAseq. 
Extensive work from Anne Croy’s laboratory has tried for many years to 
characterise the phenotype, development and origin of DBA+ve and DBA-ve uNK 
cells, which belong to group 1 ILCs. Most previous findings, however, were 
supported by histology, which has limitations to identify ILC subsets. We were 
able to integrate DBA staining in our flow cytometry panel and that allowed us to 
assign ILCs to the classically defined DBA+ve and DBA-ve subsets. DBA+ve group 
1 ILCs express mainly angiogenic factors, while DBA-ve cells appear to be the 
primarily IFN-γ producers371. WT bone marrow transplant in a lymphoid mice 
(Rag2-/- Il2rg-/-) showed that DBA+ve group 1 ILCs can develop from peripheral 
circulating progenitors, while DBA-ve cells are extremely rare in transplanted 
mice370. This was the first evidence suggesting that DBA-ve subset is tissue 
resident. Here, we refined this model by showing that DBA stain mainly 
EOMES+ve cells and correspond to bona fide uNK cells. Additionally, we 
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identified that the historically defined DBA-ve uNK cells were instead non-NK 
uILC1s. This finding supports the idea that non-NK uILC1s may be the main 
source of IFN-γ and the main tissue resident cells among uILC1s. By contrast, 
uNK cells, or more specifically CD49a+ve utrNK cells described in Boulenouar et 
al. 56, are DBAbright and indeed produce less amount of IFN-g when compared to 
cNK cells56. Additional studies are needed to further assess the relative 
contribution to IFN-g production by uILC1s and cNK cells. IFN-g is a key 
cytokine important in the arterial remodelling process during pregnancy (as 
described in Chapter 1.3.3) and uILC1s may be involved in this. However Tbet-/- 
mice do not display alteration in the spiral artery remodelling423 and the majority 
of uterine IFN-g is produced by CD49a-ve cNK cells56. Finally, group 1 ILCs 
(including uNK cells and uILC1s) are the only uILCs in the decidua. Decidual 
stromal cells may be important in the regulation, survival and activation of all 
uILC1 subsets. Furthermore, uILC1s may be able to interact with the invading 
trophoblast in a similar fashion as bona fide uNK cells. Unpublished data from 
our laboratory identified the expression of Ly49s on uILC1s, which may mediate 
a direct interaction with trophoblast cells. 
The location of uILC2s and uILC3s in the myometrium may be important in 
leukocyte modulation but also for tissue and vascular remodelling. uILC3s may 
regulate the formation of the MLAp. LTi-like uILC3s could promote MLAp 
formation in a similar way as they do in secondary lymphoid organs. However, 
MLAp is present in LTa-/- and LTbR-/- pregnant mice, but decidual development 
is delayed, with the normal MLAp cellularity only reached with 48 hours 
delay424. Furthermore, IL-22 produced by ILC3 is known to have proliferative 
effects on intestine epithelial cells. In the uterus, the proliferation of uterine 
epithelial cells is important in both implantation and decidualisation and IL-22 
may be promoting this process. Further studies are needed to assess the role of 
IL-22 during pregnancy and if this cytokine and uILC3s can have a role in 
MLAp formation or epithelial cells homeostasis. Additionally, this location is 
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rich in lymphocytes and granulocytes, and considering the importance of ILC2s 
in immune cells homeostasis (Chapter 1.3.2), it is possible that a similar 
regulation can occur during pregnancy. Preliminary experiments in Rag2-/- Il2rg-
/- mice described in this Chapter showed that indeed uILC2s might be important 
for the regulation of uEo through constitutive IL-5 production. While, from these 
data and from published reports226, it is clear that mainly uILC2s constitutively 
produce IL-5, whether they also produce IL-13 in physiological conditions 
remains to be established. However, Il13-/- and Il5-/- mice do not show major 
defects in pregnancy, in that their litter sizes are normal. This would suggest that 
the two cytokines may be redundant or may play a more subtle role in 
pregnancy232,425. Nevertheless, given the importance of the balance between type-
1 and type-2 immunity during pregnancy (Chapter 1.4.3), uILC2s may indeed 
play a central role in this regulation, as they do in the adipose tissue34,209. 
Additionally, our published work on Nfil3-/- mice56,76 provided unexpected 
evidence suggesting uILC2s may play relevant roles during pregnancy (Table 
12). Nfil3-/- mice present a strong pregnancy phenotype that cannot be 
compensated by the residual utrNK cells and bona fide uILC1s. This phenotype 
could indeed demonstrate the importance of ucNK cells in the process of spiral 
artery remodelling and foetal growth, but it cannot exclude that also uILC2s may 
be important too. In fact, we can consider this mouse model as a mixed-KO for 
both ucNK cells and uILC2s. 
Table 12 Phenotype of Nfil3-/- mice in pregnancy 
Information from Boulenouar et al.,56 
We also showed that uILC2s respond to IL-25 and IL-33 which have been 
previously found in the uterine mucosa during mouse and human 
Uterine	immune	cells	composition	 Pregnacy	phenotype	
Reduced	expansion	of	utrNKs	and	uILC3s	 Reduced	MLAp	volume	
Expansion	of	uILC1s	 Reduced	spiral	artery	remodelling	
Absence	of	cNK	cells	and	uILC2s	 Placenta	abnormabilities	
	 Reduced	foetal	weight	
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pregnancy209,326,327,426–428. During pregnancy, trophoblast stimulates IL-25 
production by decidual stromal cells to induce their development and 
proliferation429. It cannot be excluded that IL-25 may be also produced in the 
myometrium to activate uILC2s. Furthermore, also IL-33 expression can be 
induced in the uterine tissue. Endometrial stromal cells release IL-33 upon 
decidualisation, to increase uterine receptivity426 and decidual Macrophages 
produce IL-33 to further promote late stages of placental development326. 
Additionally, IL-33 also prevents pre-term birth by acting on B cells and the 
expression of progesterone blocking factors428. Known sources of non-uterine IL-
33 are diverse, including stromal, parenchymal cells, adipocytes, endothelial 
cells, epithelial cells, and immune cells such as Mac, mast cells and DCs326,430. 
However, the source of IL-33 in the myometrium is unknown, as well the 
triggers that can induce the release of this cytokine. IL-33 has been proved 
central for ILC2s homeostasis as well as their activation13,22. Therefore, further 
analysis of uterine IL-33 producing cells is required to establish both the cellular 
source of a key uILC2 activator and the timing of uILC2s expansion and 
activation.  
Finally, giving the importance of ILCs in tissue remodelling (Chapter 1.3.2), one 
may expect uILCs to contribute to uterine tissue remodelling too. uILC2s and 
uILC3s are not in the decidua or in contact with the decidual spiral arteries, but 
they may be in contact with the main uterine vessels, which enter the uterine wall 
through the MLAp (in the myometrium), where these subsets have been 
localised. uILC2s and uILC3s in the myometrium may be directly involved in the 
remodelling of the initial section of the uterine arteries, or regulate tissue 
homeostasis, or modulate the activation of other cells (i.e. uMac, uDCs, uEo, 
mast cells431,432) which may be directly involved in the spiral artery remodelling 
process (Chapters 1.4.4 and 1.4.5). 
Origin and development of uILCs (including NK cells) is also a topic that needs 
further studies. We mentioned that uILCs may be plastic and transdifferentiate 
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into another ILC subset, but they may also be generated from progenitors in situ. 
Here, we investigated the role of NFIL-3 and the presence of committed ILCs 
progenitor. We could identify NK committed progenitors but not ILCs 
progenitors. Parabiosis experiments from Sojka et al.,48 have established that 
NFIL-3 independent utrNK cells are indeed tissue resident cells and we can 
speculate that they may derive from the committed NK progenitor we have found 
in the uterus. Additionally, DBA-ve uNK cells (i.e. non-NK uILC1) have been 
identified as tissue resident too and uILC1s too may, therefore, develop from this 
NK committed progenitor or from yet-undefined progenitors. Recent studies on 
ILCs precursors by single-cell RNA sequencing made it possible to identify of 
early progenitors134 in the bone marrow and foetal tissues120. Along with this 
line, further analysis of the single-cell atlas of the uterine tissue may be important 
for the identification of novel populations and possibly also novel progenitors 
committed to uILCs. uILC2s is the only subset strictly dependent on NFIL-3 and 
may potentially be of bone marrow origin. Therefore, only parabiosis 
experiments may be able to really understand the origin and tissue residency of 
this subset. 
In conclusion, here we present the first evidence of the existence and 
functionality of uILCs in humans and mice. The work summarised in this chapter 
forms the basis for further studies on uILCs. In particular, the potential of these 
cells as tissue remodeller and regulators of immune homeostasis justifies further 
studies of uILCs in such a dynamic organ as the uterus, characterized by cyclic 
remodelling, transformation and immune cells infiltration. Based on the results in 
Nfil3-/- mice, we decided to focus our study on uILC2s. 
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4 UILC2 ARE RELEVANT TO 
PREGNANCY 
Certain methods in this chapter describe elements that are presented in the 
following first author manuscript written by the author of this dissertation. 
Therefore, some sections are taken verbatim or with minor changes from this 
source. 
Balmas E, Rana BMJ, Hamilton S R, Kieckbusch J, Hawkes DA, McKenzie 
ANJ, Colucci F Group 2 innate lymphoid cells prevent endotoxin-induced fetal 
demise. In preparation.  
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4.1 Hypothesis and specific questions 
The results from Chapter 3 suggest that uILC2s may be relevant during 
pregnancy. In this chapter, we aim to characterise the dynamics of uILC2s 
activation and function. 
Firstly, we decided to analyse the expression of ILC2s activators in the uterus 
and to identify timing and regulation of uILC2s during pregnancy. We focus on 
IL-33, given the importance of this cytokine for uterine tissue 
receptivity223,327,426, placental growth326 and labour428. We aim to identify the 
expression of IL-33 at different time points in pregnancy, focusing on 
midgestation, when we can identify differences between myometrium and 
decidua. We also aim to characterise the specific cell populations regulating 
uILC2s during pregnancy and the effects of IL-33 on uILC2s in vivo. 
Once we identify IL-33 producing cells we can continue the analysis of uILC2s 
activity at different stages of pregnancy. We hypothesise that uILC2s may be 
regulating IL-5 and IL-13 in a different way during pregnancy and that uILC2s 
may be also the source of uterine Amphiregulin (Areg). In particular, Areg 
produced by ILC2 has been shown to induce tissue remodelling after damage due 
to influenza virus in the lung40. The importance and expression of Areg in the 
uterus has been established. This cytokine is involved in hormone receptivity in 
the mammary gland433 and it is expressed in the uterus with its peak before 
implantation434–437. uILC2s could be promoting uterine tissue growth, 
implantation and tissue receptivity through Areg. Additionally, the importance of 
Areg in the regulation of Treg may suggest that uILC2s could also be important 
players in uTreg	modulation	during	pregnancy.		
Furthermore, considering the constitutive IL-5 expression and lack of IL-13 
production upon IL-25 and IL-33 stimulation, we hypothesised that fundamental 
differences may exist between uILC2s and ILC2s in other tissues. These cells 
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may be able to produce different cytokines and growth factors, or they may 
express receptors and ligands different from other ILC2s. Therefore, we want to 
use a data-driven approach to identify specific characteristics of uILC2s and 
specific genes regulated during pregnancy. 
Finally, we want to identify the importance of uILC2s during pregnancy by 
taking advantage of specific mouse models KO for ILC2s.   
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We start our analysis of uILC2s by asking the following questions: 
i. Where and when is IL-33 expressed in the uterus? 
ii. Which cells express IL-33 in murine myometrium or decidua?  
iii. Do uILC2s produce IL-5, IL-13 and Areg during pregnancy? 
iv. Do uILC2s differ from ILC2s in other tissues?  
v. How do uILC2s respond to pregnancy? 
vi. How does the lack of uILC2s affect pregnancy? 
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4.2 IL-33 regulate uILC2s homeostasis and activation 
4.2.1 IL-33 is localised in the myometrium and regulates uILC2s 
We took advantage of an Il33 reporter mouse model to localise Il33 gene 
expression in the uterus. The Il33 citrin mouse model is a knock-in model where 
citrin (YFP protein) is expressed instead of IL-33. Therefore, we used 
heterozygous mice to maintain the physiological activation of the IL-33 promoter 
and thus IL-33 expression. However, we didn’t assess the dose-dependent effect 
of IL-33 in the heterozygous mice. We first assessed whether either stromal cells 
or leukocytes expressed Il33 (Figure 40). We found that only CD45-ve cells were 
positive for Il33 expression at midgestation (without dissection of myometrium 
and decidua at this stage). Analysis of expression of additional marks (including 
stem cell marker CD34, mesenchymal markers CD90.2 and SCA-1, lymphatic 
and stromal cells markers Podoplanin and PDGFRa, and endothelial cells marker 
CD31a) showed that all Il33 expressing cells were SCA-1+ve and CD31a-ve, 
whereas the other markers had a bimodal distribution. This first analysis excludes 
endothelial cells as potential IL-33 producing cells in the uterus. 
 
Figure 40 IL-33 is expressed by non-leukocytes CD45-ve cells 
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(A) Flow cytometry analysis of Il33 expression in the mouse uterus at midgestation shows that Il33 
expression is restricted to the CD45-ve fraction of cells extracted from Il33Cit/wt. (B) Analysis of the 
expression of CD34, CD90.2, SCA-1, PDGFRa, and CD31a by Il33+ve cells. Il33cit/wt unstained was used 
to set up negative gates. 
We further identified four cell types among SCA-1+ve cells: CD90+ve 
Podoplanin+ve; CD90+ve Podoplanin-ve; CD90-ve Podoplanin+ve; and CD90-ve 
Podoplanin-ve. All of them were IL-33 producers, with the exception of CD90+ve 
Podoplanin-ve cells, while CD90-ve Podoplanin-ve showed low expression. We 
concluded that SCA-1+ve CD90+ve and –ve Podopanin+ve PDGFRa+ve cell subsets are 
the main IL-33 producers. 
 
Figure 41 Gating strategy applied for the identification of IL-33 producing 
stromal cells 
Dot plots representative of the gating strategy used for the characterisation of SCA-1+ve Il33+ve cells. We 
identified four cell types among SCA-1+ve cells, distinguished by their expression of CD90 and 
Podoplanin. Only CD90+ve PDGFRa+ve Podoplanin-ve cells were found negative for citrin (green). The 
majority of citrin positive cells are among CD90+ve and -ve PDGFRa+ve Podoplanin+ve (red and blue). Data 
are representative of N=3 independent experiments at midgestation. Experiments did not require pooling 
and 1 single pregnant uterus was analysed per experiment. 
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Once we identified CD45-ve SCA-1+ve Il33+ve cells in the pregnant uterus (which 
include CD90+ve Podoplanin+ve PDGFRa+ve; CD90-ve Podoplanin+ve PDGFRa+ve; 
and CD90-ve Podoplanin-ve PDGFRa-ve), we studied WT mice to quantify and 
analyse these cells at different time points. Staging of these cells with dissection 
of myometrium from decidua made us realise that CD90+ve Podoplanin-ve 
(Il33+ve) start developing at implantation and are decidua-specific, thus they may 
be considered decidual stromal cells. On the contrary, Podoplanin-ve cells are 
present in higher frequency in the virgin uterus, while during pregnancy SCA-
1+ve CD90+ve Podoplanin+ve PDGFRa+ve cells expand and constitute the main 
population in the myometrium (Figure 42 A and B). We dissected myometrium 
from decidua and analysed the identified cells and their expression in the two 
compartments. From this analysis, we realised that Il33 is not expressed in the 
decidua and none of IL-33 expressing cells was found in this tissue. 
Immunohistochemistry on WT and Il33cit/cit pregnant tissues confirmed Il33 
expression in the myometrium (Figure 43). Additionally, we confirmed that 
SCA-1+ve CD90+ve Podoplanin-ve PDGFRa-ve decidual stromal cells could not be 
found in the myometrium; instead, all other stromal cells identified can be found 
and all express Il33 (Figure 42 C). Finally, we gated on CD45+ve Il33+ve cells to 
measure the proportion of IL-33 producers. In the virgin uterus, CD90+ve were 
the main cells positive for Il33. In the myometrium at midgestation both CD90+ve 
and CD90–ve Podoplanin+ve PDGFRa+ve contribute to IL-33 production, but fewer 
CD90–ve Podoplanin-ve PDGFRa-ve produce IL-33 at this stage of pregnancy 
(Figure 42 D). 
Chapter 4: uILC2 are relevant to pregnancy 
Elisa Balmas - January 2018   123 
 
Figure 42 Stromal cell analysis and staging of IL-33 producer cells 
(A) Representative plots of CD45-ve SCA-1+ve CD90+ve cells in virgin (V), implantation (6.5) and 
midgestation (Mid, divided between myometrium= Myo and decidua= Dec) uteri. Green gate shows how 
CD90+ve SCA-1+ve PDGFRa+ve Podoplanin-ve (identified as Il33cit-ve in Figure 41) are decidua specific 
and they develop at implantation and remain in the decidua. Red gate shows how CD90+ve SCA-1+ve 
PDGFRa+ve Podoplanin+ve (identified as Il33c+ve in Figure 41) cells are myometrium specific, they 
proliferate during pregnancy and remain instead in the myometrium. (B) Identification of all CD45-ve 
SCA-1+ve cells identified in Figure 41 in the mouse virgin uterus and at Mid by flow cytometry. 
Percentages of CD45-ve SCA-1+ve cells in V, implantation and Mid uteri. Totals represent the total 
percentage of SCA-1+ve CD45-ve per sample. (C) Identification of CD45-ve SCA-1+ve cells in Myo and Dec 
and their Il33 expression. Comparison and identification where all the different CD45-ve SCA-1+ve cells 
reside in myometrium and decidua. (D) Quantification of the contribution to Il33 by the identified CD45-
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ve SCA-1+ve cells in V and Mid. Quantification of the total CD45-ve Citrine+ve cell percentages in V and 
Mid uteri. N=3 Independent experiments per time point. Experiments did not require pooling and 1 single 
uterus was analysed per experiment.  
 
Figure 43 Spatial distribution of Il33 
Il33 expression in the uterus at mid-gestation detected by immunohistochemistry. Paraffin sections of 
C57BL/6 (control) and Il33 citrin mice at mid gestation have been stained with an anti YFP antibody and 
expression of Il33 have been identified by VectorRed staining (red). 5 X magnification, scale bar 500um. 
Inset: 30X magnification, scale bar 100um. 
We characterised IL-33 producing cells and their fluctuations in virgin and 
midgestation. We then used this reporter mouse model to further identify Il33 
also at term, to then have a much more complete picture of Il33 production and 
potentially of uILC2s activation. Our analysis by flow cytometry and ELISA 
confirmed that Il33 was detectable in the myometrium at term and no Il33 gene 
expression or residual IL-33 protein was detected in the decidua at 
midgestation (Figure 44 A and B). Additionally, considering the importance of 
IL-33 in ILC2s stability and proliferation in other tissues22,34,237 we explored 
whether IL-33 is needed for uILC2 homeostasis and presence in the pregnant 
myometrium. For this purpose, we analysed uILC2s in Il33cit/cit (Il33KO) 
pregnant myometrium. The number of uILC2s was drastically reduced in IL-33 
deficient mice (Figure 44 C), thus suggesting that IL-33 regulates uILC2 
homeostasis and, potentially proliferation of uILC2s in the uterus. 
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We demonstrated that IL-33 is vital for uILC2s and was localised in the 
myometrium, consistent with the anatomical location of mouse uILC2s.  
 
Figure 44 IL-33 is required for uILC2 compartmentalisation homeostasis. 
(A) Flow cytometry analysis of cells extracted from Il33Cit/wt virgin (V), midgestation (Mid dissected 
between M=myometrium and D=decidua) and term (Term) uteri show the localisation and % of cells 
expressing Il33 gene in the uterine tissue. Il33 gene expression is restricted to the uterine tissue and it is 
not detectable in the decidua (N=3 biological replicates). (B) IL-33 ELISA on tissue homogenates from V 
and pregnant uteri (N=3 biological replicates per time point). Experiments did not require pooling and 1 
single uterus was analysed per experiment and per every time point. This experiment was done in 
collaboration with Dr. Batika Rana (D) Analysis by flow cytometry of uILC2 from Il33wt/wt and Il33cit/cit 
pregnant uteri (N=3 pool of 5 Mid uteri per replicate). Data in are displayed as mean ± SEM. A-B data 
from the different time points were analysed by one-way Anova and data in C, WT and KO data were 
analysed using Student-T test: ns, P>0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
4.2.2 Activation of uILC2s 
We next quantified intracellular cytokine production ex vivo in unstimulated 
uILC2s and upon stimulation with either, IL-25 and IL-33, or with PMA and 
Ionomycin (as a positive control). We confirmed our previous observations on 
virgin uILC2s (Chapter 3.3.4). uILC2s, constitutively produce IL-5 also 
throughout gestation. We also showed here that more than ~90% of uILC2s 
constitutively produce Areg at midgestation but reduce down to ~50% at term. 
IL-13, however, was only induced by PMA and Ionomycin stimulation. This 
peculiar cytokine production by uILC2s strongly suggests that these cells may be 
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different from the same cell subset identified in other tissues, because IL-13 is 
readily produced by ILC2s from other tissues (Figure 51).  
 
Figure 45 Activated uILC2s from pregnant tissues express IL-5 and Areg 
constitutively but not IL-13 
Flow cytometry analysis of ex-vivo cultured uILC2s from midgestation (Mid) and term pregnant uteri 
without stimulation (NS) or with PMA-Ionomycin (PMA/IONO) or with IL-25 and IL-33 cocktail 
(25/33) stimulation. (A) Representative plots of Amphiregulin (B) and IL-13 and IL-5 expression in 
uILC2s gated as CD45+ve, NK1.1-ve, CD11b-ve, NKp46-ve, Lin (CD3 and CD19)-ve, GATA-3hi, and ST2+ve. 
In red we present the FMO control per each cytokine marker. Analysis of the percentages of uILC2s 
expressing Areg, IL-5 and IL-13 at (C) midgestation and (D) at term (N=5 independent experiments per 
time point). All experiments required pooling of ±15-20 pregnant uteri per experiment. Per every 
experiment, the single cell suspension had been equally distributed to be tested for all the three 
experimental conditions. Data in C-D are displayed as mean ± SEM and were analysed using One-way 
Anova: ns, P>0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
Considering the importance of Areg for hormone and uterine receptivity433–437, 
Areg produced by uILC2s could be important for tissue growth, implantation, 
tissue receptivity and Treg activation207,438.	 We investigated Areg expression 
from other cells than uILC2s in our experiment. Interestingly, only uILC2s 
produced Areg in our conditions (Figure 46) and only at term Lin+ve cells 
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(including T cells) started to produce it at low levels. However, times of 
activation and activators for T cells or stromal cells may be different. Likely, 
CD3 stimulation and longer activation may stimulate more uterine T cells in this 
context to produce Areg. 
To study cytokines and other factors involved in uILC2 biology, we performed 
an RNAseq analysis in comparison with RNAseq data obtained from ILC2s in 
other tissues.  
 
Figure 46 Areg expression by uterine ILC2s, T cells and stromal cells 
(A and C) Flow cytometry analysis of in vitro cultured uterine cells from midgestation (Mid) and (B and 
D) term pregnant uteri without stimulation (NS) or with PMA-Ionomycin (PMA/IONO) or with IL-25 
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and IL-33 (IL25/IL33) stimulation. We analysed Areg expression in Lin+ve CD4+ve cells (Lin include 
CD3+ve and CD19+ve cells), stromal cells (CD45-ve) and uILC2s. N=5 independent experiments per time 
point. All experiments required pooling of ±15-20 pregnant uteri per experiment. Per every experiment, 
the single cell suspension had been equally distributed to be tested for all the three experimental 
conditions. Absolute numbers have been normalised to the number of organs pooled per experiment. Data 
are displayed as mean ± SEM and were analysed using One-way Anova: comparisons between Lin+ve and 
stromal cells were ns (P value not shown), P>0.05; ****, P < 0.0001. 
4.3 uILC2s have characteristics of tissue residency 
In preparation to do RNA sequencing on bulk uILC2s, we started by setting up 
the conditions to sort these cells efficiently. Our analysis of uILC2s extracellular 
markers at page 96 showed that ST-2, CD25, SCA-1 and CD90 are specific 
markers for uILC2s. We then identified a gating strategy to best recognise 
uILC2s with only extracellular markers (Figure 47). uILC2s can be identified by 
high co-expression of CD90 and ST-2. Indeed, the gating strategy we use for 
uILC2s (page 93, Figure 24), shows that all GATA-3bright after CD45+ve Lin-ve 
CD11b-ve NK1.1-ve NKp46-ve gating are ST-2+ve and no ST-2-ve cells can be 
detected (Figure 48). 
 
Figure 47 Gating strategy to sort uILC2s 
Gating strategy used to sort uILC2s by extracellular markers. Dot plots are from uILC2s sorted at 
midgestation. Representative for N=3 uILC2s sorted from virgin; N=3 uILC2s sorted from midgestation; 
N=3 uILC2s sorted from term) 
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Figure 48 All CD45+ve Lin-ve CD11b-ve NK1.1-ve GATA-3bright cells are ST2+ve 
Representative dot plots identifying uILC2s in virgin (V), midgestation (Mid) and term (Term). All ST-
2+ve cells previously gated as CD45+ve Lin-ve CD11b-ve NK1.1-ve are GATA-3 bright cells. This is confirmed 
in all time points of pregnancy analysed. (N=8 independent experiments at virgin and at mid gestation; 
N=4 independent experiments at term). 
Despite ICOS is considered a good marker for ILC2s20,26,27, this does not seem to 
be the case in the uterus. Indeed, if in virgin mice we gate on CD45+ve Lin-ve 
CD11b-ve NK1.1-ve NKp46-ve CD90.2+ve cells, most of ICOS+ve cells are GATA-
3bright, but at midgestation, only half of ICOS+ve cells are GATA-3bright (Figure 
49). 
 
Figure 49 ICOS is not a good marker to identify uILC2s in virgin and 
pregnant uterus  
ICOS expression by uILC2s (GATA-3hi in red) extracted from virgin (V) and pregnant (Mid) uteri. ICOS 
stain also for ~14% and ~40% of GATA-3low cells (Black). Dot plots are gated on live CD45+ve Lin-ve 
CD11b-ve NK1.1-ve NKp46-ve CD90.2+ve cells and they are representatives of 3 experiments. 
Uterine group 2 innate lymphoid cells and reproduction 
130  Elisa Balmas - January 2018 
Once we set up the best way to sort uILC2s, we analysed their transcriptomes 
and compared it to that of ILC2s in other tissues to gain a deeper understanding 
of potential tissue-specific features of these cells. ILC2s were sorted from virgin, 
midgestation and term uteri as well as from lung (L), and pooled mesenteric, 
para-aortic and inguinal lymph nodes (LN) of non-pregnant mice. Principal 
component analysis showed that uILC2s clustered separately from the L and LN 
ILC2s (Figure 50 A), suggesting uterine-specific features. To identify tissue-
specific genes in uILC2s we generated a gene list contrasting uILC2s (isolated 
from virgin, midgestation and term) to L and LN (Figure 50 B). We found 3,279 
genes up-regulated in uILC2s (Figure 50 B red). These included Il5 and Areg, 
which is in line with the constitutive expression of IL-5 and Amphiregulin in 
uILC2s (Figure 45). In addition, Arg1, Csf1, Foxp3, Ctla4, Tigit and a number of 
granzyme genes (Gzma, Gzmc, Gzmd, Gzme, Gzmf, Gzmg, Gzmk,) were up-
regulated in uILC2s, among others (Figure 52 A and B). Cell-intrinsic arginase-1 
promotes proliferation of ILC2s in the lung 439. CSF-1 is a crucial regulator of 
macrophages and DC cell dynamics in the uterus290. Immunoregulatory 
molecules CTLA-4 and TIGIT on uILC2s may be important in regulating 
immunological tolerance in allogeneic pregnancies. Among the 3,150 down-
regulated genes in uILC2s compared with ILC2s in L and LN, we found Ahr 
(Figure 50 B blue). The aryl hydrocarbon receptor (AhR) has never been 
associated before with ILC2s but instead with uNK cells and ILC3s (see Chapter 
1.1.3). Despite a lower expression compared to ILC2s in other tissues, AhR was 
significantly expressed in uILC2s (~300-500 normalised read counts in the uterus 
and ~1000-2000 normalised read counts in other tissues). Regulation of AhR 
may be associated with uILC2 maturity, plasticity or activation. To select gene 
signatures in an unbiased way, we analysed this gene list by GO on DAVID 6.8, 
taking into account the differences in Fold changes (Figure 50 C and Appendix 
page 244). We show enrichment in terms including immune response, 
inflammatory response, immune system process, response to glucocorticoid, 
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calcium homeostasis, response to estradiol, response to lipopolysaccharide and 
response to ethanol. 
 
Figure 50 Tissue-specific characteristics of uILC2s 
 (A) PCA analysis on RNA sequencing data from uILC2s sorted from the uterus of virgin (V) mice, or 
from the uterus of pregnant mice at midgestation (Mid) and term (Term), as well as from ILC2s sorted 
from lungs (L), and lymph node (LN) of virgin mice (N=3 replicates per group). All experiments required 
pooling of ±10 virgin uteri or ±5 pregnant uteri per experiment. (B) Mean Average plots representing the 
genes differentially expressed between uILC2s and L, LN and ILC2s. Coloured are the genes with a 
difference in Log2 Fold change higher than 2 and lower than -2 FC: in red are the uterine specific up-
regulated genes and in blue are the non-uterine or the genes down-regulated in the uterus; (C) Gene 
Ontology analysis of the genes differentially expressed between uILC2s and L, LN and ILC2s. Gene 
categories were considered significant when adjusted Benjamini P-value < 0.05 P-value and enriched 
score are in the figure. This experiment was done in collaboration with Dr. Batika Rana (library prep and 
sequencing) and Dr. Russell Hamilton (first computational analysis). 
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Figure 51 Unlike uILC2s, more lung ILC2s express IL-13 than IL-5  
Representative plots of IL-13 and IL-5 expression from ex vivo activated ILC2s from virgin uteri (V) and 
lungs (L). ILC2s non-stimulated (NS), activated by PMA and Ionomycin (P/I) or IL-25 and IL-33 
cocktail (IL-25/IL-33) are gated as CD45+ve Lin-ve CD11b-ve NK1.1-ve NKp46-ve GATA-3+ve ST-2+ve 
(Representative of N= 6 independent experiments). All experiments required pooling of ±30 virgin uteri 
or ±3 lungs per experiment. Per every experiment, the single cell suspension had been equally distributed 
to be tested for all the three experimental conditions.  
The functional ex vivo profile of uILC2s only partially overlaps with that of 
ILC2s in other sites, where IL-13 is produced by a larger fraction of cells (Figure 
51). Parallel ex vivo activation of lung ILC2s confirmed that indeed IL-13 is 
highly produced by lung ILC2s even without stimulation. Additionally, while 
uILC2s co-express IL-5 and IL-13 in PMA and Ionomycin activated cells the 
expression of IL-13 and IL-5 in the lung is mutually exclusive (Figure 51). 
However, it seems possible that uILC2s may indeed produce IL-13 in 
physiological conditions. In fact, not only Il5 but also Il13 and many other genes 
and cytokines related to type-2 immunity are interestingly up-regulated in 
uILC2s (Figure 52 A and B), including Gata3 as well as Il1rl1, which encodes 
for the IL-33 receptor, although Il4 was not expressed by uILC2s. Therefore, 
uILC2s appear transcriptionally more type-2 than ILC2s from other locations in 
the body and this characteristic increase during gestation. This feature is likely to 
be dependent on the microenvironment and uILC2s may be more activated than 
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ILCs from other healthy tissues, or there is higher transcriptional activity may 
reflect adaptability to quick pregnancy-related changes.  
Other sets of genes enriched in uILC2s over other tissues are those related to 
tolerance and usually expressed by Treg. In Figure 52 B we show how genes 
such as Foxp3, Ctla4, Tigit, Tgfb and Areg are all up-regulated in uILC2s, and 
mainly early in pregnancy. Cd28 is instead always constitutive expressed (which 
explains why it was not among the differentially regulated genes). Specific 
analysis of these genes only among uterine ILC2s, showed that Foxp3, Ctla4, 
Cd28, Areg and Tgfb2 are also differentially regulated during pregnancy (Figure 
52 C and Figure 53 D-E). These genes may have functional roles during 
pregnancy and we can speculate that uILC2s mediate regulatory function early in 
pregnancy and may promote the development of Treg, which are important for 
the maintenance of pregnancy. However, our experiments have all been 
performed in syngeneic conditions and it is difficult to test the role of Tregs. It is 
possible that in allogeneic pregnancies uILC2s may be more relevant and could 
show a stronger expression of tolerogenic co-stimulatory molecules and 
cytokines.  
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Figure 52 uILC2s express Ctla4 and they are even more skewed towards 
type-2 immunity than lung and lymph node ILC2s 
(A-B) Examples of differentially expressed genes between uILC2s (sorted from Virgin (V), midgestation 
(Mid) and term (Term) tissues) than other tissue ILC2s (Lung, and Lymph node). (A) Genes relative to 
type-2 immunity and (B) genes relative to tolerance. Comparison of uILC2s normalised gene expressions 
to ILC2s normalised gene expression from other tissues. Scale bar refers to Log10 normalised read counts. 
(C) Normalised read counts of selected genes involved in immune tolerance and differentially expressed 
by uILC2s: Foxp3, Ctla4, Cd28, Tgit, Il10, Areg. Here we show their changes at different stages of 
pregnancy. (D-E) Validation of Ctla4 and Foxp3 protein expression by flow cytometry on uILC2 at Mid 
and lungs from pregnant females. Expression of CTLA-4 and FOXP-3 have been tested on ILC2s in 
comparison to the expression on ILC2s in the FMO control. Data in B, C, E are displayed as mean ± 
SEM. Data in D and E are representative of N=3 independent experiments per time point and organ. All 
experiments required pooling of ±10 virgin uteri, or ±5 pregnant uteri or ±2 lungs per experiment. Data in 
C time points have been compared between each other’s per every gene and they were analysed by two-
way Anova. Data in C and E were analysed by One-way Anova. ns, P>0.05; *, P < 0.05; **, P < 0.01; 
***, P < 0.001. 
 
Finally, we validated our sequencing data by flow cytometry to identify CTLA4 
and FOXP3 expressing uLC2s. Expression of Ctla4 in uILC2s in normalised read 
counts is 4-fold higher than lungs and it accounted for ~13000-9000 reads in 
uILC2s comparing to ~2000 reads in lung ILC2s. We detected CTLA4 
expression in both organs and while lung ILC2s were mostly negative for the co-
stimulatory molecule (~28% positive), 60% uILC2s from virgin and 70% uILC2s 
from midgestation were positive (Figure 52 D-E). FOXP3 was not detectable in 
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lung ILC2s and it was low expressed by only ~15-20% of uILC2s (Figure 52 D-
E). 
4.4 Modulation of uILC2s during pregnancy 
Having established that uILC2s have tissue-specific gene signatures, we 
hypothesised that they may be influenced by or regulate tissue homeostasis 
during pregnancy (Chapter 1.4.1). In order to track changes in uILC2s that occur 
early in pregnancy and throughout pregnancy, we compared gene signatures in 
uILC2s from virgin mice, and those from dams at midgestation and at term. 
Unbiased cluster analysis showed patterns of genes specifically regulated in both 
virgin and pregnant uterus (Figure 53 A). Here are presented genes highly 
differentially regulated with fold change >7.5. Among these genes, we identified 
regulators of monocytes, macrophages and dendritic cell dynamics (Ccl7, Ccl22 
and Cxcl17) and Mucin genes (Muc20 and Muc4), which may be involved in cell 
protection and survival, and interaction with epithelial cells440–442. To track gene 
expression changes in early pregnancy, we compared uILC2 transcriptomes of 
virgin mice with those of mice in midgestation (Figure 53 B and C, up regulated 
genes at midgestation are highlighted in red and down regulated genes in 
midgestation are in blue). Unbiased GO analysis showed that granzyme genes 
and their regulator Serpin genes were differentially regulated, with granzymes 
up-regulated in uILC2s at midgestation, and granzyme inhibitors Serpin9, 
Serpinb2, Serpinc1 highly expressed in uILC2s both in virgin and pregnant mice 
(Figure 53 C and Appendix page 244). To gain insights into the changes in gene 
expression throughout pregnancy, we further compared the transcriptomes of 
uILC2s from the uterus of virgin mice and the uterus of dams at term. The 
expression of Ctla4, Cd28, and AhR was down regulated throughout gestation 
(genes highlighted in blue in Figure 53 D and E and Figure 52 C). Comparative 
pathway analysis also showed significant up-regulation in gene signature relative 
to T helper cell differentiation, granulocyte adhesion and diapedesis, 
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communication between innate and adaptive immune cells, IL-10 signalling and 
Ctla4 signalling pathways (Figure 53 F). In addition, GO analysis also showed 
factors that can potentially be important in controlling recruitment and 
homeostasis of T cells, Eosinophils and myeloid cells (Cxcl2, Ccl5, Csf1, Csf3, 
Csf2, Csf2rb, Csf2rb2), genes involved in AhR signalling (Mgst1, Ers1, Gsto1, 
Arnt, Nfix, Ncoa7, p27Kip1, Rip140, Tgfb1, Tgfb2) and others that mediate the 
response to oestrogens and estradiol, including genes involved in tissue 
remodelling, tolerance and proliferation, such as Tgfb1, Tgfb2, Areg, Pam, Postn 
and the oestrogen receptor Ers1 (Figure 53 E and Appendix page 244).  
An interesting finding was the expression of non-cytotoxic granzymes in uILC2s. 
We mentioned in Chapter 4.3 and Figure 50 B that we found granzymes among 
the differentially expressed genes between uterine and other tissues ILC2s 
(Figure 54 A). This observation is of particular interest, because ILC2s have 
never been associated with cytotoxic activity, although both uterine and other 
ILC2s express Gzmc (Figure 54 A). However, in the uterus these genes have a 
peculiar expression with higher expression at midgestation (Figure 54 B). We 
also validate our data in both uILC2s at midgestation and lungs ILC2s by flow 
cytometry. We confirmed a differential expression of Gzmc between uterine and 
lungs ILC2s and absence of Gzmb in both cell types. However, we were unable 
to discriminate the differential expression of other granzymes, due to the lack of 
antibodies identifying mouse granzymes (Figure 54 C). Taken together, these 
data suggest that uILC2s have unique immunomodulatory functions that change 
during gestation. The role of Serpins and Granzymes in uILC2s still needs to be 
established, but we can hypothesise that these molecules may be involved in 
vascular remodelling and in particular in the remodelling of the extracellular 
matrix. Serpin genes encode for inhibitors of proteases and plasminogen 
activators and mediate perforin-independent granzyme activities involved in 
remodelling, matrix cleavage, cell proliferation, release of growth factors, and 
protection from apoptosis443–450. The combined patterns of non-cytotoxic 
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granzymes and Serpins expression suggest that uILC2s may play roles in tissue 
remodelling. 
 
Figure 53 Gene expression patterns in uILC2 during pregnancy 
(A) Heat map of the genes most differentially expressed during pregnancy and with a fold change >7.5. 
Colour scale represents data in regularised log transformed read counts; (B) Mean Average plot showing 
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the differentially expressed genes among uILC2s sorted from Virgin (V) and midgestation uteri (Mid); 
(C) Summary of the Gene Ontology analysis of the genes specific for V and Mid uILC2s; (D) Mean 
Average plot showing the differentially expressed genes among uILC2s sorted from V and term (Term); 
(E) Summary of the Gene Ontology analysis of the genes specific for V and Term uILC2s; (F) From the 
same gene list, we compared the pathways up- and down- regulated in uILC2 sorted from the different 
time points. Pathways were considered significantly different between time points when adjusted P-value 
< 0.05. Scale bars represent the enrichment scores. This experiment was done in collaboration with Dr. 
Batika Rana (library preparation and sequencing) and Dr. Russell Hamilton (first computational analysis) 
 
Figure 54 Granzymes are regulated during pregnancy 
(A) Normalised read counts of the expression of granzymes and related genes differentially expressed 
between uterine and other tissue ILC2s. (B) Normalised read counts of the expression of granzymes and 
related genes differentially expressed among uILC2s. (C) Flow Cytometry data on uILC2 expression of 
granzymes (gated as CD45+ve NK1.1-ve NKp46-ve CD11b-ve CD3-ve CD19-ve CD90+ve CD127+ve GATA-
3+ve ST-2+ve). Granzyme expression in uILC2s has been determined in comparison to the expression to the 
ILC2 FMO control. Data in C are representative for N=3 independent experiments. All experiments 
required pooling of ±10 virgin uteri or ±5 pregnant uteri or ±2 lungs per experiment. Data in A-B are 
displayed as mean ± SEM.  
4.5 Insufficient arterial remodelling in ILC2KO mouse models 
We established that uILC2s are regulated during pregnancy and have specific 
characteristics due to the microenvironment. Given the importance of ILC2s in 
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tissue growth, remodelling and immune homeostasis we hypothesised that 
uILC2s may play a role in the maintenance of pregnancy and arterial 
remodelling. We decided to study their potential role in physiological in ILC2 
deficient mice Roraflox/flox Il7racre/wt (hereafter referred to as ILC2KO mice). 
Before starting our study, we made sure this KO mouse model is also devoid of 
uterine ILC2s. We analysed the pregnant myometrium at midgestation and 
confirmed the lack of uILC2s in this model.  
 
Figure 55 uILC2s are not present in the uterus of Roraflox/flox Il7racre/wt mice 
Flow cytometry data from virgin uteri at from WT and Roraflox/flox Il7racre/wt females confirm that uILC2 
are absent in Roraflox/flox Il7racre/wt females (Roraflox/flox Il7racre/wt N=3; C57BL/6 N=6). All experiments 
required pooling of ±5 pregnant uteri per experiment. Absolute numbers have been normalised to the 
number of organs pooled per experiment. 
Stereological and immunohistochemical assessment of decidual spiral arteries in 
ILC2KO mice showed reduced remodelling (Figure 56). Two researchers 
analysed this set of data independently and both confirmed the reduced 
remodelling. Decidual arteries in ILC2KO mice show similar lumen area but 
increased vessel thickness (Figure 56 A and C). Additionally, smooth muscle 
actin was still present all around ILC2KO decidual vessels while it is 
disappearing WT (Figure 56 B). This finding was surprising because uILC2s are 
not found in the mouse decidua and because uterine vascular remodelling has 
been typically associated with uNK cell functions, specifically IFN-g production 
in mice248. We hypothesised that uILC2s may be somehow important in the 
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regulation of group 1 ILCs in decidua or in the myometrium at midgestation. It 
should be noted, however, that ILC2s and ILC1s are known to counter-regulate 
each other 34,216,217. 
 
Figure 56 uILC2s affect vascular remodelling 
(A and C) Stereological and immunohistochemical analysis and comparisons of relative thickness and 
lumen areas of the uterine arteries from serial sections of midgestation decidua collected from WT and 
Roraflox/flox Il7racre/+ females mated with WT males. Pooled data from 4 litters per cross, n=12–20 total 
implantation sites per cross. (B) Smooth muscle actin staining on uterine arteries from WT and Roraflox/flox 
Il7racre/+ confirm the reduced remodelling. 12.3X magnification, scale bar 100um. Slides stained by 
Sophie Trotter under Elisa Balmas supervision (C) Data analysed by an independent researcher for 
confirmation (Data obtained by Sophie Trotter). Data in A are displayed as mean ± SEM. Data in A and 
C were analysed by unpaired Student’s T-tests: P-value displayed, P > 0.05; *, P < 0.05; ****, P < 
0.0001.  
We analysed uILC1s proportions and Ifng expression in WT and KO mice. Total 
uILC1s numbers in WT and KO deciduae were comparable (Figure 57 A). Ifng 
transcripts were slightly but not significantly reduced in the decidua of ILC2KO 
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mice. Moreover, they showed similar expression of Ifng within sorted uterine 
group 1 uILCs, which also comprised normal frequencies of uILC1, conventional 
NK cells and tissue-resident NK cells (Figure 57 B-D). Overall, no alterations 
among the decidual group 1 uILCs have been found in ILC2KO females mated 
with WT. 
 
 
Figure 57 Analysis of Decidual group 1 ILCs in WT and ILC2KO mouse 
models. 
(A) Fold changes of group 1 uILCs absolute cell numbers in the decidua of WT (black) and ILC2KO 
(blue) mouse model WT females were mated with WT males, or ILC2KO females were mated with WT 
males. (B) mRNA expression of tissue Ifng from dissected deciduae. Data in B are representative of N=3 
deciduae homogenates per mouse model (every homogenate contains a pool of 4 deciduae from a 
pregnant uterus). (C) mRNA expression of Ifng uILC1s sorted from the deciduae of WT and KO mouse 
models. N=3 independent experiments, group 1 ILCs have been sorted from a pool of deciduae from 1 
pregnant uterus per every experiment. (D) Frequency composition of uILC1s in WT and KO mouse 
models. Experiments in A and D are representative of N=3 independent experiments. For these 
experiments, we required pooling deciduae from ±5 pregnant uteri per experiment. Absolute numbers in 
A have been normalised to the number of organs pooled per experiment. Data are displayed as mean ± 
SEM. Data in A-C were analysed by unpaired Student’s T-tests: ns or displayed, P > 0.05. Data in D WT 
and KO proportions were analysed as two-way Anova: ns, P > 0.05. 
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We decided to analyse uILC1s and Ifng also in the myometrium, although the 
contribution of myometrium-derived leukocytes in the process of arterial 
remodelling is not clear. One possibility is that the arteries may be affected by 
immune cells residing in the MLAp. Also in the myometrium, total group 1 
uILCs numbers were comparable between mouse models (Figure 58 A). 
However, while Ifng transcripts were normal in virgin uteri, they were 
significantly reduced in the myometrium at midgestation and term of ILC2KO 
mice (Figure 58 B). Surprisingly, increased Ifng expression was detected within 
sorted group 1 uILCs (Figure 58 C), thus suggesting that group 1 uILCs may be 
even more active without uILC2s. In this context, it is still unclear which group 1 
uILC subset (ucNK cells, utrNK cells, uILC1s) may be regulated by uILC2s and 
account for this phenotype. Thus, the cause of suboptimal arterial remodelling in 
ILC2KO mice remains to be determined. However, we can hypothesise that IFN-
g expression in the myometrium may be important for arterial remodelling. In 
this context, where group 1 uILCs are virtually normal, one may think that Ifng 
derived from leukocytes other than group 1 uILC1 may contribute to this 
process.  
  
Figure 58 Analysis uILC1s in WT and ILC2KO myometrium 
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(A) Fold changes of group 1 ILCs absolute cell numbers in the myometrium of WT (black) and ILC2KO 
(blue) mouse models. Group 1 ILCs include all live CD45+ve, Lin-ve, CD11b-ve NK1.1+ve NKp46+ve 
TBET+ve cells, which include NK cells subsects and ILC1s. Experiments representative of N=3 
independent experiments. For these experiments, we required pooling myometri from ±5 pregnant uteri 
per experiment. Absolute numbers have been normalised to the number of organs pooled per experiment. 
(B) mRNA expression of tissue Ifng from dissected myometri. N=3 uteri per time point and mouse model. 
(C) mRNA expression of Ifng uILC1s sorted from the myometri of WT and KO mouse models. N=3 
independent experiments, group 1 ILCs have been sorted from one full pregnant myometrium per every 
experiment. Data are displayed as mean ± SEM. Data in A and C were analysed by unpaired Student’s t-
tests: ns, P > 0.05; *, P < 0.05. Dada in B WT and KO were analysed as one-way Anova: *, P < 0.05. 
Whatever the cause, suboptimal uterine vascular remodelling may lead to 
downstream effects on foetal growth. Here we found that foetal weight at term 
was reduced in litters carried by ILC2KO females (Figure 59 A). We used 
different ILC2KO models and mating strategies to confirm the phenotype. As 
controls, we used WT females mated with WT males, or WT females mated with 
ILC2KO males. We compared foetal weights and placental weights from these 
controls with those from ILC2KO females (Roraflox/flox Il7racre/wt and Il33cit/cit) 
mated with WT males. From all these matings, when mothers were deficient for 
ILC2s, their offspring are growth restricted and placentae are slightly but not 
significantly heavier. Placentae from Il33cit/cit mice were, however, significantly 
heavier than in the other matings. Additionally, the genotype of the fetuses was 
not affecting fetal weight, because no differences were identified when WT 
females were mated with Roraflox/flox Il7racre/wt males. Ultrasound biometry of 
growing foetuses at gd18.5 revealed typical signs of growth restriction, including 
reduced head and abdomen diameter and asymmetrical growth restriction 
showed by an increased head-to-abdomen diameter ratio (Figure 59 B). Femur 
length was reduced, but at the same rate of WT females mated with ILC2KO 
controls. Given these preliminary results, we believe that we would need to 
increase the number of foetuses analysed by ultrasound biometry to overcome 
the biological and the inter-litter variability, thus increasing the statistical power. 
Based on this pilot experiment, we based our power calculation and we identified 
that the number of mothers needed for this study is 25 in total. These data show 
that ILC2s may impact on normal pregnancies by regulating mechanisms 
involved in uterine tissue remodelling and foetal growth.  
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Figure 59 Lack of maternal uILC2s affects foetal growth 
(A) Foetuses and placental weights from WT, Rora flox/flox Il7racre/wt, Il7ra cre/wt, Il33cit/cit females mated 
with WT males and from WT females mated with Roraflox/flox Il7ra cre/wt males. (N=13 litters analysed 
from WTxWT matings; N=8 litters analysed from Roraflox/flox Il7racre/wt xWT matings; N=4 litters analysed 
from Il33cit/cit xWT matings; N=7 litters analysed from WTx Roraflox/flox Il7racre/wt matings). P-values for 
the effect of maternal lack of ILC2s were obtained by using a mixed model approach (taking into account 
inter-litter variability but not the sex of the fetuses). (B) Ultrasound biometry analysis of E18.5 foetuses 
from Roraflox/flox Il7racre/wt females mated with WT males (N=9 foetuses from 3 dams) and Il7racre/wt 
females mated with WT males (N=6 foetuses from 3 dams), and WT females mated with Roraflox/flox 
Il7racre/wt males (N=10 foetuses from 3 dams). Measurements of head diameter, femur length and 
abdomen diameter (as shown in the picture). (C) Head/thorax (HD/AD) ratio obtained from ultrasound 
biometry analysis of E18.5 foetuses from Roraflox/flox Il7racre/wt and Il7racre/wt females mated with WT 
males of WT females mated with Roraflox/flox Il7racre/wt males. This experiment was done in collaboration 
with Dr. Norman Shreeve, who did tissue preparation, CT scan and data generation. Data are displayed as 
mean ± SEM. Controls data were compared to KO and controls data in B and they were analysed by two-
way Anova: p-values displayed: ns, P > 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.  
Finally, we analysed foetal weights from Il33 transgenic breeders in the ARES 
animal facility and investigated whether postnatal growth may also be affected. 
In this case, we considered matings between WT females and WT males as 
controls and Il33cit/wt females (IL-33Het) or Il33cit/cit females (IL-33KO) mated 
with WT males. Weights after birth identified a quick catch up and litters born 
from IL-33KO mothers reached the weight of those born from WT or IL-33Het 
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in 7 days after birth (Figure 60). This finding is expected from published data 
from our laboratory259, which showed similar results when other foetal growth-
restricted mouse models have been analysed (i.e. mice with a catalytically 
inactive p110d of the PI3 kinase pathway). A quick catch up on weight after birth 
in IUGR conditions is a well-known effect451–453. However, the metabolical stress 
that these mice go through after birth may have repercussion on future health. 
Indeed, foetal growth restrictions correlate with metabolic syndromes, type-2 
diabetes, cardiovascular diseases and obesity later in life 453–458.  
 
Figure 60 Foetal growth restricted pups from IL-33 deficient mice catch up 
after birth 
Analysis of newborn weight at 7 and 14 days after birth. We analysed the weight of pups born from IL-33 
KO mothers (Il33cit/cit), IL-33 Het mothers (Il33cit/wt), WT mothers (Il33wt/wt) mated with WT males. (N=8 
litters from Il33cit/cit mothers; N=6 litters from Il33cit/wt mothers; N=9 litters from Il33wt/wt mothers). P-
values were obtained by using a mixed model approach (taking into account inter-litter variability) This 
experiment was done in collaboration with Dr. Batika Rana (data collection). 
4.6 Conclusions and discussion 
Our analysis of IL-33 uterine expression showed that uILC2s localisation is 
likely to be dependent on this cytokine. The importance of uILC2s localisation is 
still unclear. However, uILC2s may be needed to activate specific cell types or 
functions in the myometrium. Indeed, Il33+ve cells develop preferentially in the 
myometrium. The phenotype of these cells is peculiar, since they present 
expression of lymphatic markers (Podoplanin) as well mesenchymal stem cells 
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markers (SCA-1, CD90 and CD34). These cells may be potentially lymphatic 
stromal cells part of the MLAp, which indeed have lymphatic vessels to help cell 
movement to the draining lymph node. The decidua, instead, does not have 
lymphatics and it may be the reason why these cells do not develop in this 
uterine structure. Considering that MLAp is an aggregate of lymphocytes, similar 
to some extent to a secondary lymphoid organ, it is possible that it contains cells 
able to sustain, activate and promote the proliferation of uterine leukocytes. 
Additional studies on the differentiation potential, activation of these cells and 
IL-33 (or other cytokines) release and activation may be important to understand 
uterine leukocytes activation and development. Additionally, NKp described in 
Chapter 3 as well as other leukocytes, uMac and uterine granulocytes may be 
dependent on these mesenchymal stromal cells for their development and 
function in the uterus. Multipotent mesenchymal bone marrow stromal cells459 
are identified by similar extracellular markers and they	 provide ligands and 
cytokines for leukocyte development and activation459. These cells can 
potentially have similar functions of bone marrow mesenchymal stromal cells, 
but in the uterus. Other studies identified mesenchymal stromal cells in tissues 
other than the bone marrow, such as placenta460, endometrium461,462, amniotic 
fluid460,463, adipose tissue464–466, lung, liver and spleen460 where they have 
immunoregulatory functions459.  Additional studies on these cells identified from 
this work will be required to fully identify them as mesenchymal in term of 
developmental origin and function.  
Il33 may not be the single cytokine expressed by these uterine cells, which may 
provide additional cytokines that could modulate uILC2s activity. High levels of 
Il13 transcripts were detected on all uILCs, but IL-13 protein release was 
induced in uILC2s only by PMA-Ionomycin activation and still, IL-13 was 
detected on only ~50% stimulated uILC2 from midgestation or term. Without 
stimulation, uILC2s express only IL-5 and Areg. The peculiar pattern of uILC2s 
cytokine expression at steady state shows that these cells have potentially more 
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accessible IL-5 promoter than IL-13. The accessibility of several GATA binding 
sites is responsible in T cells for the regulation of IL-13, IL-5 and IL-4 
expression467. In this context, GATA-3 expression or the cytokine 
microenvironment or accessible tissue ligands may change the uLC2s epigenetic 
landscape and may be responsible for the tissue-specific cytokine expression 
profile. For instance, studies on the modulation of the uILC2s epigenetic 
landscape during pregnancy, associated with our RNAseq analysis, may be 
informative as to how uILC2s are modulated by the uterine microenvironment. 
However, Il13 mRNA was detected and at high levels in uILC2s at all time 
points. This is consistent with the idea that IL-13 is in fact produced in 
physiological conditions and that uILC2s may be activated by cytokines other 
than IL-33 and IL-25 to produce IL-13. Alternative uILC2 activators may include 
IL-2, and our preliminary data show that IL-2 supports uILC2s proliferation in 
vivo. However, there is no evidence of IL-2 expression in the mouse uterus, 
therefore uILC2s expansion in this condition may not be physiological. 
Alternatively, TGF-b1 has been shown to mediate uILC2s activation in 
Asthma468. Indeed, TGF-b receptor Tgfbr2 is expressed at high level in uILC2s 
and it can be found among the up-regulated genes when compared to other ILC2s 
(normalised read count ~4000-6000 in uterine and ~2000 in the lung). We can 
speculate that the high level of uterine TGF-b not only modulates uNK cell 
function and tolerance, but also uILC2s. Additionally, uILC2s express TGF-b1 
and TGF-b2 themselves and they may need these cytokines to further bust their 
activation. Furthermore, oestrogens may also play an important role in the 
regulation of uILC2s activation. Recent studies identified that uILC2s quantities 
are modulated by oestrogens469.  This is in line with our sequencing data, which 
also showed the specific expression of oestrogen receptor (Figure 53) and 
increase response to glucocorticoids (Figure 50) on uILC2s. Finally, IL-13 
expression probably needs direct activation in uILC2s, which still need to be 
assessed. We can hypothesise that IL-13 expression needs to be actively induced 
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for specific events that need tight regulation in the uterus, including cell 
migration and/or smooth muscle cells contraction during labor. 
Other factors identifying uILC2s tissue residency are Ahr and Ctla4, which were 
identified from the GO category Immune system processes. AhR is important for 
EOMES+ve uNK cells maturation and Ahr-/- females mated with B6 males 
implantation defects and abnormal uterine arterial remodelling. uNK cells may 
be responsible for the pregnancy phenotype in Ahr-/- mice421 but also other ILCs 
may contribute to it. One possibility is that AhR expression could be one of the 
mechanisms shared by ILC2s and ILC3s to induce the formation of lymphoid 
aggregate structures in pregnancy160, such as the MLAp. Another possibility is 
that AhR can mediate uILC2 plasticity and phenotype98, or AhR ligands at the 
feto-maternal interface may regulate uILC2s activation and function (i.e. 
Tryptophan is one of the known Ahr ligand expressed by the trophoblast). 
CTLA4 is a molecule expressed by Tregs to mediate their tolerogenic role and it 
was expressed by ~60% of uILC2s compared to ~30% of lung ILC2s (Figure 
52). Ctla4 was up-regulated in uILC2s together with other Tregs genes (Foxp3, 
Tgit, Areg, Tgfb1 and Tgfb2). Additionally, pathways and GO analysis on 
uILC2s from different days in gestation show that both Ctla4 and Cd28 were 
differentially expressed and higher levels could be found early in gestation 
(Figure 52 and Figure 53). While CD28 is known to potentiate T cells activation 
in a cell-intrinsic function and it mediates cytokine expression in T cells, CTLA4 
can have both cell-intrinsic and cell-extrinsic functions470–473. CD28 and CTLA4 
both bind CD80 and CD86 on DCs and mediate TCR co-stimulatory signals: 
CD28 is activatory, while CTLA4 is inhibitory during T cells activation471,473–477. 
CTLA4 can also modulate DCs activation and phenotype; it promotes 
tolerogenic DCs by up-regulating IDO and IFN-g expression471–473. Additional 
tolerogenic effect of CTLA4 is the induction of TGF-b expression by T cells, 
which further promote tolerogenic DCs471,472,474,476,478. We can speculate that 
when TCR stimulation does not occur (as it is surely the case for uILC2s), 
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CTLA4 may be promoting a tolerogenic microenvironment and IFN-g expression 
by DCs, while CD28 could amplify uILC2s cytokine production. Additionally 
the low expression of Foxp3 in uILC2s may be promoted by CTLA4 stimulation 
itself 474. However, all our experiments have been performed in syngeneic 
conditions, and potentially uILC2 may have tolerogenic functions in early 
gestation when in allogeneic conditions. Here in syngeneic pregnancy, CTLA4 
may be promoting IFN-g production by uDCs in the myometrium and this may 
be an additional factor contributing to uterine vascular remodelling. Indeed, 
uILC2s-modulated DCs may be the source of IFN-g missing in ILC2KO 
myometrium (Figure 58). However, additional studies are needed to assess this 
function of CLTA4 on uILC2s. Tolerogenic or not, uILC2s in our matings 
produce also other factors that can suggest a role for uILC2 in tolerance and 
tissue remodelling, such as Tgfb1, Tgfb2 and Areg. In particular, Areg expression 
is another feature of Treg and it is known to amplify Treg suppressive 
functions207,435,438. Areg is expressed by ~90% of uILC2s and in this cell 
population, it could be important for uterine tissue growth and formation, but 
also to promote implantation and to increase oestrogen receptivity. In fact, Areg-/- 
mouse models have been described to have implantation problems and reduced 
oestrogen receptivity in the mammary gland479. Treg can express Areg, but 
uILC2 may be more effective in the uterus where the microenvironment changes 
quickly and because they can produce this protein constitutively. 
Together with uILC2s characteristics and activation, we showed that uILC2s 
have a role in uterine vascular remodelling. The role of group 1 uILCs in this 
process and the production of IFN-g by uNK cells is well established307,362,384. 
Therefore, we studied this phenotype by identifying alterations in group 1 uILCs 
and IFN-g expression in both WT and ILC2KO mouse models. However, no 
alterations in group 1 uILCs were found in either decidua or myometrium. 
However, only in the myometrium tissue expression of Ifng was altered, thus 
suggesting that, if this is important for spiral artery remodelling, other cells help 
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uNK cells in this process, or in the production of IFN-g. Alternatively, uILC2s 
may be promoting an anti-inflammatory environment that supports vascular 
remodelling, or uILC2s regulate decidua formation at implantation and this may 
have effects on decidual cell compositions at midgestation. Therefore, additional 
analysis of myometrium and decidual leukocytes composition and activity would 
be important to further establish the role of ILC2s in modulating the 
microenvironment. Leukocyte deregulation could affect uterine vessels. Indeed, 
pro-inflammatory cytokines (IFNg, IL-1b, IL-12, TNFa and IL-6), when in 
excess, can inhibit vascular remodelling and induce foetal death259,260,305,306. 
Furthermore, in analogy with the vascular events in pregnancy, regulation of 
local immune cells are known to be important in cardiovascular pathology312 and 
pulmonary fibrosis480. For example, elevated IL-1b and TNFa levels promote 
proliferation of vascular smooth muscle cells via inhibition of matrix MMPs, 
which leads to vascular wall thickening typical of pulmonary arterial 
hypertension. Moreover, vascular fibrosis may be induced by type-2 responses 
(in particular IL-13) 258,313–317. Therefore a balance of type-1 and type-2 
responses seems important for the regulation of vascular adaptations in both the 
lung480 and the uterus. We can speculate that alterations in the balance between 
type-2 immunity and inflammation in the myometrium can affect myometrium 
and decidual microenvironment. This hypothesis will be assessed in Chapter 5. 
Finally, the reduced vascular remodelling is likely the main cause of IUGR in our 
ILC2KO mice. Vascular remodelling is necessary for the effective transport of 
nutrients and hormones to the developing foetus, therefore alteration of this 
process is usually associated with IUGR. Here, we studied for the first-time 
foetal growth by combining foetal weight and ultrasound scan analysis and we 
found that mice born from ILC2KO mothers show asymmetric foetal growth 
restriction. The evaluation of the asymmetric foetal growth is the main parameter 
used in the clinic to evaluate IUGR in humans. Indeed, this methods combined 
were able to assess that not only foetuses from ILC2KO mothers were lighter 
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than controls, but also that these mice fully recapitulate the main clinical signs of 
foetal growth restriction described in human. We have previously seen features 
of IUGR in mice models in which uNK cells are deficient56,276,481. This study 
suggests that NK-deficient models such as Rag2-/- Il2rg-/- and Nfil3-/- need to take 
into consideration that also other lymphocytes, including uILC2s, could 
contribute to the pregnancy phenotype in these mice. IUGR is characterised by 
increased susceptibility to metabolic and cardiovascular diseases482 and this work 
offers a new model to study IUGR. Preliminary data on IL-33 deficient mice 
showed that foetal growth-restricted mice born from ILC2KO mothers can 
potentially catch up with their weight (Figure 60). However, this fast growth 
after birth can induce metabolic challenges that can affect these mice later in 
life452,482,483. We think that additional studies on ultrasound scan analysis on 
developing foetuses and newborns from ILC2KO and other models of innate 
immunity deficiency might be a powerful tool to further evaluate organ 
formation and unravel the mechanisms behind IUGR in these mice. In addition, 
studies on the immune system of growth restricted mice would also be important 
for general observations on the metabolic role of ILC1 or ILC2 in the adipose 
tissue. The use of IL-33KO, ILC2KO, Rag2-/- Il2rg-/- and Nfil3-/- 74,210,211 to study 
adipose tissue homeostasis would need to take into consideration that if the mice 
used are born smaller from KO mothers, this may affect their immune system 
and metabolism later in life. Therefore, we suggest that further studies on the 
development of the immune system and on immune responses later in life in 
growth restricted mice are important to discriminate the importance of maternal 
adaptations of the immune system and the importance of tissue-resident cells on 
metabolism. 
Overall, the work from this chapter shows for the first time the role of uILC2 
during pregnancy and vascular remodelling.  
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5 ILC2 MODULATE UTERINE 
TYPE-2 IMMUNITY 
Certain methods in this chapter describe elements that are presented in the 
following first author manuscript written by the author of this dissertation. 
Therefore, some sections are taken verbatim or with minor changes from this 
source. 
Balmas E, Rana BMJ, Hamilton S R, Kieckbusch J, Hawkes DA, McKenzie 
ANJ, Colucci F Group 2 innate lymphoid cells prevent endotoxin-induced fetal 
demise. In preparation.  
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5.1 Hypothesis and specific questions 
In this chapter, we aim to investigate the cellular and molecular mechanisms that 
affect vascular remodelling and foetal growth in ILC2KO dams. We focused on 
the indication from Chapter 3.3.4 that ILCs affect uEo and myeloid cells 
composition. Therefore, our intention is to study in detail the uterine 
microenvironment in WT and ILC2KO mice. We hypothesise that the lack of 
uILC2s could have its main effects on type-2 immunity. As a consequence, 
reduction of type-2 immunity activation can affect cell composition and 
alternative activation of uMac and uDCs. In Chapter 1.4.3 and 1.4.4 we discuss 
how the balance between type-2 and type-1 immunity can affect pregnancy 
outcome. The lack of uILC2s can potentially affect this balance. As a 
consequence, this could affect vascular remodelling in physiological conditions. 
However, unbalanced type-1/type-2 immunity could also induce foetal demise in 
complicated pregnancies. We aim to explore this hypothesis by identifying 
differences in the cytokine microenvironment and myeloid cells in myometrium 
and decidua.  
To appreciate the contribution of ILC2s to the uterine microenvironment we set 
out to repeat our analysis on uterine myeloid cells (as in Chapter 3.3.4) in a 
mouse model in which ILC2 are selectively lacking (ILC2KO mice). More 
specifically, we aim to assess whether uILC2s indeed regulate uEo homeostasis. 
Additionally, considering the importance of Eo in adipose tissue to promote type-
2 polarisation of Mac, we want to explore if similar mechanisms apply to the 
uterus, namely if in the absence of ILC2s the modulation of DCs or Mac 
activation may be affected.  
Finally, we hypothesised that alteration of the immune microenvironment 
influence immune responses to infections with potential repercussion on 
pregnancy. To this end, we mimic a bacterial infection in dams with LPS 
endotoxin.   
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We aim to analyse the role of uILC2s during pregnancy by asking the following 
questions: 
vii. Is the cytokine and immune microenvironment altered in the myometrium 
of ILC2KO mice? 
viii. Is the decidua altered? 
ix. Does LPS affect pregnancy outcome in ILC2KO? 
x. How do ILC2KO contribute to infections during pregnancy? 
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5.2 Alteration in myeloid cells and cytokines in ILC2KO mice 
Our results in Chapter 3.3.4 showed that uEo, uDCs and uMac are altered when 
ILCs are missing. Indeed, alteration in the balance of uterine myeloid cells can 
seriously affect cytokine production and vascular remodelling. ILC2KO mice 
have problems in uterine vascular remodelling and foetal growth, but they do not 
have alterations in group 1 uILCs. While group 1 uILCs have been extensively 
described in this process307,362,384, we can hypothesise that other cells may be 
involved and altered in this mouse model. For example, as described in Chapter 
1.4.4 also uMac and uDCs have been described in vascular remodelling. 
Therefore, we decided to investigate myeloid cells composition and alterations in 
WT and ILC2KO mice. 
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Figure 61 Gating strategy to identify uDCs, uMac, uEo, monocytes and 
neutrophils 
Flow cytometry strategy to identify uterine monocytes (live, CD45+ve Cd11b+ve, Ly6Chigh), uterine 
neutrophils, (live, CD45+ve, Cd11b+ve, Ly6C+ve, Ly6G+ve), uEo (live, CD45+ve, CD11b+ve, Ly6C-ve, Ly6G-
ve, SiglecF+ve, size, MHC II-ve), uMac (live, CD45+ve, Cd11b+ve, Ly6C-ve, Ly6G-ve, F4/80high, MHC II+ve), 
uDCs (live, CD45+ve, MHC IIbright CD11c+ve, F4/80-ve, CD80+ve, Ly6C-ve, Ly6G-ve). N=10 WT biological 
replicates per time point, N=7 Roraflox/flox Il7racre/+ biological replicates per time point. Experiments did 
not require pooling and every experiment have been performed on one full virgin or pregnant uterus per 
experiment. 
We designed a gating strategy to identify uEo, uterine monocytes, uterine 
neutrophils, uMac, and uDCs defined as CD11b+ve and CD11b-ve (Figure 61). We 
based our strategy on the study by Tagliani et al., 290 on uterine myeloid cells 
dynamics in the mouse decidua and we identified IFN-g activated or M1 and 
alternatively activated or M2 uMac as MHC II high and low respectively. The 
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role of uDCs different subsects is not completely clear. However, unlike other 
organs CD11b+ve uDCs are not monocyte-derived, indeed few uDCs derive from 
Ly6Chi monocytes but mainly from blood DCs precursors290. CD11b-ve uDCs are 
instead conventional uDCs which are partially dependent on FLT3 to develop290. 
Indeed, Flt3-/- specifically lack the CD11b-ve subset among uDCs290. 
Additionally, CD11b–ve cells are the main population of uDCs that expand in the 
myometrium and decidua, while CD11b+ve uDCs are in low quantity in the 
decidua287,290. 
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Figure 62 Abnormal type-2 immunity in the uterus ILC2s deficient females 
when compared to WT females 
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(A) Fold changes comparing absolute myeloid cell numbers from Roraflox/flox Il7racre/+ and WT virgin (V) 
uteri, midgestation myometrium (Mid) and uteri at term (Term) (N=10 WT biological replicates per time 
point, N=7 Roraflox/flox Il7racre/+ biological replicates per time point). Experiments did not require pooling 
and every experiment has been performed on one virgin or pregnant uterus per experiment. (B) Fold 
changes comparing absolute numbers of ILC1s and T cells (defined as CD45+ve CD3+ve CD4+ve) from 
Roraflox/flox Il7racre/+ and WT myometrium from Mid pregnant females (N=6 independent experiments). 
Every experiment has been performed on one pregnant uterus analysed per experiment. (C) Fold changes 
comparing absolute uDCs numbers from Roraflox/flox Il7racre/+ and WT spleens from Mid pregnant females. 
(N=3 independent experiments). Every experiment has been performed on one spleen analysed per 
experiment. (D) Percentage of cells expressing IL-4 after 4h in vitro culture of uterine myeloid cells 
without stimulation from Mid myometrium (N=3 independent experiments). Every experiment has been 
performed on ~3 pregnant uteri analysed per experiment without pooling. (E) Analysis of type 2 cytokine 
gene expression in uterine tissue homogenates by real time PCR in Roraflox/flox Il7racre/+ and WT at 
different stages of pregnancy (N=3 biological replicates per time point). Every experiment has been 
performed on one virgin or one pregnant uterus analysed per experiment. Live CD45+ve CD3+ve CD4+ve T 
cells have been sorted from one pregnant uterus per experiment.   (F) Real time PCR analysis of type 2 
cytokine gene expression on T cells sorted from Roraflox/flox Il7racre/+ and WT Mid myometrium (N=3 
biological replicates). Experiments from A-D Mid uteri have been dissected and myometrium has been 
analysed independently while decidua and embryos have been discarded. Data in A-C are displayed as 
mean ± SEM and WT and KO data per cell type were analysed using Student T-test and data in D-E were 
analysed by using one-way Anova: ns (or P value not showed), P > 0.05; *, P < 0.05; **, P < 0.01; ***, P 
< 0.001; ****, P < 0.0001. 
To measure the impact of uILC2s on the microenvironment in the uterus we 
analysed myeloid cells composition of the uterine tissues in ILC2KO mice before 
pregnancy, at midgestation and at term. Group 1 ILCs were in normal 
frequencies (Figure 62 B). uT cells were also normally represented (Figure 62 
B). In virgin ILC2KO uteri, we found absent or extremely infrequent uEo with 
increased uDCs. Instead, uMac, neutrophils, and monocytes were in normal 
frequencies. At midgestation, uEo were very low in numbers, with elevated 
uDCs (Figure 63), uMac and uterine neutrophils. At term, uEo were still virtually 
absent, whereas the uDCs were normal and the uMac were even below the 
frequency in WT animals. Additionally, in both virgin and pregnant uteri at 
midgestation MHC IIhigh and low uMac were unbalanced as well as CD11b+ve and 
–ve uDCs (Figure 62 A and Figure 63). Therefore, the lack of uILC2s has a clear 
impact on myeloid cells in the uterus, reducing uEo and enhancing uDCs, uMac 
and neutrophils at midgestation (Figure 62 A). Analysis on cytokines expressed 
in the uterine tissue, highlight that Il4 was low in virgin IL2KO mice at term, and 
essentially absent at midgestation. This is consistent with the absence of uEo, 
which are the main producers of IL-4 at midgestation in WT mice, followed by 
uDCs and uMac (Figure 62 D and E). Il5 was low in virgin mice and at 
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midgestation but normal at term. Il13 was undetectable in virgin mice and at 
midgestation (Figure 62 D). Transcripts of Areg were normal in virgin and 
pregnant ILC2KO dams (Figure 62 D), this was surprising given that Areg is 
constitutively produced by uILC2s (Figure 45), which are the main producers 
(Figure 46). Arg-1, which mediates differentiation of alternatively activated Mac 
and DCs, was low in virgin mice but normal in pregnant mice. uT cells may be 
the source of residual type-2 cytokines in ILC2KO mice (Figure 46 at page 127 
and Figure 62 E). Fewer Il5 and Il13 transcripts were detected in sorted CD3+ve 
CD4+ve uT cells from the pregnant myometrium of ILC2KO mice (Figure 62 E). 
In summary, type-2 cytokines are reduced in the uterus of both virgin ILC2KO 
mice and early during pregnancy. This set of data show how uILC2 clearly 
influence type-2 immunity in the pregnant myometrium, by inducing uEo 
recruitment and/or survival and by influencing myeloid cells dynamic and uT 
cells activity. 
 
Figure 63 uDCs in WT and ILC2KO pregnant myometrium 
Dot plots representative of uDCs in WT (left) and Roraflox/flox Il7racre/+ (right) myometrium at 
midgestation. Representative of N=10 WT biological replicates and N=7 Roraflox/flox Il7racre/+ biological 
replicates. uDCs gated as live CD45+ve MHC II high F4/80-ve Ly6G-ve Ly6C-ve. 
Among uDCs, decidual uDCs cannot migrate to the draining lymph node. 
Instead, uDCs in the myometrium have been demonstrated to respond to CCL21 
expressed by the lymphatic tissue in the myometrium287. DCs with the ability to 
migrate express CCR7 (the receptor for CCL21 and CCL19) and indeed Ccr7-/- 
mice have higher numbers of DCs in myometrium and endometrium287. We 
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explored the hypothesis that uDCs in ILC2KO may be in higher numbers due to 
their inability to migrate from the uterus. In WT mice CCR7+ve cells are mainly 
the CD11b+ve uDCs (~30%) and in minimal part CD11b-ve uDCs (Figure 64 A). 
Considering the importance of IL-13 in inducing DCs migration, we cultured 
uterine leukocytes in trans-well with a CCL21 gradient in the bottom well. We 
add in the culture IL-13 to test whether this cytokine was stimulating uDCs 
migration ex vivo. We used CD45+ve cells as an internal control for migration and 
similar % of CD45+ve cells migrated in both conditions. However, IL-13 
preferentially increased uDCs migration by ~2 fold (Figure 64 B). The ratio 
between CD11b+ve and CD11b-ve migrated uDCs was, as expected based on 
CCR7 expression, towards CD11b+ve uDCs. However, the ratio between uDCs 
subsets was not different between IL-13 stimulated and not stimulated uDCs. 
Additionally, no difference between CD11b+ve and CD11b-ve uDCs was identified 
between migrated and non-migrated uDCs (Figure 64 C). Therefore, there was 
not a preferential uDC subset migration due to the treatment. Interestingly, fold 
change of CCR7 geometric mean between migrated and non-migrated uDCs 
showed that IL-13 increases CCR7 expression on uDCs (Figure 64 D). IL-13 
could have an impact on CCR7 expression but both subsets can be affected in the 
same way. These data suggest that IL-13 promotes uDCs migration in the 
myometrium of WT mice. We can speculate that the increased number of uDCs 
in the ILC2KO myometrium could be partially dependent to the absence of IL-13 
(Figure 62 E) in ILC2KO mice. However, we need to take into consideration that 
CD11b+ve and CD11b-ve are both over represented in the ILC2KO myometrium, 
although the majority of CCR7+ve cells are CD11b+ve uDCs. Therefore, it is likely 
that only the over representation of CD11b+ve uDCs is due to the absence of IL-
13, while other factors are maybe influencing CD11b-ve uDCs.  
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Figure 64 IL-13 promote uDCs migration from the myometrium 
(A) Percentages of CCR7+ve DC subsets in WT dams at midgestation. (N=11 independent experiments); 
(B) Percentage of DCs migration with and without IL-13 in the culture. Percentage of CD45+ve cells 
migration with and without IL-13 in the culture. (N=9 independent experiments); (C) Ratio between 
uDCs subsets of migrated and not migrated cells with and without IL-13. (N=11 independent 
experiments); (D) Fold change of geometric mean of CCR7 expression in migrated and not migrated cells 
with and without IL-13. (N=11 independent experiments). Data in A-D are displayed as mean ± SEM. In 
C data of treated and migrated cells were analysed using one-way Anova. In data in B and D, the same 
uterus has been divided into two to be treated with or without IL-13, then cell migrated in treated and 
untreated were compared by paired Student T-test: ns or showed P value, P > 0.05; *, P < 0.05; ***, P < 
0.001. 
DCs, similarly to Mac are known to be plastic and their polarisation may 
promote either pro-inflammatory or tolerogenic or type-2 immune 
responses340,341,345,348,484. In the context of ILC2KO myometrium, we observed a 
strong reduction of type-2 immunity and this could indeed affect uDCs and uMac 
activation. In turn, activation of pro-inflammatory uDCs and uMac may increase 
uterine inflammation and it can alter uT cells polarisation. Therefore, we 
performed additional studies on uDCs phenotype in WT and ILC2KO 
myometrium. Consistent with the PCR data, fewer uDCs and uMac in ILC2KO 
mice expressed arginase as detected by intracellular flow cytometry (Figure 65 A 
and B), suggesting that indeed uMac were less polarised towards the alternatively 
activated type in ILC2KO mice. Moreover, the ratio of MHC class IIhi versus 
MHC class IIlo uMac was lower in ILC2KO (Figure 65 C). We then quantified 
transcripts of alternative activation markers (for type-1 and type-2 polarization) 
in sorted uDCs and uMac from midgestation myometrium of ILC2KO and WT 
mice. Type-2 polarization markers Arg1, Retnla, Chi3l3, Clec7a, Mrc1 and Il4 
were reduced in uDCs from ILC2KO mice, whereas inflammatory Il1b was 
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slightly but significantly increased (Figure 65 D). In addition, uMac too 
contained reduced Arg1, Chi3l3 and Il4 in ILC2KO mice (Figure 65 E). 
However, uMac showed a slight but not significant increase in Il1b and Il6. 
Overall, these data showed that the homeostasis in the ILC2KO myometrium is 
altered and this can potentially be relevant for the maintenance of pregnancy and 
tissue homeostasis in physiological conditions. In addition, the gathering of cells 
with a pro-inflammatory phenotype may be harmful to the foetus in pathological 
conditions, where the immune microenvironment needs to fight pathogens and 
protect from tissue damage. 
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Figure 65 Phenotype of uDCs and uMac in WT and ILC2KO pregnant 
myometrium 
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(A) Flow cytometry analysis and representative histograms of Arg-1 expression on uDCs from Roraflox/flox 
Il7racre/+ and WT midgestation myometrium (N=5 WT biological replicates per time point, N=3 
Roraflox/flox Il7racre/+ biological replicates per time point). (B) Flow cytometry analysis and representative 
histograms of Arg-1 expression on uMacs from Roraflox/flox Il7racre/+ and WT midgestation myometrium 
(N=5 WT biological replicates per time point, N=3 Roraflox/flox Il7racre/+ biological replicates per time 
point). Experiments did not require pooling and every experiment has been performed on one virgin or 
pregnant uterus per experiment.  (C) Fold changes comparing absolute cell numbers of MHC II hi 
(Classically activated Macrophages) Macrophages and MHC II low (Alternatively activated Macrophages) 
Macrophages absolute cell numbers from midgestation myometrium of Roraflox/flox Il7racre/+ and WT 
(N=10 WT biological replicates, N=7 Roraflox/flox Il7racre/+ biological replicates per time point). 
Experiments did not require pooling and every experiment has been performed on one virgin or pregnant 
uterus per experiment. (D) Analysis by real time PCR of a gene signature for alternative activation 
polarisation gene signature (Arg1, Retnla, Chi3le, Clec7a, Mrc1 and Il4) and for type-1 polarisation 
(Myd88, Il1b and Il6) on sorted uDCs isolated from midgestation myometrium of Roraflox/flox Il7racre/+ and 
WT (N= 3 biological replicates). (E) Analysis by real time PCR of genes signature for type-2 polarisation 
(Arg1, Retnla, Chi3le, Clec7a, Mrc1 and Il4) and type-1 polarisation (Il1b and Il6) on sorted uMac 
isolated from midgestation myometrium of Roraflox/flox Il7racre/+ and WT (N= 3 biological replicates). 
uDCs and uMac in D and E have been sorted from one full pregnant uterus per experiment. Data in A-E 
are displayed as mean ± SEM.  In C WT and KO data per cell type were analysed using Student T-test 
and data in A, B, D and E were analysed by using one-way Anova: ns, P > 0.05; *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001. 
Whatever role uILC2s have in the myometrium, this tissue is not in direct contact 
with the trophoblast, which is found in only the decidua in mice. Alterations in 
the myometrial microenvironment may affect the regulation of the first branches 
of the uterine arteries that go through the myometrium, but it is unlikely to 
directly affect the trophoblast or the decidual arteries. Our observation that 
ILC2KO dams have reduced arterial remodelling suggests that, in some way, 
alterations in the myometrium can indeed affect processes in the decidua. 
Therefore, we set out to study also the decidual immune microenvironment. Like 
in the myometrium we found increased uDCs ( Figure 67) and uMac, while 
monocytes, neutrophils, group 1 uILCs and uT cells were in normal quantities 
(Figure 66 A). We also found MHC IIhigh uMac over-represented compared to 
MHC IIlow uMac (Figure 66 B) and uDCs subsets were over-represented too. 
Interestingly, while type-2 immunity (Arg, IL5, Il4, Il13) was generally normal, 
inflammation was more pronounced in ILC2KO deciduae, with higher Il6 and 
Il1b transcripts (Figure 66 C). Within decidual uDCs and, to some extent, uMac 
too, there was a reduced expression of alternative activation markers (Figure 66 
D and E). uMac showed a milder phenotype with a reduction in Il4 and Mrc1 
expression and increase in Il1b (Figure 66 D). Decidual uT cells showed also 
reduced Il5 and Il13 expression (Figure 66 F), thus suggesting that uDCs and 
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uMac alteration in decidua and myometrium can alter uT cells polarisation in 
ILC2KO. 
 
Figure 66 Abnormal cell numbers and inflammation in the decidua of mice 
lacking ILC2s 
(A) Fold changes comparing absolute myeloid cell numbers from Roraflox/flox Il7racre/+ and WT virgin (V) 
midgestation (Mid) decidua (N=10 WT biological replicates, N=7 Roraflox/flox Il7racre/+). (B) Fold changes 
comparing absolute numbers of group 1 uILCs and T cells from Roraflox/flox Il7racre/+ and WT deciduae 
from Mid pregnant females (C) Analysis of type-2 and inflammatory cytokine gene expression by real 
time PCR in Roraflox/flox Il7racre/+ and WT at different stages of pregnancy (N=3 biological replicates). 
Experiments did not require pooling and every experiment has been performed on a pool of deciduae 
from a pregnant uterus per experiment.  (D) Analysis by real time PCR of a gene signature for alternative 
activation polarisation (Arg1, Retnla, Chi3le, Clec7a, Mrc1 and Il4) and for type-1 polarisation (Myd88, 
Il1b and Il6) on sorted uDCs isolated from Mid myometrium of RORaflox/flox IL7Racre/+ and WT (N= 3 
independent experiments). Experiments did not require pooling and every experiment has been performed 
on a pool of deciduae from a pregnant uterus per experiment. (E) Analysis by real time PCR of a gene 
signature for type-2 polarisation genes signature (Arg1, Retnla, Chi3le, Clec7a, Mrc1 and Il4) and type-1 
polarisation (Myd88, Il1b and Il6) on sorted uMac isolated from Mid myometrium of Roraflox/flox Il7racre/+ 
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and WT (N= 3 independent experiments). Experiments did not require pooling and every experiment has 
been performed on a pool of deciduae from a pregnant uterus per experiment. (F) Real time PCR analysis 
of type-2 and regulatory cytokine gene expression on T cells sorted from Roraflox/flox Il7racre/+ and WT Mid 
decidua. Experiments from A-F Mid uteri have been dissected and decidua has been analysed 
independently while myometrium and embryos have been discarded. Data in A-F are displayed as mean ± 
SEM. In A-B WT and KO data per cell type were analysed using Student T-test and data in C-F were 
analysed by using one-way Anova: ns or not showed, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
 
 Figure 67 uDCs in WT and ILC2KO pregnant decidua 
Dot plots representative of uDCs in WT (left) and Roraflox/flox Il7racre/+(right) decidua at midgestation. 
Representative of N=10 WT biological replicates and N=7 Roraflox/flox Il7racre/+ biological replicates. 
Experiments did not require pooling and every experiment has been performed on a pool of deciduae 
from a pregnant uterus per experiment. 
This increase in uDCs and uMac in both myometrium and decidua was then also 
assessed by immunohistochemistry and we confirmed that uDCs and uMac 
densities in the ILC2KO pregnant uterus are altered. Indeed, more cells stained 
for F4/80 or were double positive for CD11c and MHC II (Figure 68). 
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Figure 68 uMac and uDCs in WT and ILC2KO pregnant uteri 
Immunohistochemical analysis of (A) uMac identified as F4/80 positive (brown staining) and (B) uDC 
identified as MHC II positive (red staining) and CD11c positive (brown staining). 14X magnification, 
scale bar 250um; particular 4X magnification, scale bar 100um. Slides stained by Sophie Trotter under 
Elisa Balmas supervision. 
5.3 More foetal demise in ILC2KO dams exposed to LPS 
We assessed whether alterations in the decidua and myometrium 
microenvironment in ILC2KO uteri could affecting foetal survival. However, 
because gestation goes to term and litter sizes are normal in ILC2KO mice, the 
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skewing towards type-1 immunity observed in the myometrium seems well 
tolerated during pregnancy (Figure 69). 
 
Figure 69 Number of mice born from WT and ILC2KO dams 
Number of newborns and mortality rate before weaning of neonates born from Roraflox/flox Il7racre/wt  dams 
and controls. Data are displayed as mean ± SEM. Data in A were analysed with a Student T-test: ns, 
P>0.05. 
However, the alteration in the microenvironment may predispose ILC2KO dams 
to unbalanced responses to infection that may be dangerous for the foetus. 
Indeed, uterine or systemic infections need to be resolved, but at the same time, 
compensatory mechanisms need to be in place to avoid embryo death485. 
Exposure to LPS, which is a standard way to mimic the effect of a bacterial 
infection, induces foetal demise or pre-term labour by inducing nitric oxide and 
excessive IL-1b expression195,263,300,301,322,336,486. However, type-2 immunity and 
IL-10 prevent the detrimental effects of LPS in pregnancy254,300,301,346,487. We 
tested the hypothesis that the unbalanced uterine immune environment of 
ILC2KO dams can be harmful during infections. Therefore, we injected a very 
low dose of LPS that causes about 50% foetal loss in WT mice over two days 
when injected early during pregnancy (gd7.5). The same dose caused over 80% 
foetal loss in ILC2KO mice (Figure 70 A and B). Additionally, we used Il7cre/wt 
females mated with WT males to control for the effects of the Cre recombinase 
in the response to LPS and we found that foetal demise was similar to that in WT 
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dams, causing ~40% of foetal death. Therefore, when uILC2s are absent, 
foetuses are more at risk to die in the uterus as a consequence of an infection. 
 
Figure 70 Foetal demise in response to LPS injection 
(A) Resorption rate at E9.5 in Roraflox/flox Il7racre/wt after in vivo injection of 0.002mg/g of LPS in 
Roraflox/flox Il7racre/wt, WT and Il7cre/wt E7.5 pregnant females (N=4 Roraflox/flox Il7racre/wt  PBS injected; N=5 
C57BL/6 PBS injected; N=6 Roraflox/flox Il7racre/wt LPS injected; N=8 C57BL/6 LPS injected N=3 Il7racre/+ 
PBS injected, N=2 Il7racre/+ LPS injected). (B) Representative pictures of PBS and LPS treated WT and 
Roraflox/flox Il7racre/wt pregnant females mated with WT. Arrows identify where signs of embryo death were 
identified. Data in A are displayed as mean ± SEM. Data in A were analysed by one-way Anova: ns or 
not showed, P > 0.05; **, P < 0.01.  
 
We next analysed the effects of LPS injection on the molecular and cellular 
composition in the uteri of WT and ILC2KO dams. We found a slight, yet a 
significant increase of Il12, and a significant reduction of Retnla in ILC2KO 
dams uterine tissue (Figure 71 A). We then assessed by flow cytometry the cell 
populations affected by LPS. After LPS injection, RELMa was particularly 
reduced in uDCs in both WT and ILC2KO uteri (Figure 71 B). RELMa is also 
known as FIZZ1, and it is a protein up-regulated on Mac and DCs in response to 
IL-4. It has been used as a marker for Mac and DCs alternative activation341,488. 
Reduction of RELMa shows that, among the cells types we analysed, LPS 
affects only uDCs phenotype and it reduces alternative activation in uDCs. 
However, no change was detected in RELMa+ve uMac or monocytes. Moreover, 
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in response to the LPS challenge, neutrophils were increased two-fold in both 
ILC2KO and WT mice treated with LPS in comparison with PBS injected mice 
(Figure 71 C and D). Interestingly, while uDCs were reduced in number in WT 
mice, this was not observed in ILC2KO mice (Figure 71 D). LPS is known to 
induce migration of uDCs from the myometrium to the draining lymph node. 
This observation supports the hypothesis that uDCs in ILC2KO mice may indeed 
have defective migration. The data suggest that the uterine immune 
microenvironment and the polarisation of myeloid cells are further altered in 
response to LPS. Therefore, the persistence of unbalanced uDCs in the 
myometrium may increase the inflammation and cause the foetal loss in ILC2KO 
dams. Overall these results suggest that, during responses to infection, uILC2s 
prevent foetal loss. In order to detect even more immediate changes in response 
to LPS, we set out to repeat the experiment and analyse the uterine tissue 24 
hours after the LPS challenge.  
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Figure 71 Molecular and celluar effects 2 days post LPS challenge. 
(A) Gene expression analysis of Retnla and Il12 by real time PCR on midgestation uteri (day 9.5) from 
Roraflox/flox Il7racre/wt and WT injected with LPS 2 days before dissection. (B) Fold change of the number 
of cells RELMa+ve from PBS and LPS treated uteri. (C) Fold change of the number of cells from PBS and 
LPS treated Roraflox/flox Il7racre/wt uteri. (D) Absolute cell numbers of uterine neutrophils and uDCs in WT 
and Roraflox/flox Il7racre/wt treated with PBS or LPS. (One set of experiment, N=4 Roraflox/flox Il7racre/wt PBS 
injected; N=5 C57BL/6 PBS injected; N=6 Roraflox/flox Il7racre/wt LPS injected; N=8 C57BL/6 LPS 
injected). For experiments from A-D midgestation myometrium and decidua have been processed 
together without separation and only embryos have been discarded. Experiments did not require pooling 
and every experiment has been performed on a full pregnant uterus per experiment. Data in A-D are 
displayed as mean ± SEM. Data in A and D were analysed by one-way ANOVA and data in B and C fold 
changes of treated and untreated cell types were analysed by Student T cells: ns or not showed, P > 0.05; 
*, P < 0.05; **, P < 0.01. 
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Uterine tissue transcripts of Il5, Il13 and Il4 were increased in WT, but reduced 
in ILC2KO mice 24 hours after LPS challenge (Figure 72 A). Other responses in 
LPS-treated ILC2KO mice, such as tissue Retnla and Il1b, were qualitatively 
similar, but exaggerated, displaying reduced Retnla and increased Il1b (Figure 72 
A). At the protein level, we detected significantly increased IL-1b in the uterus 
of both LPS-treated strains, but not in the plasma, suggesting a localised 
response. Moreover, the levels of IL-1b were higher in both uterus and plasma of 
LPS-treated ILC2KO mice (Figure 72 B). IL-5 protein was, as expected, much 
reduced in both tissue and plasma of ILC2KO mice (Figure 72 B). These results 
show that, during responses to bacterial infection, uILC2s prevent foetal loss in 
mice by modulating the balance between type-1 and type-2 immunity. In 
particular, uILC2s promote the production of type-2 cytokines and their 
deregulation creates an environment skewed towards type-1 cytokines that are 
more prone to abortion during infection.  
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Figure 72 Molecular and celluar effects 1 day post LPS injection. 
(A) Gene expression analysis of Retnla, Il10, Il1b, Tnfa and Il6 by real time PCR of midgestation (day 
9.5) Roraflox/flox Il7racre/wt  and WT uteri 24h after 0.002mg/g LPS Injection. (B) Multiplex ELISA of IL-1b 
and IL-5 midgestation (day 9.5) Roraflox/flox Il7racre/wt  and WT uterine tissue homogenates and plasma 
collected 24h after LPS Injection. (For experiments from A-B midgestation myometrium and decidua 
have been processed together without separation and only embryos have been discarded. This represents 
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one set of experiment, N=3 Roraflox/flox Il7racre/wt PBS injected; N=3 C57BL/6 PBS injected; N=5 
Roraflox/flox Il7racre/wt LPS injected; N=5 C57BL/6 LPS injected. Data in A-B are displayed as mean ± 
SEM. Data in A were analysed by one-way Anova: ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 
0.001; ****, P < 0.0001. 
5.4 Conclusions and discussion 
Our analysis of the cellular and molecular changes in the uterus of ILC2 deficient 
mice showed that uILC2s are crucial for the establishment of type-2 immunity. 
Despite the redundancy of type-2 cytokines, IL-4 plays key roles in polarizing 
type-2 immunity234. Indeed, here both IL-4 and IL-13 are affected by the lack of 
uILC2s. ILC2s are central players in the regulation of Mac polarisation in the 
adipose tissue via Eo34,209,213. Therefore, the complete absence of uEo appears 
crucial also in the uterus to promote type-2 polarisation and IL-4 production. uEo 
are dependent on IL-5 for their homeostasis and proliferation in the uterus232,415. 
uILC2s provide IL-5 to uEo, which accumulate, proliferate, and promote the 
polarisation of the immune response by producing IL-4. Indeed, uEo are 
localised only in the myometrium with uILC2s and published studies had already 
confirmed the importance of IL-5232, and in particular ILC2-derived IL-5213, for 
uEo accumulation in the uterus. Additionally, the reduced type-2 polarisation in 
ILC2KO uteri is greater in the myometrium. However, studies on Il5-/- mice 
showed also that these mice do not have major pregnancy alterations232. This 
suggests that uILC2s may be involved in roles other than uEo homeostasis during 
pregnancy. uEo are likely involved mainly in the regulation of uMac and uDCs 
that is driven by IL-4 (A summary of the hypothesised roles of uILC2s is 
depicted in Figure 73).  
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Figure 73 Hypotesised role of uILC2s. 
Summary of the proposed mechanism and role of uILC2s in the regulation of uEo, uDC and uMac to 
further modulate type-1 and type-2 immunity during pregnancy. 
Alteration in the homeostasis and the alternative activation of uMac and uDC 
may be responsible for the reduced remodelling of ILC2KO uterine spiral 
arteries. In this context, the main players of arterial remodelling (group 1 uILCs) 
are normal but arterial remodelling is insufficient and type-2 immunity is altered. 
We noticed instead increased expression of inflammatory cytokines and reduced 
alternative activation by both uMac and uDCs. We hypothesised that 
alternatively activated uMac and uDCs may be involved in the process of spiral 
arteries remodelling. In addition, these cells can collaborate with group 1 uILCs 
for this purpose. Furthermore, the alteration of the immune microenvironment 
and the increased inflammation in the decidua may also inhibit the remodelling 
and foetal growth259,260,305–307,322,489. Alternative activated Mac and their markers 
have been studied in the context of lung fibrosis, but their role could be both pro- 
and anti- fibrotic according to the pathological stage of injury or repair480. In the 
uterus, the role of alternatively activated uMac in spiral arteries remodelling has 
been already studied in in vitro models for human decidua299,309,359, but in mice, 
in vivo, little is known about the role of this subset, or in particular about uMac 
mechanisms of polarisation and function. Therefore, studies on Il4raflox/flox 
LysMcre/cre or Il4raflox/flox Cd11ccre/cre490, where alternative activation is inhibited on 
either uMac or uDCs, may help to understand the role of these cells during 
pregnancy. Alternatively, experiment on these KO mice could assess if 
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maintenance of the immune homeostasis is indeed required for the successful 
remodelling or if additional factors in ILC2KO mice affect spiral arteries. 
However, even if alterations of the microenvironment affect arterial remodelling, 
it is still unclear how myeloid cells and cytokines in the decidua can be altered in 
ILC2KO, given that ILCs are localised in the myometrium, not the decidua. 
uDCs cannot move away from the decidua287, however, circulating monocytes 
and progenitors can reach the decidua290. Potentially, cells from the myometrium 
may be reaching the decidua by blood vessels. Alternatively, uILC2s may be 
important in the process of decidua formation. uMac quantities and proportions 
are dependent on CSF-1 differential expression in the myometrium and 
decidua290. Similarly, uDCs may be dependent to CSF-2 uterine concentrations, 
but it still needs to be addressed. Therefore, alteration in the decidual stromal 
cells may also alter cytokine production and, in turn, cell quantities or 
proportions. Additionally, the absence of a population, even if small, can 
promote the homeostatic proliferation of cells because activators and cytokines 
may be more abundant. However, this cannot be the case for the decidua, where 
uILC2s are missing.  
A key role of type-2 immunity for maternal tolerance of the foetus has been 
proposed for almost a decade291, but mice deficient for type-2 cytokines do not 
show embryo mortality 232,234,296,415. It is therefore unlikely that type-2 immunity 
is involved in only tolerance. However, the protective role of IL-10 in preventing 
LPS-induced preterm birth in rat and mice is well established491. Furthermore, 
human and mouse studies show that uterine and placental deficiency in IL-4 is 
associated with preeclampsia, foetal growth restriction254 and foetal demise in 
response to inflammatory stimuli303. In addition, a recent study showed that IL-4 
and IL-13 can down-regulate LPS-induced inflammation in explanted human 
tissues492. Finally, human genetic association showed that excess of IL-1b493,494 
or reduced IL-33495 are usually associated with recurrent miscarriage. All 
together this line of evidence shows that type-2 immunity is protective towards 
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inflammatory challenges from the environment. In this Chapter, we showed that 
ILC2KO dams are less able than WT dams to protect the foetuses from 
inflammatory stimuli. Our data show that ILC2KO dams have a greater in situ 
inflammatory response characterised by reduced type-2 immunity and increased 
IL-1b. Additionally, alternative activation of uDCs is reduced, together with, 
potentially, the migration ability of uDCs. These data suggest that additional 
studies on LPS activated or non-activated uDCs in ILC2KO mice may help to 
better understand the role of uDCs at midgestation and the role of uILC2s in 
regulating them. Interestingly, also uT cells polarisation seems insufficient in 
both myometrium and decidua (Figure 62 and Figure 67). Although uT cells 
activation and polarisation is still unclear in the uterus, these data suggest that 
antigen presenting cells (both uDCs and uMac) in ILC2KO mice may lose the 
potential to promote type-2 polarisation of uT cells in the uterus. Instead, uTreg 
activation may be preserved, given the unaltered expression of IL-10 and Areg. 
This observation needs however further analysis on uT cells subsets in ILC2KO 
mice (Th2, gdT and Treg), to further establish the relationship between uT cells 
subsects and uILC2s.  
A common feature in physiological and pathological pregnancies in ILC2KO is 
the increase of IL-1b. While this cytokine is known to have beneficial effects in 
implantation or at term298,367,436,493,496, its expression must be regulated to avoid 
foetal demise or foetal abnormalities322,486. Expression of IL-1b can not only 
interfere with vascular remodelling but it can also induce the development of 
placental abnormalities 322,486. Indeed inflammation and, in particular, LPS-
mimicked inflammation during pregnancy, cause abnormalities in the labyrinth 
zone of the placenta and alterations in nutrient transport322,486. We can speculate 
that in our model the placenta may be affected too and this can also favour foetal 
growth restriction. Therefore, further analysis of placenta morphology in normal 
and LPS challenged pregnancies in WT and ILC2KO dams may be relevant to 
understand the role of ILC2s to protect from inflammation during pregnancy. 
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Additionally, giving the role of IL-1b in activating ILC3s (See chapter 1.1.3) it 
would be interesting to study the activity of uILC3s in this model. Interestingly, 
we found an increase in Neutrophils after LPS challenge, which we can 
hypothesise it may be due to an increase in uILC3 activity497. Further analysis of 
uILCs other than uILC2s and their relationship with uILC2s would be of extreme 
importance to further understand the role of uILCs in maintaining the balance in 
the uterine microenvironment. 
In conclusion, our data addressed for the first time the role of uILC2s in 
pregnancy. We show that uILC2s promote the development of a protective 
microenvironment with the development of alternative activated uMac and uDCs 
and these cells can further protect the foetus when inflammatory stimuli or 
infections occur during gestation. 
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6 CONCLUSION AND FUTURE 
DIRECTIONS   
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6.1 Conclusion 
The work of this dissertation has shown for the first time the existence of uILCs 
in mouse and human explanted tissues. I addressed their functionality and 
activation by in vivo and in vitro studies. I have focused my work on uILC2s and 
have identified functional characteristics of activation, development and 
modulation of uILC2s that may be specific for the uterus. Finally, I have found 
that deletion of uILC2s deeply affects the microenvironment and type-2 
immunity of the uterus. Furthermore, this microenvironment alteration had 
consequences on pregnancy, because ILC2KO mice have reduced arterial 
remodelling, reduced foetal growth and increased foetal demise after LPS 
challenge. 
This work changes the classical view that type-2 immunity is important for 
maternal tolerance of the foetus293–295,330. uILC2s do regulate uterine type-2 
immunity, but my work suggests that type-2 is not necessarily regulating 
tolerance. My work suggests that type-2 immunity is rather involved in vascular 
remodelling and foetal growth during normal pregnancies and, during 
complicated pregnancies, in protecting the foetus in response to bacterial 
endotoxin. Additionally, I discovered that the main cells regulated by uILC2s are 
myeloid cells. Indeed, the absence of uILC2s deeply influences the polarisation 
of uMac and uDCs. 
6.2 Future directions 
6.2.1 Activators of uILC2s. 
We have identified some of the activators of uILC2s, but the picture is 
incomplete. We established that IL-33 is an essential regulator of uILC2s 
homeostasis and activation during pregnancy. However, when uILC2s were 
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activated in vitro with IL-33 and IL-25, we were unsuccessful to induce uILC2s 
expression of IL-13. However, uILC2s do express Il13 in our RNAseq data. 
Therefore, additional work on uILC2s activators in vivo needs to be carried out. 
Receptors for IL-25, TGF-b or oestrogens have been identified by flow 
cytometry or RNAseq. They may be potential additional activators of uILC2s in 
physiological conditions. We believe that further studies in vitro and in vivo with 
KO mouse models will be important to assess whether these cytokines may be 
indeed uILC2s activators and at which time point of pregnancy they may be 
regulating uILC2s. 
Finally, IL-13 production by uILC2s may be important in the context of labour. 
Asthma and excess of type-2 activation have been associated with preterm 
labour498–501. IL-13 and the increase of type-2 cytokine produced by uILC2s at 
term may be important for the induction of labour. In particular, the IL-13 
receptor is typically expressed on smooth muscle cells and this cytokine mediates 
airway contraction during asthma17,502–504. In the pregnant uterus, IL-13 may be 
involved in the induction of labour by activating myometrium contraction. 
However, IL-33 prevent preterm labour, therefore consistent with our data, IL-33 
is unlikely to induce uILC2 production of IL-13. Therefore, it would be 
important to assess how ILC2KO mice respond to induction of labour by LPS 
and mifepristone. LPS mediates the induction of labour by triggering uterine 
inflammation, which inhibits progesterone as a downstream effect, while 
mifepristone directly inhibits progesterone and acts downstream to the LPS 
pathway. Studies of these two labour-inducers in ILC2KO dams would assess 
whether and when uILC2s could have a role in the induction of labour. Indeed, 
uILC2s may be protective towards LPS or inflammation, but once progesterone 
is inhibited, they may be involved in smooth muscle contraction. Furthermore, 
studies on IL-13 expression and regulation in uILC2s could assess whether this 
may be the mechanism used by uILC2s to promote labour.  
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6.2.2 uILC2s regulates myeloid cells 
We discovered that the main cells regulated by uILC2s are myeloid cells. uILC2s 
absence deeply influences uMac and uDCs polarisation. Further analysis of 
uDCs and uMac activation in ILC2KO mouse models or in type-2 KO mouse 
models may be important to understand the contribution of these cells during 
pregnancy. 
For instance, the role of alternatively activated uDCs and uMac is not ben 
established yet. Work on human uMac suggests that these cells may be involved 
in arterial remodelling and in the regulation of uterine NK cells309,351,359. Our data 
support this notion and, in addition, suggest that other cells too may be involved 
in this process. Therefore, additional studies with specific mouse models KO for 
alternative activated uMac or uDCs will be able to identify the exact mechanism 
involving uDCs and uMac. Additionally, other ways for uILC2s to regulate 
uDCs may involve CTLA4. We found expression of CTLA4 on uILC2s. 
However, little is known if CTLA4 affect the activation of uDCs and potentially 
their expression of IDO and IFN-g. Cell-extrinsic effects of CTLA4 regulation, 
involve IDO expression478 by DCs and induction of IFN-g expression475,478,505. 
Therefore, in vitro activation of WT and ILC2KO uDCs with Ctla4-Fc may help 
to understand if uILC2-CTLA4 can activate and modulate uDCs. Furthermore, 
this should be associated with in vivo analysis of uDCs in WT and ILC2KO 
mice. 
We identified alterations in the quantities of uMac and uDCs in myometrium and 
decidua of ILC2KO mice. Analysis of the microenvironment and differential 
expression of Csf-1, Csf-2 in myometrium and decidua from WT and KO may 
help to understand the reason(s) for this alteration. Given the myometrial 
localisation of uILC2s, the reason for such alterations in the decidua in ILC2KO 
could be established early in gestation, when myometrium and decidua are not 
yet distinct. Therefore, uILC2s may be involved in the decidualisation process 
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thus altering decidual stromal cells ability to produce the right amount of growth 
factors. 
Finally, one of the main reasons for this alteration in uDCs numbers may be 
related to the reduced migration of uDCs when uILC2s are absent. Furthermore, 
while uDCs are known to migrate out from the myometrium when stimulated 
with LPS, we found that this is unlikely to happen in our model of ILC2KO. 
Indeed, while uDCs from WT dams reduced after LPS challenges, uDCs in 
ILC2KO dams did not change in numbers when challenged. Additionally, LPS 
promotes phenotypic changes in uDCs and this may be increasing uterine 
inflammation in ILC2KO dams exposed to LPS. Therefore, additional studies on 
uDCs ability to migrate from the myometrium may support our study and would 
be important in the context of the role of uILC2s in protecting the foetus towards 
inflammatory stimuli or infections. 
6.2.3 uILC2s regulate arterial remodelling and foetal growth 
Our data showed reduced remodelling of uterine spiral arteries and reduced 
foetal growth. These are processes usually associated with group 1 uILCs and, 
specifically with uNK cells, which produce IFN-g (the key cytokine in murine 
decidual vascular remodelling). However, insufficient arterial remodelling in 
ILC2KO dams is not associated with a reduced activity of group 1 ILCs. We did 
find reduced IFN-g in the myometrium though, and this may indirectly affect 
decidual vascular remodelling. Whether and how myometrium and decidua affect 
each other in this context is unclear. Given the importance of NK-derived IFN-g 
in vascular remodelling248,318 it would appear relevant to assess the role and the 
cellular source of myometrium-derived IFN-g and how it may affect artery 
remodelling. Current studies in the laboratory on the uterine single cell atlas of 
the CD45+ve cells from myometrium and decidua may be able to identify 
additional sources of uterine IFN-g. Additionally, we can investigate whether 
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CTLA4 on uILC2s induce IFN-g expression in uDCs. Finally, Decidual 
inflammation may also suppress vascular remodelling, but the mechanism would 
need to be assessed.  
6.2.4 uILC2s in human decidua 
We have described uILCs in mouse pregnant uteri and human decidua, and we 
identified a possible role for uILC2s in murine pregnancy. With this work, we set 
out the basis for a comprehensive and long-term study on human uILCs function 
in physiological and complicated pregnancies. We identified that uILC2s are 
relevant to protect towards inflammation and for the establishment of uterine 
type-2 immunity. Therefore, this study could be relevant to support additional 
studies on human uILC2s and type-2 immunity in the context of recurrent 
miscarriages and infections. Maintenance of the uterine microenvironment could 
be really important in human pregnancy considering that type-2 immunity and 
alternative activation of macrophages are important for pregnancy maintenance 
and vascular remodelling299.We will need to establish if human uILC2s have this 
function in the human decidua and if it can be important for uterine vascular 
remodelling and protection towards infections in pregnancy. Additional in vitro 
studies of uILC2s in human decidual and myometrium will be important to 
establish if human and mouse uILC2s may have similar roles and potential. In 
parallel, in vitro studies on uDCs and uMac cultured with or without uILC2s may 
be important to understand the possible regulation of myeloid cells in the human 
setting. On the very long term, studies on uILC2s activation may help to develop 
therapies or changes in the clinical practice for the maintenance of type-2 
immunity during pregnancy and, in this way, promoting foetal growth and foetal 
protection.  
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GO ANALYSIS RESULTS FIGURE 50 C 
Term	 Count	 P	Value	
Fold	
enrichment	
GO:0006955~immune	response	 81	 4.76E-07	 2.080646536	
GO:0006954~inflammatory	response	 93	 2.51E-06	 1.888890137	
GO:0002376~immune	system	process	 92	 8.64E-04	 1.678306383	
GO:0051384~response	to	glucocorticoid	 27	 0.011553029	 2.515270479	
GO:0055074~calcium	ion	homeostasis	 15	 0.009490705	 3.742962023	
GO:0007155~cell	adhesion	 103	 0.028917521	 1.4838079	
GO:0032355~response	to	estradiol	 31	 0.042157795	 2.144482532	
GO:0032496~response	to	lipopolysaccharide	 50	 0.040852014	 1.773315341	
GO:0045471~response	to	ethanol	 34	 0.044390181	 2.030370282	
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GO ANALYSIS RESULTS FIGURE 53 C 
 
Term	 Count	 P	Value	 Fold	enrichment	
GO:0006955~immune	response	 16	 2.79E-05	 3.732094943	
GO:0019835~cytolysis	 6	 3.79E-05	 15.22694737	
GO:0006508~proteolysis	 23	 1.39E-04	 2.507300898	
GO:0018149~peptide	cross-linking	 7	 2.39E-04	 7.930701754	
GO:0031424~keratinization	 6	 3.43E-04	 9.760863698	
GO:0016485~protein	processing	 8	 4.08E-04	 5.901917585	
GO:0033630~positive	regulation	of	cell	adhesion	
mediated	by	integrin	 4	 0.001516501	 16.91883041	
GO:0006275~regulation	of	DNA	replication	 4	 0.001516501	 16.91883041	
GO:0043065~positive	regulation	of	apoptotic	
process	 13	 0.006926102	 2.462068604	
GO:0032956~regulation	of	actin	cytoskeleton	
organization	 5	 0.007784773	 6.344561404	
GO:0007166~cell	surface	receptor	signaling	
pathway	 10	 0.007936967	 2.897060002	
GO:0006821~chloride	transport	 6	 0.008512076	 4.758421053	
GO:0001819~positive	regulation	of	cytokine	
production	 4	 0.01035901	 8.751119177	
GO:0030216~keratinocyte	differentiation	 6	 0.010906495	 4.478513932	
GO:0008544~epidermis	development	 5	 0.016301447	 5.116581777	
GO:0002376~immune	system	process	 13	 0.018373428	 2.153506482	
GO:0055114~oxidation-reduction	process	 19	 0.020883288	 1.783234714	
GO:0097192~extrinsic	apoptotic	signaling	
pathway	in	absence	of	ligand	 4	 0.028050881	 6.042439432	
GO:0055072~iron	ion	homeostasis	 4	 0.028050881	 6.042439432	
GO:0007411~axon	guidance	 7	 0.030403315	 2.980666431	
GO:0006954~inflammatory	response	 11	 0.045877859	 2.02878417	
GO:0007157~heterophilic	cell-cell	adhesion	via	
plasma	membrane	cell	adhesion	molecules	 4	 0.04822058	 4.880431849	
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GO ANALYSIS RESULTS FIGURE 53 E 
Term	 Count	 P	Value	
Fold	
enrichmen
t	
GO:0006955~immune	response	 46	 2.35376E-09	 2.68244324	
GO:0006954~inflammatory	response	 53	 3.55013E-09	 2.44376275	
GO:0002376~immune	system	process	 56	 8.15599E-09	
2.31916082
6	
GO:0019221~cytokine-mediated	signaling	pathway	 29	 1.06311E-07	
3.15055275
2	
GO:0050729~positive	regulation	of	inflammatory	
response	
18	 2.19438E-07	
4.53182957
4	
GO:0032355~response	to	estradiol	 23	 2.44189E-07	
3.61200277
9	
GO:0045893~positive	regulation	of	transcription,	
DNA-templated	
66	 3.40182E-06	
1.81745248
5	
GO:0009615~response	to	virus	 19	 3.81909E-06	
3.58769841
3	
GO:0008284~positive	regulation	of	cell	proliferation	 62	 7.35711E-06	
1.81440409
1	
GO:0010628~positive	regulation	of	gene	expression	 49	 1.23163E-05	
1.94789165
9	
GO:0045944~positive	regulation	of	transcription	
from	RNA	polymerase	II	promoter	
97	 1.71015E-05	
1.54628757
8	
GO:0042102~positive	regulation	of	T	cell	
proliferation	
15	 3.51202E-05	
3.71751644
7	
GO:0042127~regulation	of	cell	proliferation	 32	 3.94398E-05	
2.23596877
7	
GO:0045086~positive	regulation	of	interleukin-2	
biosynthetic	process	
7	 4.09728E-05	 9.25248538	
GO:0060397~JAK-STAT	cascade	involved	in	growth	
hormone	signaling	pathway	
7	 7.20329E-05	
8.54075573
5	
GO:0032729~positive	regulation	of	interferon-
gamma	production	
13	 7.23673E-05	
3.96535087
7	
GO:0045672~positive	regulation	of	osteoclast	
differentiation	
9	 9.95941E-05	
5.71010526
3	
GO:0045087~innate	immune	response	 46	 0.000114832	 1.82406140
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4	
GO:0048661~positive	regulation	of	smooth	muscle	
cell	proliferation	
16	 0.000122977	
3.17228070
2	
GO:0071345~cellular	response	to	cytokine	stimulus	 10	 0.000147025	
4.80648591
2	
GO:0043065~positive	regulation	of	apoptotic	
process	
40	 0.000157937	
1.89389892
6	
GO:0097191~extrinsic	apoptotic	signaling	pathway	 11	 0.000175848	
4.25549850
2	
GO:0051384~response	to	glucocorticoid	 15	 0.000215242	
3.17228070
2	
GO:0050679~positive	regulation	of	epithelial	cell	
proliferation	
15	 0.000248786	
3.13054016
6	
GO:0050852~T	cell	receptor	signaling	pathway	 12	 0.000272445	
3.73209494
3	
GO:0050728~negative	regulation	of	inflammatory	
response	
16	 0.00032274	
2.91703972
6	
GO:0048333~mesodermal	cell	differentiation	 6	 0.000329685	
8.65167464
1	
GO:0008285~negative	regulation	of	cell	proliferation	 43	 0.00035111	
1.77614674
7	
GO:0044344~cellular	response	to	fibroblast	growth	
factor	stimulus	
9	 0.000406546	
4.75842105
3	
GO:0007155~cell	adhesion	 51	 0.000413563	
1.66790016
3	
GO:0007259~JAK-STAT	cascade	 8	 0.000517232	
5.28713450
3	
GO:0034605~cellular	response	to	heat	 10	 0.00057412	
4.06702654
1	
GO:0032496~response	to	lipopolysaccharide	 26	 0.000654017	
2.09338320
4	
GO:0042130~negative	regulation	of	T	cell	
proliferation	
10	 0.000699913	
3.96535087
7	
GO:0072676~lymphocyte	migration	 4	 0.000950286	
15.8614035
1	
GO:0001666~response	to	hypoxia	 25	 0.001028238	
2.06528691
5	
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GO:0071260~cellular	response	to	mechanical	
stimulus	
14	 0.001099265	
2.84691857
8	
GO:0032689~negative	regulation	of	interferon-
gamma	production	
8	 0.001124026	
4.69967511
4	
GO:0002250~adaptive	immune	response	 20	 0.001153866	
2.28221633
2	
GO:0001974~blood	vessel	remodeling	 10	 0.001217724	 3.68869849	
GO:0010634~positive	regulation	of	epithelial	cell	
migration	
9	 0.001501071	
3.96535087
7	
GO:0007050~cell	cycle	arrest	 14	 0.001571785	 2.74147715	
GO:0050680~negative	regulation	of	epithelial	cell	
proliferation	
13	 0.00168522	
2.86386452
2	
GO:0055114~oxidation-reduction	process	 63	 0.001863135	
1.47820772
3	
GO:0007229~integrin-mediated	signaling	pathway	 15	 0.001984477	
2.55829088
9	
GO:0030335~positive	regulation	of	cell	migration	 25	 0.002204879	
1.95337481
6	
GO:0019218~regulation	of	steroid	metabolic	process	 4	 0.00226412	
12.6891228
1	
GO:0060666~dichotomous	subdivision	of	terminal	
units	involved	in	salivary	gland	branching	
4	 0.00226412	
12.6891228
1	
GO:0001525~angiogenesis	 28	 0.002354251	
1.85823974
2	
GO:0030216~keratinocyte	differentiation	 14	 0.002452324	 2.61246646	
GO:0031663~lipopolysaccharide-mediated	signaling	
pathway	
8	 0.002669545	
4.09326542
2	
GO:0001837~epithelial	to	mesenchymal	transition	 8	 0.002669545	
4.09326542
2	
GO:0042493~response	to	drug	 36	 0.002793201	
1.68439683
3	
GO:0006919~activation	of	cysteine-type	
endopeptidase	activity	involved	in	apoptotic	process	
12	 0.002926197	 2.84084839	
GO:0006935~chemotaxis	 17	 0.002969182	
2.28511745
5	
GO:0010575~positive	regulation	of	vascular	
endothelial	growth	factor	production	
7	 0.003105832	 4.62624269	
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GO:0042104~positive	regulation	of	activated	T	cell	
proliferation	
7	 0.003105832	 4.62624269	
GO:0046641~positive	regulation	of	alpha-beta	T	cell	
proliferation	
5	 0.003613076	
7.20972886
8	
GO:0042511~positive	regulation	of	tyrosine	
phosphorylation	of	Stat1	protein	
5	 0.003613076	
7.20972886
8	
GO:0033209~tumor	necrosis	factor-mediated	
signaling	pathway	
7	 0.003871996	
4.44119298
2	
GO:0098609~cell-cell	adhesion	 23	 0.003977175	
1.93022370
7	
GO:0050731~positive	regulation	of	peptidyl-
tyrosine	phosphorylation	
15	 0.004307938	
2.35565398
6	
GO:0010694~positive	regulation	of	alkaline	
phosphatase	activity	
4	 0.004316237	
10.5742690
1	
GO:0072602~interleukin-4	secretion	 4	 0.004316237	
10.5742690
1	
GO:0000122~negative	regulation	of	transcription	
from	RNA	polymerase	II	promoter	
65	 0.00442165	
1.41425408
5	
GO:0010718~positive	regulation	of	epithelial	to	
mesenchymal	transition	
8	 0.004631776	
3.73209494
3	
GO:0046427~positive	regulation	of	JAK-STAT	
cascade	
7	 0.004769609	
4.27037786
8	
GO:1900025~negative	regulation	of	substrate	
adhesion-dependent	cell	spreading	
5	 0.005151661	
6.60891812
9	
GO:0007219~Notch	signaling	pathway	 17	 0.005272961	
2.15715087
7	
GO:0042346~positive	regulation	of	NF-kappaB	
import	into	nucleus	
6	 0.005436831	
5.00886426
6	
GO:0051496~positive	regulation	of	stress	fiber	
assembly	
9	 0.005628967	 3.24437799	
GO:0007166~cell	surface	receptor	signaling	pathway	 25	 0.005831984	
1.81066250
1	
GO:0071364~cellular	response	to	epidermal	growth	
factor	stimulus	
8	 0.006441723	
3.52475633
5	
GO:0045429~positive	regulation	of	nitric	oxide	
biosynthetic	process	
9	 0.006476558	
3.17228070
2	
GO:0032722~positive	regulation	of	chemokine	 6	 0.006878889	 4.75842105
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production	 3	
GO:0018108~peptidyl-tyrosine	phosphorylation	 11	 0.007141705	
2.68423751
7	
GO:0003179~heart	valve	morphogenesis	 4	 0.007200961	
9.06365914
8	
GO:0007595~lactation	 9	 0.007417346	
3.10331807
8	
GO:0046627~negative	regulation	of	insulin	receptor	
signaling	pathway	
8	 0.007522227	
3.42949265
1	
GO:0001819~positive	regulation	of	cytokine	
production	
7	 0.008376334	 3.82861464	
GO:0043392~negative	regulation	of	DNA	binding	 7	 0.008376334	 3.82861464	
GO:0016311~dephosphorylation	 15	 0.008466931	
2.18276195
1	
GO:0045954~positive	regulation	of	natural	killer	cell	
mediated	cytotoxicity	
6	 0.008568289	
4.53182957
4	
GO:0030279~negative	regulation	of	ossification	 6	 0.008568289	
4.53182957
4	
GO:0048873~homeostasis	of	number	of	cells	within	
a	tissue	
8	 0.008730959	
3.33924284
4	
GO:0071356~cellular	response	to	tumor	necrosis	
factor	
15	 0.009156382	 2.16291866	
GO:0071850~mitotic	cell	cycle	arrest	 5	 0.009416625	
5.66478696
7	
GO:0000724~double-strand	break	repair	via	
homologous	recombination	
11	 0.009791847	
2.56581527
3	
GO:0042327~positive	regulation	of	phosphorylation	 7	 0.00992449	
3.70099415
2	
GO:0032570~response	to	progesterone	 7	 0.00992449	
3.70099415
2	
GO:0033077~T	cell	differentiation	in	thymus	 8	 0.01007628	
3.25362123
3	
GO:0031424~keratinization	 8	 0.01007628	
3.25362123
3	
GO:0045589~regulation	of	regulatory	T	cell	
differentiation	
4	 0.010985751	
7.93070175
4	
GO:0050714~positive	regulation	of	protein	secretion	 8	 0.011566455	 3.17228070
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2	
GO:0051482~positive	regulation	of	cytosolic	calcium	
ion	concentration	involved	in	phospholipase	C-
activating	G-protein	coupled	signaling	pathway	
7	 0.011665677	
3.58160724
4	
GO:0043029~T	cell	homeostasis	 7	 0.011665677	
3.58160724
4	
GO:0010820~positive	regulation	of	T	cell	chemotaxis	 5	 0.012210552	
5.28713450
3	
GO:0007565~female	pregnancy	 12	 0.012428051	
2.34983755
7	
GO:0071456~cellular	response	to	hypoxia	 14	 0.012572038	
2.15591892
4	
GO:0071222~cellular	response	to	lipopolysaccharide	 23	 0.012594597	
1.74551330
5	
GO:0021915~neural	tube	development	 9	 0.013732073	
2.79907120
7	
GO:0097190~apoptotic	signaling	pathway	 9	 0.013732073	
2.79907120
7	
GO:0042060~wound	healing	 13	 0.014810931	
2.19359835
8	
GO:0097192~extrinsic	apoptotic	signaling	pathway	
in	absence	of	ligand	
8	 0.015013662	
3.02121971
6	
GO:0032755~positive	regulation	of	interleukin-6	
production	
9	 0.015359388	
2.74524291
5	
GO:1903543~positive	regulation	of	exosomal	
secretion	
5	 0.015483562	
4.95668859
6	
GO:0061028~establishment	of	endothelial	barrier	 5	 0.015483562	
4.95668859
6	
GO:0006469~negative	regulation	of	protein	kinase	
activity	
13	 0.016013166	
2.17050784
9	
GO:0051091~positive	regulation	of	sequence-
specific	DNA	binding	transcription	factor	activity	
14	 0.016914666	
2.07532382
4	
GO:0030890~positive	regulation	of	B	cell	
proliferation	
8	 0.016986325	
2.95095879
2	
GO:0046426~negative	regulation	of	JAK-STAT	
cascade	
8	 0.016986325	
2.95095879
2	
GO:0034612~response	to	tumor	necrosis	factor	 6	 0.018164939	 3.80673684
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2	
GO:0031295~T	cell	costimulation	 6	 0.018164939	
3.80673684
2	
GO:0051897~positive	regulation	of	protein	kinase	B	
signaling	
13	 0.018636861	
2.12575510
9	
GO:0001843~neural	tube	closure	 13	 0.018636861	
2.12575510
9	
GO:0071407~cellular	response	to	organic	cyclic	
compound	
11	 0.018832397	
2.32633918
1	
GO:0035556~intracellular	signal	transduction	 37	 0.019866124	
1.46717982
5	
GO:0008625~extrinsic	apoptotic	signaling	pathway	
via	death	domain	receptors	
7	 0.020783277	
3.17228070
2	
GO:0002230~positive	regulation	of	defense	
response	to	virus	by	host	
15	 0.021341799	
1.95017256
3	
GO:0032735~positive	regulation	of	interleukin-12	
production	
6	 0.021354303	
3.66032388
7	
GO:0048304~positive	regulation	of	isotype	
switching	to	IgG	isotypes	
4	 0.021413178	
6.34456140
4	
GO:0097011~cellular	response	to	granulocyte	
macrophage	colony-stimulating	factor	stimulus	
4	 0.021413178	
6.34456140
4	
GO:0045785~positive	regulation	of	cell	adhesion	 9	 0.023275932	
2.54915413
5	
GO:0043032~positive	regulation	of	macrophage	
activation	
5	 0.023555001	
4.40594541
9	
GO:0022408~negative	regulation	of	cell-cell	
adhesion	
5	 0.023555001	
4.40594541
9	
GO:0045786~negative	regulation	of	cell	cycle	 7	 0.023651587	
3.08416179
3	
GO:0009749~response	to	glucose	 11	 0.024167488	
2.23686459
7	
GO:0007160~cell-matrix	adhesion	 11	 0.024167488	
2.23686459
7	
GO:0006885~regulation	of	pH	 6	 0.024886825	
3.52475633
5	
GO:0043123~positive	regulation	of	I-kappaB	
kinase/NF-kappaB	signaling	
17	 0.025637181	
1.80969033
3	
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GO:0002053~positive	regulation	of	mesenchymal	
cell	proliferation	
7	 0.026773399	
3.00080606
9	
GO:0006366~transcription	from	RNA	polymerase	II	
promoter	
16	 0.02730969	
1.83900330
5	
GO:0045647~negative	regulation	of	erythrocyte	
differentiation	
4	 0.028088217	
5.76778309
4	
GO:0050777~negative	regulation	of	immune	
response	
4	 0.028088217	
5.76778309
4	
GO:0051024~positive	regulation	of	immunoglobulin	
secretion	
4	 0.028088217	
5.76778309
4	
GO:0042542~response	to	hydrogen	peroxide	 9	 0.028152892	
2.46125226
9	
GO:0071347~cellular	response	to	interleukin-1	 11	 0.028280182	
2.18094298
2	
GO:0030193~regulation	of	blood	coagulation	 5	 0.028386513	
4.17405355
5	
GO:0060749~mammary	gland	alveolus	development	 5	 0.028386513	
4.17405355
5	
GO:0032753~positive	regulation	of	interleukin-4	
production	
5	 0.028386513	
4.17405355
5	
GO:0030968~endoplasmic	reticulum	unfolded	
protein	response	
8	 0.02962662	
2.64356725
1	
GO:0001657~ureteric	bud	development	 8	 0.02962662	
2.64356725
1	
GO:0048662~negative	regulation	of	smooth	muscle	
cell	proliferation	
7	 0.030156357	
2.92183748
8	
GO:0034097~response	to	cytokine	 11	 0.030512876	 2.15401776	
GO:0006486~protein	glycosylation	 14	 0.030733593	 1.91430732	
GO:0046330~positive	regulation	of	JNK	cascade	 10	 0.031006477	
2.26591478
7	
GO:0016049~cell	growth	 8	 0.032754432	
2.58961689
9	
GO:0007093~mitotic	cell	cycle	checkpoint	 6	 0.033022598	
3.28166969
1	
GO:0045840~positive	regulation	of	mitotic	nuclear	
division	
6	 0.033022598	
3.28166969
1	
GO:0051607~defense	response	to	virus	 18	 0.03444018	 1.70961235
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4	
GO:0030154~cell	differentiation	 63	 0.03461325	 1.28111336	
GO:0006915~apoptotic	process	 48	 0.035468827	
1.33569713
8	
GO:0035457~cellular	response	to	interferon-alpha	 4	 0.035733735	
5.28713450
3	
GO:0043922~negative	regulation	by	host	of	viral	
transcription	
4	 0.035733735	
5.28713450
3	
GO:0032024~positive	regulation	of	insulin	secretion	 8	 0.036094942	
2.53782456
1	
GO:0071560~cellular	response	to	transforming	
growth	factor	beta	stimulus	
9	 0.036723304	
2.34020707
5	
GO:0009314~response	to	radiation	 6	 0.037642219	
3.17228070
2	
GO:0042832~defense	response	to	protozoan	 6	 0.037642219	
3.17228070
2	
GO:0021983~pituitary	gland	development	 6	 0.037642219	
3.17228070
2	
GO:0016337~single	organismal	cell-cell	adhesion	 13	 0.03909193	
1.90924301
5	
GO:0043434~response	to	peptide	hormone	 10	 0.0392315	
2.17279500
1	
GO:0051591~response	to	cAMP	 8	 0.039652671	
2.48806329
5	
GO:0000082~G1/S	transition	of	mitotic	cell	cycle	 9	 0.039930997	 2.3024618	
GO:0006310~DNA	recombination	 11	 0.040686761	
2.05265221
9	
GO:0040018~positive	regulation	of	multicellular	
organism	growth	
7	 0.041935993	
2.70804450
1	
GO:0071479~cellular	response	to	ionizing	radiation	 6	 0.042637708	
3.06994906
6	
GO:0006959~humoral	immune	response	 8	 0.043431626	
2.44021592
4	
GO:0009636~response	to	toxic	substance	 11	 0.043554081	 2.02878417	
GO:0031274~positive	regulation	of	pseudopodium	
assembly	
4	 0.04433158	
4.88043184
9	
GO:0061158~3'-UTR-mediated	mRNA	 4	 0.04433158	 4.88043184
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destabilization	 9	
GO:0006260~DNA	replication	 14	 0.046097242	
1.80536300
1	
GO:0031668~cellular	response	to	extracellular	
stimulus	
5	 0.046173357	
3.60486443
4	
GO:0015701~bicarbonate	transport	 5	 0.046173357	
3.60486443
4	
GO:0042981~regulation	of	apoptotic	process	 20	 0.046330765	
1.59411090
5	
GO:0048565~digestive	tract	development	 7	 0.046423048	
2.64356725
1	
GO:0030155~regulation	of	cell	adhesion	 7	 0.046423048	
2.64356725
1	
GO:0055072~iron	ion	homeostasis	 7	 0.046423048	
2.64356725
1	
GO:0010977~negative	regulation	of	neuron	
projection	development	
9	 0.046893305	
2.23050986
8	
GO:0010629~negative	regulation	of	gene	expression	 25	 0.047253644	
1.49635882
2	
GO:0009968~negative	regulation	of	signal	
transduction	
8	 0.047435283	
2.39417411
5	
GO:0006355~regulation	of	transcription,	DNA-
templated	
163	 0.049983481	
1.13444878
1	
 
 
